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Abstract
The cystic fibrosis transmembrane conductance regulator (CFTR) AF508 mutant 
(AF508CFTR) contributes to 70% cystic fibrosis cases, and it undergoes aberrant proteostasis, 
misfolding, intracellular retention and degradation. Targeting AF508CFTR proteostasis 
components has been successful in the partial rescue of AF508CFTR at the plasma membrane. 
Drug screening has identified correctors which rescue a fraction of the AF508CFTR at the plasma 
membrane. However, all these correctors are marginally effective and are not therapeutically 
viable.
This thesis project used a systems-biology-based meta-analysis approach of gene 
expression induced by corrector drugs to infer their mechanisms of action, and this led to the 
identification of a group of genes that are commonly regulated by many of these drugs. These 
groups of genes were used to determine the networks/ pathways/ molecules that might be correlated 
with their correction. These include components of RNA processing, the cell cycle, ubiquitin 
ligases, and kinases, many of which have led to partial rescue of AF508CFTR when they have been 
depleted by RNA interference. Furthermore, two of these pathways are characterised here: the 
MAP3K11-JNK cascade and the CaM kinase (CAMKK2) cascade. Several members of these 
cascades rescued AF508CFTR. The MAP3K11-initiated pathway has a role in ER-associated 
degradation and plasma-membrane stability of AF508CFTR. MAP3K11 also appears to link 
oxidative stress and inflammation to intracellular proteostasis of AF508CFTR. Some upstream 
activators and downstream targets of MAP3K11 can also rescue AF508CFTR. Drugs that inhibit 
the MAP3K11-JNK cascade rescued functional AF508CFTR at the plasma membrane. 
Combinations of these drugs with the previously clinically studied corrector pharmacochaperone 
VX-809 led to a high level of correction of AF508CFTR, which was much greater than for VX-809 
alone. Many candidate genes and drugs that are identified in the current study open the way to the 
development of the new efficient therapeutic agents for cystic fibrosis caused by the AF508 
mutation.
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Chapter 1
General Introduction
1.1. Cystic fibrosis
Cystic fibrosis (CF) was recognised in 1938 as a cystic fibrosis of the pancreas (Andersen 1938). 
The mucus was plugging the glandular ducts during the autopsy studies of malnourished infants. 
This disease had the hallmarks of malabsorption, growth failure, and pulmonary infection. The 
thick, sticky mucus that clogs the ducts of mucus glands throughout the body gave rise to the 
alternative designation of “mucoviscidosis” (Farber 1944).
In 1946, CF was recognized as a genetic disease that is transmitted in an autosomal 
recessive pattern (Andersen and Hodges 1946). The important discovery by Dr. Paul di 
Sant’Agnese in 1948 demonstrated a five-fold excess of sodium and chloride in the sweat of 
patients with CF (di Sant’Agnese et al. 1953). This study established elevated sweat chloride 
concentration as one of the first diagnostic tests for CF. The elevated chloride levels in all CF 
patients hinted that the basic defect may not be mucus related, and further in 1983 chloride 
transport was established as the primary defect in CF, using the sweat duct (Quinton 1983).
In 1989 the gene responsible for CF was discovered, cloned, characterised, and named the 
cystic fibrosis transmembrane conductance regulator (CFTR) (Kerem et al. 1989; Riordan et al. 
1989; Rommens et al. 1989). Several tissues, like the kidney, pancreas, intestine, heart, vas 
deferens, sweat duct and lung, express the CFTR channel at the apical membrane of epithelia 
(Bradbury 1999; Bertrand and Frizzell 2003). Loss of function of CFTR is responsible for CF, the 
most common inherited disease in Caucasians (Riordan et al. 1989). In molecular genetic terms CF 
is caused by the presence of two CF-causing mutations one in each parental CFTR gene, in 
physiological terms CF is a disorder of electrolyte transport across epithelial membranes resulting 
from absence or anomaly of the CFTR protein (Bombieri et al. 2011). There is an extensive 
variation in range and severity of symptoms and organs involved between and within individuals. 
CF is characterised by elevated sweat chloride concentrations, lung bacterial infections and 
bronchiectasis, pancreatic insufficiency, intestinal obstruction, biliary cirrhosis, and congenital
bilateral absence of the vas deferens, and fatal lung disease (Davis 2006). In contrast, the 
hyperactivity of CFTR channels can lead to secretory diarrhoeas (Al-Awqati 2002).
The lung phenotype in CF is characterised by a ferocious cycle of obstruction, 
inflammation and infection that progressively damages the airway tissue, which lead to respiratory 
failure and death (Lubamba et al. 2012). The CF lung and its airways are susceptible to chronic 
infection by Staphylococcus aureus, Hemophilus influenzae, Pseudomonas aeruginosa, 
Burkholderia cepacia complex organisms, Stenotrophomonas maltophilia, and Achromobacter 
xylosoxidans (Chmiel et al. 2013) which form biofilms and activate persistent inflammatory signals 
(Chmiel and Davis 2003). As part of the host defence strategy, neutrophils are recruited to prevent 
infection, but ultimately this inflated inflammatory response worsens lung function and leads to 
lung failure (Chmiel et al. 2013).
Patients with CF have increased levels of oxidative stress in the airways compared to 
unaffected individuals (Hull et al. 1997), which can be due to inflammation in the lungs or to 
decreased glutathione levels (Berube et al. 2010). The most common cause of death in CF is lung 
failure that is typically triggered by acute bacterial infections, which promote the progressive loss 
of the tissue architecture in lungs (bronchiectasis) (Chmiel and Davis 2003). In 1938 70% of babies 
with CF died within the first year of life (Andersen, 1938). Today the median life expectancy of 
patients with CF in the USA has improved, to 41 years in 2012 
(http://www.cff.org/UploadedFiles/research/ClinicalResearch/PatientRegistryReport/2012-CFF- 
Patient-Registry.pdf). CF affects 1 in 2500 new-boms (Collins 1992), and hence there are 
tremendous efforts to find a therapy to cure CF.
1.2. Cystic fibrosis transmembrane conductance regulator
Cystic fibrosis transmembrane conductance regulator (CFTR) is a protein that functions as a 
chloride channel in the plasma membrane (PM) (Riordan et al. 1989). CFTR is the only member of 
the ATP-binding cassette (ABC) transporter family that forms a regulated chloride channel, ATP 
binding and hydrolysis by the nucleotide-binding domains acts a timing mechanism to control the 
duration of channel openings (Hwang and Sheppard 2009). driven by the electrochemical gradient 
across the cell membrane CFTR allows the passage of several molecules across cell membranes,
mainly chloride, and including iodide, HCO3', and others (Ulek et al. 1999). The CFTR channel 
allows the passage of negatively charged chloride ions into and out of cells, and this helps to 
control the movement of water in tissues, which is necessary for the production of thin, freely 
flowing mucus (http://ghr.nlm.nih.gov/gene/CFTRT
CFTR single-channel conductance have been thoroughly characterised and established as 
an apical epithelial chloride channel (Venglarik et al. 1994) and demonstrated to behave as an 
ohmic low-conductance channel (Hanrahan et al. 1998). Although the primary function of CFTR is 
anion conductance, it is also known to have regulatory effects on other molecules. When stimulated 
by cAMP agonists, CFTR inhibits the amiloride sensitive epithelial Na+ channel (Stutts et al. 1997). 
Additionally CFTR regulates the outwardly rectifying chloride channel (ORCC) that can only be 
activated by protein kinase A (PKA) and ATP when CFTR is functionally active (Jovov et al. 
1995). CFTR has been shown to control many other ion channels, such as the Ca2+-activated 
chloride conductance (CaCC) channel, the renal outer medullar K+ (ROMK) channel, the sodium/ 
proton exchanger NHE3, and an aquaporin channel (Stutts et al. 1995; Mall et al. 1996; Mall et al. 
1996; McNicholas et al. 1996; Schreiber et al. 1997). Moreover, CFTR has been shown to be 
expressed in intracellular vesicles, where it might have a role in intracellular and intravesicular pH 
regulation (Lukacs et al. 1992). CFTR also appears to control exocytosis/ endocytosis processes 
(Jouret et al. 2007), and to regulate proinflammatory cytokine expression, and possibly other 
cellular functions (Vandivier et al. 2009).
The coding gene for the CFTR protein is located on the long arm of chromosome 7 at 
position 31.2 (http://ghr.nlm.nih.gov/gene/CFTR). which translates into a 1480-amino-acid protein 
with a predicted molecular mass of 168,138 Da (Riordan et al. 1989). The predicted structure has 
two repeated motifs, each of which contains a hydrophobic domain of six helices that span the 
membrane (membrane-spanning domain, MSD; or transmembrane domain, TMD) and are linked 
by a hydrophilic cytosolic ATP-binding domain (nucleotide-binding domain, NBD), followed by a 
large and highly charged cytoplasmic domain, known as the R domain. The second MSD is 
followed by another NBD on the C-terminus (Figure 1.2). The R domain consists of 241 amino 
acids arranged in alternating clusters of positive and negative charges, and there are several 
consensus sequences for phosphorylation by PKA and PKC (Riordan et al. 1989).
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Figure 1.2. Model of proposed domain structure of CFTR.
a. Model of CFTR primary structure containing two nucleotide-binding domains (NBD1 and 
NBD2), two membrane-spanning domains (MSD1 and MSD2), and a regulatory region (R 
domain), b. Homology model of CFTR constructed from Savl866 exporter (Serohijos et al. 2008).
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The domains of CFTR assemble to form the channel across the membrane, which is gated 
by cAMP dependent PKA phosphorylation of the R domain (Gadsby et al. 2006). There are two 
glycosylation sites, between the 7th and 8th membrane-spanning helices, at amino acids 894 and 
900. CFTR is core glycosylated in the endoplasmic reticulum (ER), which is an immature form that 
is also called “band B”. After folding, CFTR leaves the ER, progresses through the secretory 
pathway, and passing through the Golgi complex it attains the complex glycosylation to the mature 
form that is usually found on the PM, also known as “band C”. This band C moves at a higher 
molecular weight than band B on SDS-PAGE; there is also a third form of CFTR that has mobility 
on SDS-PAGE slightly faster than band B, which is referred to as “band A” (Gregory et al. 1990), 
which might be the non-glycosylated form.
The R domain is a target of protein kinases, including PKA, PKC and AMP-activated 
protein kinase (AMPK) (Ostedgaard et al. 2001). There were 10 PKA sites identified in vitro 
(Picciotto et al. 1992; Gadsby and Naim 1999), and six of these sites are phosphorylated on full- 
length CFTR purified from cells (Picciotto et al. 1992). Many of these phosphorylation sites 
stimulate channel activity in an additive/ synergistic way, although phosphorylation at S737 and 
S768 were reported as inhibitory under certain conditions (Wilkinson et al. 1997). Mutating as 
many as four (Ostedgaard et al. 2000) or more (Chang et al. 1993) of these phosphorylation sites 
can abolish the function of the CFTR channel. There are also five PKC phosphorylation sites 
located in the R region, four of which have been studied in vitro, with one verified in the full-length 
protein (Picciotto et al. 1992; Jia et al. 1997; Chappe et al. 2004). PKC phosphorylation on the R 
region does not stimulate the channel activity by itself, but might be involved in enhancing the 
effects of PKA phosphorylation (Bozoky et al. 2013). The cellular-energy-level-activated kinase, 
AMPK, phosphorylates the R region on inhibitory site (s768), this phosphorylation can fix CFTR 
into a state that is insensitive to PKA and PKC phosphorylation (King et al. 2009), which might 
decrease the channel open probability. It has been also noted that cAMP-dependent stimulation and 
PKA phosphorylation can overcome the inhibitory effect of AMPK phosphorylation. (Kongsuphol 
et al. 2009), The phosphatase 2 (PP2) isoforms, PP2A, PP2B and PP2C, and alkaline phosphatase 
can dephosphorylate CFTR (Thelin et al. 2005), and they can also reduce most of the CFTR 
channel activity (Hallows et al. 2000).
Once CFTR is phosphorylated, channel gating is tightly regulated by cycles of ATP 
binding and hydrolysis. Phosphorylated CFTR channels can be opened by a broad range of 
nucleoside triphosphates, including ATP, GTP, ITP, UTP, CTP, The frequency of CFTR-channel 
opening increases with ATP concentration, at saturating concentrations of ATP, a channel waits in 
the closed state for a second or so (depending on the temperature) before opening. This means that 
binding of ATP limits channel opening at low concentrations, but at saturating ATP concentrations 
some other slow step controls how quickly the channel can open once ATP has bound (Gadsby et 
al. 2006). On the assembled CFTR the ATP is known to bind tightly to ATP-binding site 1 (site 1; 
formed by the Walker A and B motifs of NBD 1 and the LSGGQ motif of NBD2), but is not 
hydrolysed at this site. Contrastingly, ATP is hydrolysed rapidly at the other ATP-binding site 2 
(site 2; formed by the Walker A and B motifs of NBD2 and the LSGGQ motif o f NBD 1) (Hwang 
and Sheppard 2009). The ATP hydrolysis at ATP-binding site 2 is known to controls the channel 
closure, whereas ligand binding at ATP-binding site 1 might modulate the rate of channel closure 
and the anion flow through the CFTR channel aperture is believed to be gated by the interaction of 
ATP with sites 1 and 2 powering NBD dimerisation and hence conformational changes in the 
MSDs (Hwang and Sheppard 2009). Opening of a CFTR channel was viewed as triggered by a 
pincer-like drawing together of ATP-bound NBD1 and ATP-bound NBD2, channel closing would 
follow hydrolysis of the ATP at the NBD2 composite site, loss of the liberated phosphate and 
subsequent disruption of the heterodimeric NBD1-NBD2 interaction (Gadsby et al. 2006).
1.3. Mutations o f CFTR
There have been about 1900 mutations reported in the gene encoding CFTR 
(http://www.genet.sickkids.on.ca/cftr/StatisticsPage.htmn. Based on the type of the defect caused, 
the CFTR mutations have been categorised into six classes (Welsh and Smith 1993; Zielenski and 
Tsui 1995; Haardt et al. 1999; Lubamba et al. 2012), as follows.
Class I: Mutations that interfere with protein synthesis: These mutations include the introduction of 
a stop codon in the mRNA, or nonsense (p.Gly542X), or a frame shift (394DelTT), or severe 
splicing mutations (1717-1G>A), which result in truncated proteins that are unstable, and hence 
these proteins do not reach the apical membrane.
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Class II: Mutations that affect protein maturation. These mutations result in the production of a 
protein that is incorrectly folded and cannot be trafficked to its site of function on the apical 
membrane (p.Phe508del (AF508), p.Ile507del, p.Asnl303Lys).
Class HI: Mutations that alter channel regulation. The mutation produces a protein that is correctly 
trafficked and localised to the apical membrane, but cannot be activated to function as a chloride 
channel (p.Gly551 Asp).
Class IV: Mutations that affect chloride conductance. These mutations produce a CFTR protein 
that is correctly trafficked to the apical membrane, but functionally this CFTR has a reduced level 
of chloride ion flow (p.Argl 17His, p.Arg334Trp).
Class V: Mutations that reduce the level of the normally functioning CFTR at the apical membrane 
(partially aberrant splicing mutation or inefficient trafficking) (C.1210-12T (5T allele), c.3140- 
26A>G (3272-26A>G), c.3850-2477C>T (3849+10kbC>T)).
Class VI: Mutations that decrease the stability of the synthesised CFTR (Q1412X, S1455X).
Class I, II, III and VI mutations confer insignificant or no functional level of CFTR at the 
apical membrane, and they lead to the severe and classic CF phenotype, with pancreatic 
insufficiency and severe lung damage, whereas class IV and V mutations make a protein that can 
retain some residual channel activity, and might thus lead to a milder phenotype. Patients with at 
least one mild CF allele of CFTR have sufficient digestion, and less severe lung disease (The 
Cystic Fibrosis Genotype-Phenotype Consortium 1993). Individuals with CFTR mutations that can 
give rise to about 10% of the normal level of CFTR mRNA can present only one symptom, such as 
congenital bilateral absence of the vas deferens in males (Anguiano et al. 1992). Some individuals 
who are heterozygous for a CFTR mutation have increased risk for characteristic CF 
pathophysiology, such as pancreatitis, or allergic bronchopulmonary aspergillosis (Casals et al. 
2004). Each class of mutation has the potential to have a significant role in the development of CF 
(Frizzell 1999); however, class I, II and V mutations with defects in early biosynthesis and folding 
are the major contributors to CF disease. Single CF mutation might have multiple mechanisms of 
CFTR dysfunction like AF508 (see section 1.4).
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1.4. The AF508 mutation o f CFTR
Among the identified CF patients, approximately 90% have an allele where phenylalanine 
at the 508 position of the protein is deleted (Phe508del; the Phe508 deletion mutant; AF508) 
(Welsh and Smith 1993; Amaral 2005). AF508 accounts for nearly 70% of CF cases (Collins 
1992). Patients with CF who have the AF508 mutation have no functional channel at the PM 
(Cheng et al. 1990). The AF508 mutation causes a protein folding defect that prevents its 
intracellular transport and delivery to the plasma membrane (Kartner et al. 1992), but a partial 
amount can reach the PM and function as a chloride channel (Drumm et al. 1991; Li et al. 1993). It 
was also noted that the AF508CFTR trafficking defect is temperature sensitive, as the channel 
function was partially restored at the PM by expressing AF508CFTR in insect cells or in Xenopus 
oocytes that were grown at low temperature (Drumm et al. 1991; Li et al. 1993), which was further 
confirmed in mammalian cells (Denning et al. 1992).
The AF508 mutation leads to multi-level defects, like misfolding (Qu and Thomas 1996), 
ER retention, degradation (Kopito 1999), reduced channel function (Dalemans et al. 1991), 
increased membrane instability (Lukacs et al. 1993), and reduced levels of transcripts (Ramalho et 
al. 2002). AF508CFTR is also known to lead to many other changes at the molecular level that can 
contribute to the outcome of CF. The CF foetus with homozygous AF508 mutation has excess 
inflammation-relevant molecules, like COX2, ICAM1, MMP1 and N F-kB, in the lung without any 
histological signs of inflammation (Verhaeghe et al. 2007). It has been demonstrated that loss of 
function of CFTR can be the major trigger of inflammation and N F-kB activation 
(Venkatakrishnan et al. 2000; Weber et al. 2001) in cellular models of CF with AF508 and other 
non-functional CFTR mutations. There is also evidence of hyperactivation of p38 MAPK in the 
lungs of AF508 CF patients, and when challenged with Pseudomonas aeruginosa diffusible 
material, cellular models of AF508 led to IL6 synthesis that was dependent on reactive oxygen 
species (ROS) and p38 activation (Berube et al. 2010). Primary CF cells with the AF508 mutation 
also have hyperactive AMPK (Hallows et al. 2006), which might be an adaptive response to reduce 
inflammation, because pharmacological activation of AMPK reduces inflammatory mediators like 
IL6, IL8 and TNFa. Also, AKT is hyperphosphorylated in CF model cells, and its inhibition can 
suppress IL8 expression (Bhattacharyya et al. 2011). The AF508CFTR condition also leads to
growth factor receptor (e.g., EGFR) phosphorylation and increased production of vascular 
endothelial growth factor (VEGF)-A (Martin et al. 2013). Several other gene products, like TNFa, 
TGF-pl, and others, can influence CF disease progression by acting as modifiers (Collaco and 
Cutting 2008). AF508 mutation causes the CFTR protein to misfold (Qu and Thomas 1996), and it 
might also cause up-regulation of the unfolded protein response (UPR) (Bartoszewski et al. 2008).
1.5. Biogenesis o f wtCFTR and A F508CFTR
The biogenesis of a functional protein has been proposed to depend on the cell control of 
the concentration, conformation, binding interactions and location of individual proteins, often 
through transcriptional and translational changes referred as “proteostasis” (Balch et al. 2008). 
Proteostasis can be influenced by the chemistry of protein folding and misfolding, and by 
numerous regulated networks of interacting and competing biological pathways, called the 
proteostasis network, which influence protein synthesis, folding, trafficking, disaggregation, and 
degradation (Balch et al. 2008). CFTR biogenesis has a complex folding, degradation and 
membrane trafficking itinerary that is managed by the proteostasis network.
There are documented transcriptional control programmes that can affect the biogenesis of 
CFTR. Very few copies of CFTR mRNA have been found in airway epithelial cells (Trapnell et al. 
1991), which might affect the amount of CFTR protein at the PM. The micro-RNAs miR-101 miR- 
144, miR-145 and miR-494 have been reported to directly target the CFTR 3'-UTR and to suppress 
the expression of the CFTR protein (Gillen et al. 2011; Hassan et al. 2012). IL-ip was 
demonstrated to increase CFTR mRNA and to induce the CFTR promoter in Calu-3 cells using 
NF-kB (Brouillard et al. 2001). TGF-pi was shown to inhibit CFTR biogenesis by reducing its 
mRNA levels and protein abundance in primary differentiated human bronchial epithelial cells, and 
to also inhibit biogenesis and impair the functional rescue of AF508CFTR in primary differentiated 
human bronchial epithelial cells from patients who were homozygous for the AF508 mutation 
(Snodgrass et al. 2013). Additionally, ER stress is reported to contribute via the UPR, to decrease 
CFTR expression at the transcriptional, translational, and maturational levels (Bartoszewski et al. 
2011). The p-adrenergic receptor has also been demonstrated to modulate expression of CFTR via 
the elevation of cAMP, which leads to activation of the PKA and, subsequently, of cAMP
responsive element binding protein 1 (CREB1) and activating transcription factor 1 (ATF-1)- 
dependent transcription of CFTR (McDonald et al. 1995; Pittman et al. 1995; Matthews and 
McKnight 1996). The endogenous CFTR protein is only expressed at the apical membranes of 
well-differentiated epithelial cells (Puchelle et al. 1992). The targeting of CFTR to the apical PM 
appears to be tightly linked to the process of epithelial differentiation and polarisation (Hollande et 
al. 1998).
The CFTR gene is translated into a large integral membrane glycoprotein and the N- 
terminus is inserted into the ER membrane co-translationally (Lu et al. 1998). Generally, the co- 
translational insertion of integral membrane secretory proteins involves the ER-membrane- 
localised translocation machinery complex (Shao and Hegde 2011). Although the structures and 
functions of many members of this complex are poorly understood and their roles in translocation 
or membrane insertion are essentially unexplored, the components of the complex are known and 
they include the heterotrimeric Sec61 complex, the ribosome, and the accessory proteins, such as 
TRAP, TRAM, RAMP4, Sec62, Sec 63 and pi 80 (Shao and Hegde 2011). In association with the 
translocation machinery, the ribosome correctly inserts the transmembrane domains and the ER 
luminal domains via polypeptide chain elongation (Fedorov and Baldwin 1997).
The translation of the CFTR protein is estimated to be completed in about 9 min (Ward and 
Kopito 1994). During the translation of CFTR on the ribosome, the insertion to the ER membrane 
takes place by combining the translocation mechanism of the signal and stop transfer signals 
(Skach 2000). The NBD1 folds largely co-translationally, but the native structure of NBD2 and the 
full channel is attained post-translationally (Du et al. 2005; Kleizen et al. 2005; Lukacs and 
Verkman 2012). Furthermore, the formation of the complete functional channel requires 
interactions between the two MSDs (Ostedgaard et al. 1997). CFTR folding appears to be 
inefficient in many heterologous expression systems, where only 20% to 40% of nascent 
synthesised wtCFTR polypeptide chains attain the terminal native conformation and a functional 
channel (Lukacs and Verkman 2012). However, in endogenous cells this is reported to be highly 
efficient, where nearly 100% of the nascent polypeptides attained the native confirmation and reach 
the PM (Varga et al. 2004). On the contrary, AF508CFTR is almost completely absent on the PM 
due to its misfolding, and ER retention and degradation (Amaral 2005).
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The CFTR has a large portion exposed on the cytosolic side, and the folding is known to 
involve both cytosolic and ER luminal chaperones and ER membrane proteins (Yang et al. 1993; 
Pind et al. 1994; Meacham et al. 2001). The chaperones that can influence the significant folding of 
the cytosolic sub-domains are members of the Hsp family, Hsp/Hsc70, Hsp90 and the co­
chaperones STIP1, AHSA1 (Ahal), and Hsp40 proteins; Hdjl and Hjd2, and JB1 (Yang et al. 
1993; Strickland et al. 1997; Meacham et al. 1999; Farinha et al. 2002; Koulov et al. 2010; Grove 
et al. 2011). From the luminal side, there are calreticulin, calnexin and ERp29 (Pind et al. 1994; 
Chanoux and Rubenstein 2012).
The Hsp70 family of proteins have been shown to reversibly bind nascent, unfolded, or 
partially unfolded proteins in an ATP-dependent manner, and to prevent inappropriate interactions 
and facilitate protein folding (Gething and Sambrook 1992). The Hsp70 family chaperones are -70  
kDa proteins, and when they are bound to ATP they can open the substrate-binding pocket for non­
native polypeptides (Mayer and Bukau 2005). Hsp70 ATPase activity is known to be regulated by 
interacting proteins, called co-chaperones (Cyr et al. 1992). Hsc70, Hdjl and Hdj2 interact with 
CFTR immediately following insertion of MSD1 (Meacham et al. 1999). The HSP70-Hdj2 
interaction with CFTR is high with the expression of the CFTR N-terminal and cytoplasmic sub- 
domains, but it is reduced when MSD2 is translated, which suggests the importance of Hdj2 
activity in the folding of the CFTR sub-domains (Meacham et al. 1999). Importantly, the Hsc70- 
Hdj2 association with AF508CFTR is stronger than that with wtCFTR and functions to prevent 
aggregation and to promote CFTR folding (Meacham et al. 1999). AF508CFTR might be 
aggregation prone and might expose the structure to Hsc70-Hdj2 molecular chaperone system 
similar to a wtCFTR translation intermediate (Meacham et al. 1999). Overexpression of Hsp70 
cannot alter wtCFTR or AF508CFTR turnover; however, Hdj-1 (Hsp40) and Hsp70 co­
overexpression led to the stabilisation of wtCFTR, but not of AF508CFTR, without any apparent 
alteration in the efficiency of maturation (Farinha et al. 2002).
The Hsp90 family of proteins are -90 kDa cytosolic proteins that assist in the folding of
nascent CFTR, their inhibition blocks CFTR maturation and increases CFTR degradation (Loo et
al. 1998). Hsp90 interacts with Hsp70 via the Hsp organiser protein (HOP) (also known as Stress
induced phosphoprotein 1-STIP1) (Chen and Smith 1998), to form a multi-chaperone complex that
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might allow the transfer of substrates between the chaperones, most likely from Hsp70 to Hsp90 
(Prodromou et al. 1999). HOP can link the nascent protein and the Hsp40/ Hsc70 complex to 
Hsp90 in the ADP state and later the co-chaperone regulator p23 in the presence of ATP, which 
displaces Hsc-Hsp40/70 and HOP, to form the protein-Hsp90-p23 complex in the ATP-bound state 
(Wang et al. 2006). Ahal or AHSA1, an Hsp90 ATPase regulator, has also been shown to 
contribute to the folding of CFTR, and depleting Ahal can also lead to partial rescue of 
AF508CFTR at the PM (Wang et al. 2006). Co-immunoprecipitation followed by mass 
spectrometry determination of both wtCFTR and AF508CFTR interactors have defined many 
proteins that bind to either wtCFTR or AF508CFTR (Wang et al. 2006). While some of the 
AF508CFTR and wtCFTR interactors are common to these two proteins, there are a significant 
number of proteins that are specific to each (Wang et al. 2006). One such interacting chaperone is 
Hspl05, which was later on found to be important in the folding and biogenesis of AF508CFTR, 
and overexpression of Hspl05 led to increase in folding of AF508CFTR, which then reached the 
PM (Saxena et al. 2012).
On the ER luminal side, calnexin is an ER transmembrane lectin with chaperone activity 
that was demonstrated to interact with newly synthesised and immature forms of both wtCFTR and 
AF508CFTR (Pind et al. 1994). Calnexin-AF508CFTR complexes were shown to last longer than 
for wtCFTR (Pind et al. 1994); moreover, calnexin overexpression led to the destabilisation of only 
immature AF508CFTR, and not of wtCFTR (Farinha and Amaral 2005). In the ER, CFTR is core 
glycosylated at Asn894 and Asn900, which forms an immature form of the protein (band B). This 
glycosylation is used to assess the folding by the lectin/ chaperone calnexin, and the defect at this 
stage can be recognised, with the resulting proteins subjected to degradation through the 
mannosidase (EDEMl,2,3)-driven ER-associated degradation (ERAD) pathway (Olivari and 
Molinari 2007) wtCFTR, but not AF508CFTR, appears to undergo EDEM1-dependent ERAD 
(Farinha and Amaral 2005). Core glycosylation has an important influence on CFTR folding and 
stability, as it enhanced the folding efficiency by chaperone-dependent and chaperone-independent 
mechanisms (Glozman et al. 2009). CFTR appears to be negatively regulated by calreticulin, as 
CFTR expression and function are enhanced by depletion of calreticulin in both cultured cells and
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mouse models (Harada et al. 2006; Harada et al. 2007). Another luminal chaperone, ERp29, has 
been demonstrated to promote biogenesis of both AF508CFTR and wtCFTR (Suaud et al. 2011).
At the end of the folding process, CFTR attains the domain assembly to form a functional 
channel. When assembled correctly, intracellular loop (ICL) 2 interacts with NBD2, ICL4 interacts 
with NBDl, and ICLs 1 and 3 interact with both NBD1 and NBD2 (Patrick and Thomas 2012). 
Importantly, the F508 position in NBDl is predicted to lie near the interface between NBDl and 
ICL4. The F508 residue interfaces with the coupling helix of cytoplasmic ICL4 and ICL1 in MSD2 
and MSD1, respectively (Lukacs and Verkman 2012). These NBD and ICL interactions serve to 
transmit ATP-dependent conformational changes involved in the chloride channel gating, and also 
appear to have a crucial role in CFTR biogenesis (Lukacs and Verkman 2012).
1.6. Trafficking o f CFTR
Once CFTR is folded, assembled and core glycosylated, it exits the ER in a COPII 
dependent manner (Yoo et al. 2002; Wang et al. 2004). COPII consists of the Sari GTPase, the 
cargo-selection protein complex Sec23 (a Sari-specific guanine-nucleotide-activating protein), the 
cargo-binding Sec24, and a coat polymer assembly factor, Sec 13/31 (Antonny and Schekman 
2001). The GTPase Sari is recruited and activated by the ER-localised transmembrane protein 
Sec 12, a Sari-specific guanine nucleotide exchange factor. Sari activation is necessary for 
recruitment of the Sec23/24 complex to the ER membrane, to select the cargo and initiate COPII 
coat assembly. CFTR exit from the ER has been shown to be dependent on Sari (Yoo et al. 2002); 
moreover, wtCFTR has been demonstrated to bind to Sec24, and AF508CFTR binding to Sec24 
was reduced (Wang et al. 2004). This binding to Sec24 was dependent on the di-acidic motif 
present on CFTR (YKDAD; residues 563 to 567) (Wang et al. 2004). Studies using CFTR 
expressed in Saccharomyces cerevisiae have demonstrated that COPII regulates the delivery of 
wtCFTR to the ERAD pathway (Fu and Sztul 2003). Immunoelectron microscopic studies have 
indicated that there is a limited amount of wtCFTR and no AF508CFTR in the Golgi and complex 
and other anterograde compartments (Bannykh et al. 2000). There are also studies that have 
reported AF508CFTR in the ER-Golgi intermediate compartment (ERGIC) in CF cells (Gilbert et 
al. 1998). So there is a proposed retention and retrieval mechanisms (i.e., selective anterograde and
retrograde trafficking) that might exert the quality control of CFTR in the early secretory 
compartments (Amaral 2004).
CFTR passes through the Golgi complex, where it is processed by multiple Golgi 
glycosyltransferases, to create the fully mature form of CFTR (band C) (Farinha et al. 2013). 
However, the glycosylation does not alter the channel function, although it was very important for 
the stability of the protein after its ER exit (Morris et al. 1993; Chang et al. 2008). Indeed, the 
complex glycosylation in the Golgi is used as a measure of the extent of conformational maturation 
and ER export of CFTR (Chang et al. 2008). Fully glycosylated CFTR exits the Golgi complex 
using post-Golgi carriers that transport it to the PM (Amaral and Farinha 2013).
The functional pool of CFTR is maintained on the PM by its continuous recycling from 
early endosomes to the PM using Rabll and Myo5b-driven recycling endosomes (Swiatecka- 
Urban et al. 2007; Silvis et al. 2009). The trafficking of CFTR from the PM to early endosomes is 
controlled by Rab5 (Gentzsch et al. 2004). Rab4 and Rab27a might help CFTR in the restraining of 
its localisation to intracellular compartments, and thus limiting the channel expression at the PM 
(Saxena and Kaur 2006; Saxena et al. 2006). CFTR was demonstrated to co-distribute with annexin 
V, which affects the functional localisation of CFTR at the PM (Trouve et al. 2007), probably due 
to a scaffolding function of annexin V (Faria et al. 2011). More recently, pleiotropic casein kinase 
2 (CK2) was demonstrated to interact and phosphorylate CFTR, which has positive influences on 
the trafficking of wtCFTR, whereas CK2 inhibition leads to decrease in the PM CFTR levels (Luz 
et al. 2011); however, the relevant mechanism of the CK2 phosphorylation that regulates the 
trafficking has not been defined.
Although recycling is considered as the main mechanism for sustaining a functional pool of 
CFTR at the PM, up to 50% of the surface CFTR has been demonstrated to exist in an immobile 
pool, using its PDZ interactions (Haggie et al. 2006). NHERF-1 has an important function in the 
targeting of endosome-associated CFTR to the apical membranes, and the anchoring of CFTR at 
the PM to the apical actin cytoskeleton using ezrin (Short et al. 1998; Swiatecka-Urban et al. 2002; 
Haggie et al. 2006). N-WASP inhibition and actin cytoskeleton disruption led to a sharp decrease 
in the surface CFTR pool, highlighting the role of the actin cytoskeleton in the CFTR recycling and
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immobilisation at the PM (Ganeshan et al. 2007). WASP proteins are known to promote actin 
polymerisation in response to signalling molecules like the Rho family of small GTPases (Benesch 
et al. 2005). One such Rho family of small GTPases, protein TC10 (a member of the Cdc42 
subfamily) increases CFTR levels at the cell surface; moreover, activated TC10 promotes the 
binding of NHERF-1 to the C-terminus of CFTR, and reduces CFTR degradation, preventing its 
binding to CFTR associated ligand (CAL) (Cheng et al. 2005; Wolde et al. 2007).
At the TGN level, the PDZ protein CAL facilitates the trafficking of CFTR to lysosomes, 
which is prevented by NHERF-1 overexpression (Cheng et al. 2004; Cheng et al. 2005; Wolde et 
al. 2007). Overexpression of NHERF1 also promotes the apical expression of the AF508CFTR 
mutant channel, and rescues chloride secretion in bronchial epithelial cell lines (Guerra et al. 2005). 
In contrast, NHERF1 depletion enhances the degradation of temperature-rescued AF508CFTR 
from the PM (Kwon et al. 2007). The effect of NHERF-1 overexpression on CFTR might be 
dependent on the activation of Racl signalling, to promote ezrin-mediated PM anchoring of CFTR, 
and RhoA stimulation to favour CFTR recycling to the PM (Moniz et al. 2013). The CFTR 
movement to late endosomes and lysosomes, away from recycling endosomes, is regulated by 
Rab7, whereas Rab9 mediates transport from late endosomes back to the trans-Golgi (Gentzsch et 
al. 2004).
CFTR has also been demonstrated to use unconventional transport to the PM. CFTR was 
not detected in the central region of Golgi cistemae (Bannykh et al. 2000), moreover it was 
insensitive to blocking of the conventional ER-to-Golgi trafficking pathway by Arfl, Rabla/Rab2 
GTPases, and syntaxin 5 (Yoo et al. 2002). There was a block in CFTR maturation that was 
dependent on syntaxin 13 function, which indicates the importance of Golgi-to-endosome recycling 
for CFTR maturation (Yoo et al. 2002). Later on, CFTR was also identified in a novel 
compartment, known as the intermediate compartment, on its way to the PM (Marie et al. 2009). 
When conventional ER-to-Golgi transport is blocked by syntaxin 5 overexpression, Sari- and Arf- 
dominant negative mutants, CFTR and AF508CFTR can reach the PM in its core-glycosylated 
form, unconventionally, using PDZ interactions with GRASP55 (Gee et al. 2011).
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L  7. Degradation o f CFTR
Around 70% of wtCFTR and nearly all of AF508CFTR cannot fold (Ward and Kopito 1994), and 
so fails the ER quality control (ERQC), and is retained in the ER and to be subsequently degraded 
by the proteasome (Cheng et al. 1990; Yang et al. 1993; Lukacs et al. 1994; Ward and Kopito 
1994; Ward et al. 1995). CFTR degradation was not affected by the treatment of lysosomal 
degradation inhibitors (Lukacs et al. 1994), but proteasome inhibitors lead to the accumulation of 
CFTR (Ward et al. 1995). Thus, CFTR was proposed as a substrate of ERAD and the proteasome.
Nascent wtCFTR and AF508CFTR are selected for proteasomal degradation with the 
assistance of the molecular chaperones. The ER membrane resident E3 ubiquitin ligase RMA1 or 
RNF5 in association with Derlin-1 and the E2 ubiquitin ligase Ubc6e promotes the ubiquitination 
of wtCFTR or AF508CFTR (Younger et al. 2006). RMA1 has a critical role in the selection of 
AF508CFTR for premature degradation, and RMA1 depletion leads to the partial rescue of the 
CFTR protein at the PM. RMA1 interacts with the transmembrane quality control component 
Derlin-1, and knock-down of Derlin-1 enhances the cell-surface expression of AF508CFTR (Sun et 
al. 2006). Over-expression of Derlin-1 promotes ER retention and proteasomal degradation of 
wtCFTR and AF508CFTR, through the complexes it forms with MSD1 of CFTR (Sun et al. 2006; 
Younger et al. 2006). Later on, DNAJB12 (JB12), which is an Hsp-40, was demonstrated to act 
with Hsc70 and RMA1 to facilitate proteasomal degradation of wtCFTR and AF508CFTR. JB12 
forms a complex that contains RMA1 and Derlin-1, which increases JB12 levels, and enhances the 
association of Hsc70 and RMA1 with immature forms of CFTR (Grove et al. 2011). Depletion of 
JB12 increased the folding efficiency of CFTR and led to the partial escape of AF508CFTR from 
the ER (Grove et al. 2011). Hsc70 down-regulation by the drug matrine increased protein levels of 
AF508CFTR, and promoted its localisation to the PM (Basile et al. 2012).
Additionally, CHIP is an E3 ubiquitin ligase that interacts with Hsc70 and Hsp70, to form 
a quality control machine that uses the polypeptide-binding activity of Hsc70 to target misfolded 
CFTR for proteasomal degradation (Meacham et al. 2001). The selection mechanism of CFTR for 
degradation by the RMA1 machinery and the CHIP complex are not entirely clear (Grove et al.
2011). However, RMA1 has been demonstrated to act early, to coincide with translation to
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recognize folding defects in CFTR that involve the misfolding and defective assembly of NBDl 
into a complex with the R-domain, while the CHIP E3 (Figure 1.7a) might act post-translationally 
to recognize misfolded regions of CFTR, which include NBD2 (Younger et al. 2006; Rosser et al. 
2008). HspBPland BAG2 co-chaperones have been shown to inhibit CHIP ubiquitin ligase 
activity, to promote maturation of the CFTR (Alberti et al. 2004; Arndt et al. 2005). FKBP8 is a co­
chaperone that is involved in modulating the activity of the core Hsp70 and Hsp90 proteins, and it 
also demonstrates an important function in folding and stability of both wtCFTR and AF508CFTR. 
Absence of FKBP8 promotes more degradation of both of the proteins, whereas overexpression of 
FKBP8 leads to partial rescue of AF508CFTR to the mature form (Hutt et al. 2012). Ubiquitinated 
CFTR is usually translocated and delivered to the proteasome, which involves Gp78 (Morito et al. 
2008), Sec61, BAP31 (Wang et al. 2008) and p97 (Dalai et al. 2004).
Gp78 has also been shown to facilitate the degradation of AF508CFTR by enhancing both 
its ubiquitination and its interaction with p97/VCP, and the silencing of gp78 leads to the 
stabilisation of AF508CFTR, preventing its degradation (Ballar et al. 2010). Valosin-containing 
protein (VCP)/p97 and gp78 have been shown to form complexes with CFTR, and interference in 
the VCP-CFTR complex using shRNA to VCP promoted the accumulation of immature CFTR in 
the ER and the partial rescue of functional chloride channels at the PM (Vij et al. 2006). Gp78 has 
been shown to assist ubiquitin chain extension, whereas UCH-L1, Uspl9, Usp25 stabilise the 
AF508CFTR nascent chain by catalysing ubiquitin cleavage (Hassink et al. 2009; Henderson et al. 
2010; Blount et al. 2012). BAP31 or BCAP31 an endoplasmic reticulum protein-sorting factor was 
also found to associate with the N-terminus of newly synthesised AF508CFTR, to promote its 
retrotranslocation from the ER (Wang et al. 2008). Depletion of BAP31 reduced the proteasomal 
degradation of AF508CFTR, and partial amounts also reached the PM. The cytosolic E3 ubiquitin 
ligases Nedd4-2 and Fbsl have also been implicated in the ERAD of AF508CFTR (Yoshida et al. 
2002; Caohuy et al. 2009). Many other proteins, like UBE4A, ERDJ5, XTP3-B, UBXD2, and 
others, have been shown to contribute to the degradation of AF508CFTR (Christianson et al. 2012) 
although the mechanism is still unknown. AF508CFTR over expression and proteasomal inhibition 
leads to the formation of aggresomes (Johnston et al. 1998) which indicates the tendency of 
misfolded proteins to aggregate if they are not degraded by the proteasome. In yeast, this
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Figure 1.7. The models of AF508CFTR degradation.
a. ER associated degradation, b. Peripheral quality control from the plasma-membrane.
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aggregated CFTR was shown to be degraded by autophagy (Fu and Sztul 2009). Either rapamycin 
treatment or serum starving BHK cells stably expressing CFTR led to decreased levels of total 
AF508CFTR but not of wtCFTR (Kaushal 2006). Rapamycin and serum starvation are known to 
induce autophagy in various cells, although there is no strong evidence for CFTR or AF508CFTR 
degradation by autophagy.
Even though AF508CFTR can be rescued at the PM, it was highly unstable and degraded at 
a faster rate (Okiyoneda et al. 2010). The rapid degradation of AF508CFTR is dependent on 
ubiquitination similar to that of several other conformationally defective PM proteins (Okiyoneda 
et al. 2011). CHIP and gp78 ubiquitin ligases were responsible for the removal of rescued 
AF508CFTR from the PM (Okiyoneda et al. 2010). This process required Hsc70 and Hsp90 a 
subset of co-chaperones, as DNAJ1 (Hdj2), Bagl, HOP and Ahal, for rapid ubiquitin-dependent 
endocytosis and lysosomal degradation (Figure 1.7b). The lysosomal delivery of rescued 
AF508CFTR from endosomal recycling was dependent on the endosomal sorting complex 
ESCRT0-III (Sharma et al. 2004; Okiyoneda et al. 2010). Degradation of wtCFTR can be regulated 
by a multifunctional protein, c-Cbl, which acts as an adaptor protein to facilitate CFTR endocytosis 
by a ubiquitin-independent mechanism, and also to ubiquitinate CFTR in the early endosomes, and 
thereby facilitate the lysosomal degradation of CFTR (Ye et al. 2010). It was also demonstrated 
that activation of the deubiquitinating UsplO enzyme stabilises wtCFTR by facilitating its recycling 
(Bomberger et al. 2009). CFTR at the PM interacted with COMMD1, which appears to protect it 
from ubiquitination and to sustain its surface expression (Flattau et al. 2011).
1.8. Therapies for cystic fibrosis
There has been a tremendous effort to find therapies for cystic fibrosis; first, to treat the 
pathogenic mechanisms of CF as a disease, and secondly, to correct the underlying basic defects 
responsible for CFTR loss-of-fimction. In the early 1950s, at the CF centre in Cleveland, USA, 
Matthews and co-workers established three pillars of treatment: nutritional repletion, relief of 
airway obstruction, and antibiotic therapy of the lung infection, which in a few years improved 
survival and quality of life without the knowledge of the basic CF defect (Davis 2006). Indeed, 
85% of these patients with CF showed pancreatic insufficiency at birth, and the others gradually
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lost this function over time, with pancreatic enzyme supplements administered to prevent some of 
the malnutrition. Later, in the 1980s, more sophisticated methods were developed to administer 
pancreatic enzymes. Calorie-dense oral supplements to enteral feedings were adapted to overcome 
the malnutrition (Davis 2006). Another severe problem in CF is the plugging of airways with thick 
and sticky airway secretions, and clearance of these secretions assumed a prominent role in therapy 
early in the history of the disease (Davis 2006). Postural drainage and clapping (the “ketchup- 
bottle” method), and other mechanical devices have been used as effective methods to clear the 
thick and sticky airway secretions. DNA-cleaving agents were also demonstrated to reduce the 
viscosity of airway secretions (Davis 2006). Administration of hypertonic saline aerosols resulted 
in a modest increase in pulmonary function through the temporary hydration and clearing o f airway 
secretions (Wark and McDonald 2003). Since the optimal strategies of therapy have not been 
established, culture-specific antibiotics have been a mainstay of CF therapy for many years. More 
antibiotic aerosol formulations are currently being developed specifically for CF patients with 
Pseudomonas, and other bacterial infections. Inflammation is elevated in the CF patients and its 
pharmacological suppression reduced the pulmonary destruction in the healthy patients with CF. 
However, even after these many interventions, many patients face the threat of respiratory failure 
that requires lung transplantation to survive. According to the CF Foundation data registry, there 
are more than 100 patients with CF who receive lung transplantation every year. This leads to the 
survival of about 80% at the 1-year mark, and 50% by 4 years, so this is not yet a perfect therapy 
(Davis 2006). Further refinements of conventional care continue to drive the median survival age 
upwards. Children with CF have to take multiple pills and aerosols daily, eat extra food, exercise 
vigorously, while incurring medical costs upwards of $25,000 a year (Davis 2006).
Since the discovery of the gene responsible for CF, gene therapy has been explored
(Rosenecker et al. 2006), although in the few trials to date, no clinical benefit has been recorded
(Griesenbach and Alton 2011). The underlying mutations resulting in CF are being uncovered since
the discovery of the gene, and the recent focus has been towards new and better pharmacotherapies
directed at either the pathogenic mechanisms or the correction of CFTR loss-of-function. Another
method is to by-pass defective CFTR using alternative chloride channels. Some efforts have been
undertaken to activate the alternative TMEM16 chloride channel (Namkung et al. 2011). There are
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several other identified candidates for alternative anion conductance, and the relevant 
pharmacological candidates to activate and potentiate these are in consideration (Lubamba et al. 
2012).
Class I mutations with a premature stop codon can be treated with gentamicin, which 
induces the read through of stop codons, and this has been shown to be beneficial in patients with 
CF (Clancy et al. 2001). Another drug, Ataluren, which acts in a similar manner, has also been 
shown to be beneficial in a phase II clinical trial for patients with CF (Kerem et al. 2008). If proved 
further, these drugs may offer a therapeutic option to a very limited number of patients with CF, as 
class I mutations are highly prevalent only in Israel, while seen in the rest of the population at only 
about 5%. Relatively rare class III mutations, which reduce the PKA-dependent open probability of 
the CFTR channel, can be treated with compounds that enhance ATP-dependent channel gating 
once CFTR has been activated by PKA-dependent phosphorylation (potentiators)(Sheppard 2011). 
Classic class III and the third most common (2%-3%) mutation G551D can be treated with 
ivacaftor or VX770, to potentiate chloride transport in epithelial cells expressing G551D CFTR 
(Van Goor et al. 2009). The less common class V and VI mutations affect mRNA and CFTR 
stability, and hence treatment for increasing mRNA and maximal activation of the normal CFTR, 
such as 4-phenylbutyrate, milrinone or genistein combinations, might prove useful (Lubamba et al. 
2012).
On the other hand, the major CF causing mutation, AF508, accounts for about 70% of 
cases, and so this is the major area where therapeutic efforts have been focused more recently. This 
is one of the class II mutations; they need drugs that increase the transport of the channel to the 
PM. AF508CFTR poses more challenges because of its multiple level problems; namely, defective 
channel activity, rapid degradation from the PM, and defective recycling. Therefore, an ideal drug 
for this mutation should increase the surface expression, gating, surface stability and recycling of 
AF508CFTR. People with CFTR gene mutations that produce only 10% of the normal levels of 
CFTR at the functional level due to reduced mRNA levels have no lung and pancreatic 
complications, although they do show the congenital bilateral absence of the vas deferens 
(Anguiano et al. 1992). These observations lead to the belief that the rescue of about 10% of the
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AF508CFTR protein might be sufficient to reduce the pathophysiological complications in patients 
with CF. Although there is varied estimates of the amount of AF508-CFTR rescue believed to 
ameliorate the decline of lung function in CF patients ranging from 5-30% of wt-CFTR (Van Goor 
et al. 2006). There are many proposed drugs that allowed a certain amount of AF508CFTR to 
traffic to the PM in different cells and that can rescue partial chloride conductance, these are 
termed correctors, while some compounds have been reported to increase the chloride channel open 
probability (potentiators).
The temperature-sensitive nature of the AF508 mutant has led to trials of chemical 
chaperones like glycerol (Brown et al. 1996), to induce the “rescue”, or to restore the functional 
channel at the PM, at least partially. However, the concentrations that need to be used in patients 
might be toxic (Gelman and Kopito 2002). Studies with chemical chaperones (Brown et al. 1996) 
and on the temperature-sensitive folding (Denning et al. 1992) have suggested that modification of 
the cellular environment that favour the folding of the proteins might help AF508CFTR to fold and 
to reach the cell surface, and to function as a channel that might ultimately rescue the CF 
phenotype.
There have been great efforts to understand the molecular basis of AF508CFTR 
dysfunction and the difference in the quality control components compared to wtCFTR, on the 
basis that, this might lead at some stage to better therapies. These efforts have put forward the 
protein quality control systems and the folding and degradation machinery activity for AF508CFTR 
as complementary approaches to rescue the functional channel. It has been demonstrated that 
inhibitors of histone deacetylases, like 4-phenylbutyrate (Rubenstein et al. 1997), suberoylanilide 
hydroxamic acid (SAHA), and trichostatin A (TSA) (Hutt et al. 2010), and inhibitors of Hsc70 
(Cho et al. 2011) can partially rescue AF508CFTR. Miglustat has also been shown to rescue 
AF508CFTR in different CF models, including mice with suspected disruption of calnexin and 
AF508CFTR (Lubamba et al. 2009; Norez et al. 2009). Miglustat is undergoing a clinical trial for 
CF caused by the AF508 mutation (Leonard et al. 2012). Simultaneously, there have also been 
searches for possible correctors and potentiators using the available large-scale chemical and drug 
libraries using high-throughput screening (Pedemonte et al. 2005; Van Goor et al. 2006; Carlile et
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al. 2007; Robert et al. 2010). There was also a reported computational model-based screening 
approach that yielded several corrector compounds (Sampson et al. 2011).
As a result of these screening efforts, several compounds and drugs have been identified, 
namely Corr4a, VRT325, VRT422, chlorzoxazone, glafenine, sildenafil, and others, that appear to 
increase the trafficking of AF508CFTR to the PM, whereas VRT532 increases the gating of 
AF508CFTR. Vertex Pharmaceuticals has further developed a corrector, VX-809, which increases 
the stability and folding of AF508CFTR and can establish about 15% of the channel activity at the 
cell surface in primary CF cells, compared to non-CF cells (Van Goor et al. 2009). VX-809 
underwent a clinical trial, but it was found to be ineffective (Clancy et al. 2012), and now VX-809 
in combination with ivacaftor are undergoing a trial to induce effective channel activity of 
AF508CFTR at the cell surface. Current efforts to identify correctors, which have been based 
largely on phenotype screens, have not been successful in identifying highly efficient molecules 
(Lukacs and Verkman 2012). A recent discoveries has demonstrated that multiple defects, 
including AF508-NBD1 energetic and the NBD1-MSD2 interface stabilization are required for 
wild-type-like folding, processing and transport function of AF508CFTR, correction of either 
individual process is only partially effective. (Mendoza et al. 2012; Rabeh et al. 2012). Thus, with 
the exception of the symptomatic therapy, there still remains no therapy for the basic defect in CF 
caused by the AF508 mutation, and thus this remains an urgent need.
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1.9 Hypothesis and aim of the study.
There have been as many as many as 90 corrector molecules reported to date. Each one of 
these drugs shows very low efficacy, and moreover, except very few, the modes of action of these 
corrector molecules are yet to be identified (Riordan 2008; Sheppard 2011; Lukacs and Verkman
2012). They have been shown to correct the trafficking of AF508CFTR with the help of cell-based 
high-throughput screening. A few of these molecules, like Corr4a, VX-809, VRT325, have been 
shown to directly bind to AF508CFTR (Wang et al. 2007; Ren et al. 2013) and to help in its folding 
and trafficking, whereas other molecules, such as thapsigargin, curcumin (Wang et al. 2007), TSA, 
SAHA, A3, Cl, FI (Hutt et al. 2010; Calamini et al. 2012) might not contribute to folding and 
trafficking of AF508CFTR through direct interactions. Instead, these molecules might modulate the 
proteostasis network, which, in turn, might contribute to the correct positioning of AF508CFTR at 
the cell surface. Correct folding, trafficking and restoration of function are proposed to be achieved 
through several mechanisms. First, there appears to be a direct energetic stabilisation of the protein 
through its folding upon use of therapeutics, generally referred to as pharmacological chaperones 
(pharmacochaperones) (Balch et al. 2011) exemplified by Corr4a and VX-809, which rescue the 
AF508CFTR trafficking to the PM (called correctors). A few pharmacochaperones can just increase 
the gating of AF508CFTR, like VX770 or ivacaftor (called potentiators) (Balch et al. 2011). There 
are very few molecules which have both CFTR corrector and CFTR potentiator actions, or dual­
acting molecules, despite the intensive efforts to develop such molecules (Sheppard 2011). 
Secondly, an alternative to the pharmacochaperones, there is a another approach to achieve the 
folding and trafficking, using proteostasis regulators (Balch et al. 2011).
The general belief is that defects in protein conformation like AF508CFTR can be rescued 
by: (i) stabilising protein folding with pharmacochaperones that bind directly; and/or (ii) enhancing 
the protein folding efficiency of the cells using proteostasis regulators (Lukacs and Verkman 2012). 
It is also possible that a combination of the various classes of pharmacochaperones (correctors, 
potentiators) and proteostasis regulators might act synergistically. Recently it has been shown that a 
proteostasis regulator molecule cystamine combined with the pharmacochaperone potentiator 
VX770 synergised in the restoration of the channel function (Luciani et al. 2012). A few studies 
have also shown that addition of combinations of different correctors can provide additive effects
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(Wang et al. 2007; Okiyoneda et al. 2013). Combinations of corrector drugs targeting NBD1- 
MAD2 interface (like VX-809) and NBD1-NBD2/ NBD2-MSD1/2 interface targeting drugs (like 
Corr4a) with pharmacochaperones (like glycerol) led to enhanced AF508-CFTR plasma membrane 
expression to ~60-l 10% that of the wild type in BHK cells (Okiyoneda et al. 2013).
It has been proposed that the proteostasis network is constituted by about a thousand 
contributing components (Balch et al. 2011). These include the Hsp/Hsc70 and Hsp90 chaperone 
systems, the normal activities of which are regulated by numerous signalling pathways that sense 
folding and metabolic stress, as well as the UPR, the HSR, calcium sensing, and inflammatory 
pathways (Balch et al. 2011). The proteostasis network is also complemented by the components of 
the ubiquitin sumoylation proteasome system in the cytosol, and the lysosomal and autophagic 
degradation pathways, which are also sensitive to multiple stress pathways. CFTR folding requires 
extensive support from the proteostasis network, moreover, wtCFTR and AF508CFTR appear to 
interact with the proteostasis network differentially (Wang et al. 2006), and modulation of the 
proteostasis network function might contribute significantly to the treatment of CF (Balch et al.
2011). It has been proposed that efforts to identify CF drugs through biological analyses of the 
proteostasis network function might strongly support the possibility to find the compounds that 
alter the folding proteostasis network of AF508CFTR, which might have great potential for the 
generation of a more wild-type-like function, and hence, might have significant benefit in the clinic 
(Balch et al. 2011). Many of the reported drugs do not have a known mechanism of action for the 
rescue, and many among them might act as proteostasis regulators that target the proteostasis 
network, which might be responsible for the rescue of AF508CFTR.
Even though with lower efficacies, all of these drugs are doing one thing in common, they 
allow the partial trafficking of AF508CFTR to the PM. Apart from this, the majority of drugs are 
not known to bind directly to AF508CFTR; moreover, a few of them, like TSA and SAHA, have 
been proposed as proteostasis regulators (Hutt et al. 2010). The proteostasis regulators might 
change the proteostasis network component or its regulators through transcription (Hutt et al. 
2010); moreover, depletion of proteostasis network components like Ahal or RMA1 partially 
restores functionality of AF508CFTR in CF models. So targeting the proteostasis network and 
related components might yield better candidates to be targeted than by drugs. It has also been
25
shown that expression of AF508CFTR leads to the UPR and further activation of ATF6, and 
depletion of ATF6 can partially rescue the AF508 to the cell surface (Kerbiriou et al. 2007). A 
recent study showed that ATF6 controls the proteostasis network (Shoulders et al. 2013). It might 
be a logical argument that ATF6-controlled proteostasis network components are helping in the 
degradation; on the other hand, ATF6 depletion might decrease the proteostasis network 
components, which results in a decrease in the ERAD and an increase in the trafficking of 
AF508CFTR. Although CFTR has been well studied and many proteostasis network components 
are known, it is still not clear how AF508CFTR is retained and degraded by the ERAD; moreover, 
the regulation of these proteostasis network components is completely unknown.
The many previously discovered AF508CFTR corrector drugs might be proteostasis 
regulators. The assumption that needed to be tested was whether most of these reported drugs 
commonly affect some gene network/ pathway by modulating gene expression, such as those 
including the known proteostasis network genes and those proteostasis network genes that are yet 
to be determined, or by modulating proteostasis network regulators. In other words, the hypothesis 
was to look at the mechanism of action of drugs that can help rescue AF508CFTR to the cell 
surface. This is possible, as drug induced changes in gene expression can be easily and reliably 
detected using microarray or gene expression profiling, and moreover, the gene expression profiles 
of many corrector drugs are available (Lamb et al. 2006; Zhang et al. 2012). So the aim of the 
project was as follows:
a) Determination of the genes that are commonly regulated among most of the available gene 
expression profiles of corrector drugs.
b) Accessing the commonly regulated genes to dissect out the networks/ pathways/ molecules that 
are involved in the rescue of AF508CFTR to the cell surface, using a systems biology approach 
and a literature-based survey.
c) Testing the networks/ pathways/ molecules found as described earlier and specifically targeting 
those using genetic tools or new drugs, to confirm their involvement in the rescue of 
AF508CFTR to the cell surface.
d) Testing the efficacy of the combinations of different pathways/ networks/ molecules found to be 
effective for the rescue of AF508CFTR.
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Chapter 2
Mechanism of action common to most of the drugs affects the 
proteostasis of AF508CFTR. 
Introduction
It has become more common in recent times to use genome-wide gene expression studies to 
infer drug mechanisms of action (Lamb et al. 2006; Iorio et al. 2009). It has been proposed that 
monitoring of genome-wide gene expression is likely to reveal insights into the actions of drugs 
and the prediction of additional drug targets (Iskar et al. 2010). The drug-induced gene expression 
has been used to assign new functions to existing drugs using systems-biology-based drug 
repositioning (Iorio et al. 2010). Using this method, the Rho-kinase inhibitor Fasudil that was used 
for treatment of cerebral vasospasm (Tanaka et al. 2005) was shown to act as an enhancer of 
cellular autophagy (Iorio et al. 2010). A study using genome-wide gene expression of breast 
cancer, myelogenous leukemia and prostate cancer and anti-correlating these with the drug-induced 
genome-wide gene expression (comparing the most up-regulated genes in the cancer tissue against 
the most down-regulated genes by the each drug treatment) was able to predict drugs for these 
cancers. This study was able to reposition four FDA-approved cancer drugs that are in use, and 22 
FDA-approved drugs that were in clinical trials for the treatment of these cancers (Shigemizu et al.
2012). The study of the mechanism of action of the antiulcer drug cimetidine by gene expression 
concluded that the gene expression changes are almost opposite to that of lung adenocarcinoma 
gene expression, this observation has led to use of cimetidine as a candidate therapeutic in the 
treatment of lung adenocarcinoma (Sirota et al. 2011).
The investigation of mechanism by the studying the gene expression have also been 
successfully used for diseases like cancer, where the gene expression from different cancers are 
used to infer the common mechanism among the many types of cancer tissue (Rhodes et al. 2002; 
Iskar et al. 2010). Comparisons of large numbers of microarrays from different cancer samples 
showed that there are commonly regulated genes among all of these different cancer samples that 
might drive neoplastic transformation and progression, and also suggested that there might be
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common molecular mechanisms by which cancer cells progress and avoid differentiation (Rhodes 
et al. 2004). More recently, dissecting out drug mechanisms of action using drug-induced gene 
expression led to the discovery of HSF1 as an important mediator o f malignancy, and its inhibition 
was shown to reduce tumours (Santagata et al. 2013). So, in principle, genome-wide gene- 
expression profiles can be used to predict the mechanisms of action of drugs. So, it might be logical 
to use genome-wide gene-expression methods to define the mechanisms of action of AF508CFTR 
corrector drugs.
Among the numerous (~90) drugs that have been shown to be correctors of AF508CFTR, 
gene-expression profiles of the 23 drugs were available, but their mechanisms of action were 
unclear. As described earlier in the section 1.9, many of these drugs might be affecting the 
proteostasis network indirectly, but rather than acting as pharmacochaperones. Although gene- 
expression profiles of the few known pharmacochaperones were available, they were not 
considered for the present analysis. It was decided to analyse gene-expression-based mechanisms 
of action of the drugs that might act by regulating the proteostasis network of AF508CFTR. Using 
the global gene-expression profiles, common pathways/ networks/ genes affected by most of the 
drugs were identified and the involvement of many of these pathways/ networks/ genes in 
proteostasis and the correction of AF508CFTR was confirmed. The targeting of different pathways 
simultaneously, or the addition of pharmacochaperones, was additive or synergistic, and rescued 
AF508CFTR more efficiently than previously reported.
Results
2.1. Corrector drugs induce transcriptional changes for the rescue o f AF508CFTR
There are several corrector compounds that allow AF508CFTR to overcome the ERQC and
reach the PM (Pedemonte et al. 2005; Van Goor et al. 2006; Carlile et al. 2007; Hutt et al. 2010;
Zhang et al. 2012). These drugs might act by direct binding, thereby promoting AF508CFTR
folding/ trafficking, or they might act by modulation of the proteostasis network of the cell, which
includes the ERQC, to allow the rescue of AF508CFTR. The known binders of AF508CFTR, like
Corr4a and RDR1 (Wang et al. 2007; Sampson et al. 2011) were not included here, and 24
probable proteostasis modulators were chosen for this analysis, as listed in Table 2.1a. There were
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no apparent chemical similarities among these modulators, nor any similarities in the characterised 
targets. If the drugs had any transcriptional action which is responsible for the correction then the 
correction must be suppressed by inhibiting the transcription. So simultaneously the drugs and 
transcription inhibitor actinomycin D was treated to the cells. It was noted that the effects of many 
corrector drugs on AF508CFTR were sensitive to actinomycin D (Figure 2.1), which suggested that 
the correctors have a transcriptional component in their mode of action. It was decided to correlate 
the mechanisms of action of these drugs on the proteostasis network, through an analysis of their 
effects on cellular gene expression profiles (the gene signature), which included both 
transcriptional and post-transcriptional (mRNA stability) effects.
Specifically, the gene signatures of two sets of drugs were used. The first set was made up 
of 11 correctors for which the gene signatures were available as Prototype Ranked Lists, as 
published by Iorio et al 2010. These were based on the drug gene signature database created using 
the Affymetrix platform (www.broadinstitute.org/cMap) (hereafter referred to as the cMap dataset; 
see Table 2.1a). The second set was made up of 13 correctors for which the gene signatures were 
obtained using the Agilent platform through treating immortalised CF bronchial epithelial 
(CFBE41o' cells stably transfected with AF508CFTR [a widely accepted cellular model for CF 
(Bebok et al. 2005)]) for 24 hours (hereafter referred to as the CFBE dataset; Table 2.1a). The 
CFBE dataset gene signature was obtained through the Thomas Laboratory in the Department of 
Biochemistry, McGill University, Montreal, Canada, in a collaboration with our Laboratory, and a 
part of these microarray data has already been published (Zhang et al. 2012). The microarray data 
from the CFBE cells were then processed to obtain ranked lists (see section 6.18). Glafenine was 
common between the cMap and CFBE datasets, and when probed using the database 
(www.broadinstitute.org/cMap). there was a significant similarity between the glafenine profiles 
found in both of the datasets (Table 2.1b), although glafenine was not one the top hits based on 
similarity. Nevertheless, the profiles of 13 corrector drugs obtained in the CFBE cell lines and 
those of the 11 drugs obtained from the cMap database were analysed separately.
2.2. Meta-analysis of the gene signatures to obtain commonly regulated genes
To extract information about the commonly regulated genes from gene signatures, a fuzzy
intersection analysis of the microarray data was used, which was similar to methods published
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Figure 2.1. Corrector drugs act through transcription.
a. HeLa cells expressing AF508CFTR-3HA were treated with the drugs alone or with lOpg/ml 
actinomycin-D for 6 hours, lysed and proteins were immunobloted for CFTR. b. The levels of band 
B were quantified from immunoblots (like a, n=3) and expressed as fold change compared to 
control (DMSO treatment). Data represent mean ± SD. The Corr-4a and VRT325 (not known to act 
by transcriptional changes) were used as controls.
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Table 2.1a. The corrector drugs used for the analysis of the gene signatures.
The CFBE dataset microarray obtained from treating drugs to the CFBE cells for 24 hour, the 
cMap dataset was made up of correctors for which the gene signatures were obtained from Iorio et 
al. 2010. The low temperature treatment was used as a positive control for correction in the CFBE 
dataset. The reference indicate the source where the corrector was originally identified.
Drugs of the CFBE dataset Drugs of the cMap dataset
4-AN, PARP1 inhibitor (Anjos et al. 2012) 
ABT888 (Anjos et al. 2012)
Glafenine (Robert et al. 2010)
GSK339 (D Y Tomas lab unpublished) 
Ibuprofen (Robert et al. 2010)
JFD03094 (Robert et al. 2008)
KM11060 (Robert et al. 2008)
Latonduine (Carlile et al. 2012)
Minocycline H (D Y Tomas lab unpublished) 
Ouabagenin (Zhang et al. 2012)
Ouabain (Zhang et al. 2012)
PJ34(Anjos et al. 2012)
Chloramphenicol (Carlile et al. 2007) 
Chlorzoxazone (Carlile et al. 2007) 
Dexamethasone (Caohuy et al. 2009) 
Doxorubicin (Maitra et al. 2001) 
Glafenine (Robert et al. 2010) 
Liothyronine (Carlile et al. 2007) 
MS-275 (Hutt et al. 2010)
Scriptaid (Hutt et al. 2010) 
Strophanthidin (Carlile et al. 2007) 
Thapsigargin (Egan et al. 2002) 
Trichostatin-A (Hutt et al. 2010)
Positive control
Low temperature (Denning et al. 1992)
Table 2.1b. Glafenine has similar effects on the CFBE with cMap dataset.
Top 200 and Bottom 200 ranked genes from CFBE cells treated with glafenine were queried with 
the cMap (http://www.broadinstitute.Org/cMan/l database to infer the similarity between the two 
gene expression profiles.
cMap Name Enrichment (similarity score) p-Value
quinostatin 0.993 0.00004
emetine 0.815 0.00223
sulfafurazole 0.812 0.00058
dequalinium chloride 0.785 0.0041
glafenine 0.761 0.00615
fluspirilene 0.752 0.00726
simvastatin 0.744 0.00806
cephaeline 0.724 0.00368
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earlier (Rhodes et al. 2002; Rhodes et al. 2004; Ramasamy et al. 2008; Clarke et al. 2013). This 
was based on the hypothesis that the rescue effect that is common to all of these drugs would be 
associated with common gene expression changes that are induced by most or all of these drugs. 
Keeping the cMap and CFBE gene-signature datasets independent, the down-regulated and up- 
regulated gene probes were intersected separately to obtain the probes that were commonly 
regulated by the correctors. To do this, the fuzzy intersection algorithm (Iorio et al. 2010) was used 
with a series of cut-offs, starting from a cut-off number the same as the number of drugs in each 
dataset (see section 6.18). The number of microarray probes present in the intersection increased 
sharply as the fuzzy intersection cut-off was decreased. For instance, in the case of the cMap 
dataset, 24 probes were commonly down-regulated when the fuzzy cut-off was set to 9; i.e., a probe 
commonly down-regulated by at least 9 out of the 11 drugs. This increased to 108 when the fuzzy 
cut-off was reduced to 8. The expected number of probes to be obtained by such an intersection of 
random drug profiles was also calculated and compared to the specific corrector drug profiles in 
each dataset (Figure 2.2a-h).
This fuzzy analysis yielded several sets of genes that were statistically significant both for 
the up-regulated and down-regulated probes of the CFBE dataset, and the down-regulated probes of 
the cMap dataset. There was no statistically significant gene sets obtained from the intersection of 
up-regulated probes from the cMap dataset. Even a very low fuzzy intersection cut-off of 5 yielded 
statistically significant numbers of probes in the intersections (Figure 2.2a-h). Moreover, at such 
low cut-offs, the enrichment over the randomly obtained probes was comparatively very low being 
false positives more than 50%). Even though statistically significant, at a cut-off of 5, the cMap 
down dataset has 2,687 probes, although 1,903 probes might have come up just at random, whereas 
the CFBE-down dataset had 7,093 probes, out of which 4,064 might have occurred at random 
(Figure 2.2a, c, e, g). Moreover, the hypothesis was to look at genes that are common to most of 
the drugs. So an optimal cut-off point for the fuzzy intersection was set to 8 in the case of the cMap 
dataset, and 9 in the case of the CFBE dataset, where the random probes (false positives) were 
below 30%. Moreover, the probes obtained from the intersection at cut-offs of 8 and 9 for cMap 
and CFBE, respectively, were also the optimal cut-offs where some biological functions by gene 
ontology were enriched. This enrichment might mean that at this cut-off it is more likely that a
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Figure 2.2. Summary of the intersection of the probes at the different cut-offs.
(a, b, c, d) Percentage of the probes in specific and random drugs of each down-regulated or up- 
regulated gene set, as indicated above the figure, (e, f, g, h) The respective number of probes in 
each gene set, as tables.
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Table 2.2a. CFBE -Up regulated genes.
The commonly up-regulated genes at a cut off of 9 (genes up-regulated in any 9 drugs out of 13 
CFBE data set) were computed using the fuzzy algorithm.
ABCA12 C14orfl47 CRNKL1 F fflL l KCND2
ABCG1 C14orf49 CTDSP2 FNBP1L KCNJ2
ACPL2 C18orfl8 CUL3 FOXOl KCNMB4
ACPP C1D CXCL10 FRAS1 KDM3A
ACYP1 C1GALT1C1 CYBRD1 FSIP1 KIAA0182
ADAM28 C20orf3 CYP4B1 G3BP2 KIAA1033
AHI1 C20orf30 DIDOl GABARAPL2 KIAA1107
AKAP9 C3orfl4 DNAJA1 GBP2 KIAA1370
AKD1 C4orf34 DPY19L2 GEMIN8P4 KIF1B
ALOX5 C5orf53 DRAM2 GK KL
ALS2CR8 C6orf35 DSC3 GNA13 KLF12
AMOT C9orf44 DTX4 GNAQ KLHL24
ANKRA2 C9orf68 DUOX2 GNPTAB KTN1
ANXA4 CAND1 ECEL1P2 GPR110 KYNU
ARAP2 CASC2 ECT2 GRAMD1C LAMTOR3
ARFGAP3 CCDC113 EFCAB7 GTF2I LAPTM4A
ARID5B CCDC121 EIF3H H2AFJ LCA5
ARMCX1 CCDC126 EIF4E HBP1 LGALS3
ARMCX3 CCDC148 ELF2 HCG26 LGALS8
ARRDC3 CCDC57 ENTPD4 HNRNPR LGR6
ATG5 CCNT2 EP300 HOOK1 LHX9
ATP6V1C2 CCPG1 EPM2AIP1 HPSE LM07
ATP7A CD 109 ERLIN2 HS2ST1 LNX1
AUH CDC37L1 ETV1 HS3ST5 LOCI 00129794
BACH1 CDC73 ETV5 HSPA4 LOCI 00169752
BACH2 CEACAM1 ETV7 IBTK LOC100287803
BANK1 CEP44 EVI5 IFIH1 LOCI 00505930
BAZ2A CH25H FAM122C IGFL2 LOC100505956
BBS12 CHD7 FAM131B IL20RA LOCI00506012
BBS2 CIITA FAM150A IMMP2L LOCI 00506046
BCL2L11 CISD2 FAM171B INPP5D LOCI 00506262
BCL6 CLCA2 FAM18B1 INTU LOC100506398
BDH2 CLDN16 FAM198B ITFG1 LOCI 0050653 8
BET1 CLIC4 FAM47E ITIH5 LOCI 00507197
BLNK CLIC5 FAM59A IVNS1ABP LOCI 00507398
BRWD1 CLK1 FAM65B JRKL LOCI 00507524
Cllorf54 CNGA1 FAM84A KAT6B LOC220594
C12orf23 COL20A1 FANCM KATNAL2 LOC286161
C12orf26 COL21A1 FAS KBTBD2 LOC401098
C12orf48 CPEB3 FASTKD1 KBTBD3 LOC401320
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Table 2.2a. CFBE -Up regulated genes (continued).
LOC541467 PAFAH1B1 RASEF STK31 WDR33
LOC541473 PAIP2 RBI STK38L WDR78
LOC728978 PAIP2B RBAK STON1 WNT8B
LPIN2 PAPOLG RBBP4 STX11 XRN1
LRP1B PBX1 RBMXL1 SUV420H1 YIPF5
LUC7L3 PCDH7 REV3L SYNP02 YPEL1
LZTFL1 PCDHB10 RFPL2 TBX20 YPEL2
MAFB PCDHB18 RFX3 TET2 YPEL5
MARCKS PCMTD1 RIC3 TFRC ZBED5
MAT2B PCMTD2 RRM2B THAP2 ZBTB26
MBD2 PDCD2 SAT1 TIGD7 ZBTB38
MBD5 PDE4B SCAF8 TLL1 ZC3H11A
MCEE PDE4D SDR16C5 TLR1 ZFAND6
MCM9 PDE5A SEC62 TLR3 ZFPM2
METTL7A PDGFD SEL1L TLR6 ZNF10
MEX3B PDK4 SEPSECS TMEM106B ZNF184
MFSD4 PFKFB2 SERTAD4 TMEM123 ZNF214
MIA3 PHC3 SGSM1 TMEM18 ZNF217
MLF1 PIK3C2G SHPRH TMEM20 ZNF230
MLLT4 PDC3C3 SIRT4 TMEM237 ZNF233
MME PITX2 SLAIN2 TMEM39A ZNF323
MMP13 PIWIL4 SLC11A2 TMEM59 ZNF404
MMP7 PLEKHA7 SLC15A2 TMEM86A ZNF449
MRE11A PLRG1 SLC16A7 TNFRSF11A ZNF483
MRPL50 PLSCR4 SLC19A2 TNNT2 ZNF525
MXRA5 PPIE SLC1A3 TP53INP1 ZNF546
MY06 PPIL6 SLC25A27 TRAK2 ZNF571
N4BP2L1 PPM1D SLC35A1 TRIM22 ZNF577
N4BP2L2 PPP1CB SLFN12 TSPAN12 ZNF586
NBR1 PPP6C SLFN13 TSPAN2 ZNF606
NEK1 PPT1 SMARCA5 TSPAN6 ZNF613
NIPBL PRPF4B SMPDL3A TTC23L ZNF649
NLGN4X PSD2 SNX16 TTC28-AS1 ZNF780A
NOTCH2NL PTPLAD2 SOS2 TTC30A ZNF850
NPNT PTPN4 SPATA18 TTC33
NR1D2 PTPRR SPATA19 TUB
NUDCD1 PXDNL SPDYE1 UBE2D1
NUP62CL QPCT SPDYE5 USP25
OK/SW-CL.58 RAD21 SPG20 UST
OPRK1 RALGPS1 SRSF1 VTCN1
OR2L13 RAPGEF2 STEAP4 WDR17
OXGR1 RAPGEF5 STIM2 WDR19
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Table 2.2b. CFBE and cMap down regulated genes.
The commonly down-regulated genes of CFBE drugs at cut-off 9 and cMap drugs at cut-off 8 
(genes down-regulated in any 9 drugs of CFBE data set or any 8 drugs of cMap data set) were 
computed using the fuzzy algorithm.
CFBE-Down regulated genes cMap-Down regulated genes
ABCG5 GJC3 OSMR AKAP1 GTSE1 SLC25A6
ADAMTS19 GNB4 PALMD AKAP8 HMGXB4 SLC4A1AP
ADAMTS9 GRIN2B PCP4 ANKLE2 HPS4 SMCR7L
ALPK1 GSC PDE11A ARID 1A HYAL3 SNAPC4
ARHGEF25 GYG2 PDE3A ASB8 JRK STAG2
ATN1 HLA-DRB4 PDZD7 C10orf26 KIF20A TAX1BP3
ATP13A4 HNF4G PIF1 Cllorf61 LMF1 TBC1D13
BASP1 HYDIN PLIN5 C14orfl06 LMNB1 TDP1
B1N2 IL25 POLR3D CAMKK2 MAP3K11 TMEM115
C14orfl62 ILDR1 PXN CCDC59 MED1 TMEM121
C16orf45 INO80B RAX2 CD2BP2 MED 13 TOP3A
C7orf69 IVL REGIB CENPA MEPCE TROAP
CAPN6 KRT34 RGL3 CENPE METTL3 UNKL
CISD3 LAIR1 RNF215 CHPF2 MK167 VPS72
CLDN17 LCN15 S100A2 COIL MPPE1 WDR6
COL14A1 LIMS3 S100A7 COMMD4 MRFAP1L1 WDR74
CRCT1 LOCI 00132234 SAGE1 COMMD9 MYB WTAP
CTSC LOCI 00505915 SHC3 CTDSP1 NCAPH2 XYLT2
DCD LOCI 00506328 SLC22A3 DGCR8 NOL3 YWHAH
DCLK1 LOCI 00510044 SLC47A1 DHX30 NR2F2 ZC3H3
DLL3 LOC388796 SOSTDC1 DHX38 NSUN5P2 ZCCHC10
DNALI1 LOC729059 SPRR1A DICER1 NUP50 ZNF443
DPCR1 LRRC31 SPRR1B DNAJC2 ORC1L
EFHD2 MAL ZFP36L2 DSN1 PAQR4
EHD1 MATN2 SPRR3 EHMT2 PATZ1
EPB41L4A MBL2 SULT1C2 ENDOG PDCD6
ERBB4 MDGA1 TCEB3C EXOSC4 PPAP2B
EVI2B METTL21A TCTN1 FAM111A PRPF4B
FAM101B METTL7A TECRL FAM120A PRPF8
FAM131C MGC10814 TEP1 FAM128B RAB17
FAM49B MIR210HG TLN2 FARSA RABIF
FAM83A MITF TMPRSS1 FBX07 RBM7
FANCD2 MRPL24 5 FOSL1 RGS19
FCRL4 NCRNA00319 UBOX5 GATAD1 SAFB
FERMT1 NOG VHL GEMIN4 SAP30L
FGFBP1 NPRL3 VNN1 GLT8D1 SART1
FLJ45340 NUDT22 VPS13D GNPTAB SC02
FLNB ODF3L2 ZAP70 GPATCH1 SENP6
FOXK1 ONECUT1 GPRC5C SETDB1
FUT6 OR8J1 GTF3C4 SH2B1
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particular associated biological function can be affected by many of these drugs commonly, and 
that this common process might be somehow relevant to AF508CFTR correction. So with both the 
“biological criterion” and the “statistical criterion” the cut-off was set to 8 for the cMap down- 
regulated probe set and to 9 for the CFBE up-regulated and down-regulated probe set.
For the CFBE dataset, these fuzzy intersections resulted in 541 up-regulated probes 
(corresponding to 402 genes, hereafter referred to as CFBE-Up) (Figure 2.2d) and 191 down- 
regulated probes (corresponding to 117 genes, hereafter referred to as CFBE-Down) (Figure 2.2c). 
For the cMap dataset, there were 108 down-regulated probes (corresponding to 102 genes, 
hereafter referred to as cMap -Down) (Figure 2.2a). Statistical analyses revealed that close to 7 
probes were obtained at random in the CFBE dataset, and that in the case of the cMap -Down 
dataset, this was close to 30 probes (Figure 2.2e). The cMap -Up dataset did not show significant 
probes at the selected cut-off (Figure 2.2b, f). It should be noted here that the statistical tests with 
the CFBE datasets yielded a relatively low number of randomly obtained probes due to the 
statistical method used (see section 6.18). Three genes were present in both the up-regulated and 
down-regulated gene sets (considering CFBE and cMap together). This might be caused by the 
disagreement between the two or more probes for the same gene, and also due to the distinct 
platforms used (Agilent vs Affymetrix); nevertheless, this is very low compared to the total number 
of genes obtained (close to 600) (Table 2.2a, 2.2b).
To summarise, three sets of genes were collected: CFBE-Up, as 402 genes; CFBE-Down, as 
117 genes; and cMap -Down, as 102 genes, and these are called the commonly regulated genes 
(Table 2.2a, 2.2b). These intersected common sets of up-regulated or down-regulated genes of the 
microarray profiles of the corrector drugs will lead to the identification of a common pathway(s) 
targeted by most of these corrector drugs. However, as the drugs or a subset of the drugs might also 
target specific idiosyncratic pathways other than the common ones, the results obtained from the 
above-described analyses might be limiting.
2.3. Analyses of commonly regulated genes to obtain commonly regulated pathways/ networks
The commonly regulated genes obtained were then analysed using a series of bio-informatic
tools to extract the commonly regulated molecular pathways/ networks that were embedded in the
gene lists. The gene ontology enriched biological processes were analysed in the different
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commonly regulated gene lists. The biological processes that had the false discovery rate (FDR) 
below 5 were considered for the analysis. The cMap -Down dataset was enriched in mitotic or cell- 
cycle and mRNA processing machineries, CFBE-Down was enriched in keratinocyte 
differentiation processes, while the CFBE-Up was enriched, in transcriptional processes (Figure 
2.3). As the numbers of commonly regulated genes were relatively low, a manual inspection of the 
list was carried out to look for genes/ proteins involved in processes that were shown to be 
involved in AF508CFTR proteostasis or others like regulatory proteins (kinases and phosphatases), 
ubiquitin pathway components, and chaperones. There were several kinases, phosphatases and 
other associated proteins present in the commonly regulated gene list. From a literature analysis of 
the accumulated knowledge about these proteins, an observation that stands out is that many 
proteins that are modulated affect the stress-activated MAPK pathway (p38 and JNK).
Specifically there were a few proteins in the CFBE-Up dataset that are known negative 
regulators of the SAPK pathway, including INPP5D (An et al. 2005), PPM ID (Hickson et al. 
2007), PPP6C (Kajino et al. 2006) and PTPRR (Su et al. 2013), while among the down-regulated 
proteins there were FLNB, an adaptor involved in promoting JNK signalling (Jeon et al. 2008), and 
MAP3K11 (also known as MAP3K11), an upstream activator of JNK signalling (Brancho et al. 
2005). Among the ubiquitin pathway components as described earlier, USP25, a deubiquitinase 
involved in the regulation of AF508CFTR proteostasis (Blount et al. 2012) is up-regulated, and so 
is an E2 ubiquitin ligase UBE2D1 (UbcH5a), which is involved in the ERAD of AF508CFTR 
(Younger et al. 2006). Among the chaperones, surprisingly, not many were modulated by the 
corrector drugs. The most important was HSP70 (HSPA4), which has been shown to rescue 
AF508CFTR when overexpressed (Trzcinska-Daneluti et al. 2009), and is present in the CFBE-Up 
dataset, along with DNAJA1, which is known to increase the degradation of AF508CFTR 
(Okiyoneda et al. 2010).
To gain further insight, the datasets were then analysed for various biologically relevant 
characteristics, including protein-protein interactions, ingenuity pathway building analysis, and also 
manual inspection, to identify interesting CFTR proteostasis-relevant molecules in the dataset. The 
results of these analyses are summarised below.
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Figure 2.3. Gene ontology enrichment in the commonly regulated gene lists.
The p-Values were plotted for each of the enriched biological processes (false discovery rate 
bellow 5) computed using DAVID (http://david.abcc.ncifcrf.gov/) gene ontology for each indicated 
gene set.
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2.4. Commonly regulated genes form macromolecular interaction complexes
STRING database identifies protein-protein interactions among the commonly regulated 
genes:
To analyse the protein-protein interactions (PPIs) among the commonly regulated genes, 
the STRING database was used (http://string-db.orgA (Franceschini et al. 2013). Among the total 
of 618 proteins (all of the commonly regulated proteins combined) that were provided as input (see 
section 6.18), significant interactions based on a cut-off score of >0.7, were seen between 166 
proteins, with a total of 166 interactions among them (Figure 2.4a). Upon manual inspection of the 
network, sub-networks relating to the components of the centromere/ kinetochore/ cohesin, RNA 
processing machinery, transcription factors, phosphodiesterases, collagen and keratinocyte 
differentiation markers were found. In addition, several genes from both the up-regulated and 
down-regulated datasets interacted among themselves, suggesting that similar pathways are 
targeted by both up-regulated and down-regulated genes, mainly in the network of the RNA 
processing machinery and phosphodiesterases. For one of the phosphodiesterases present in the 
network, PDE3A (present in the cMap -Down dataset), its inhibition is known to promote CFTR- 
mediated chloride conductance (Penmatsa et al. 2010).
Ingenuity pathway analysis identifies embedded commonly regulated pathways/ networks 
among commonly regulated genes:
To dissect the pathways/ networks from the identified commonly regulated genes 
Ingenuity Pathway analysis (IPA), a well-characterised pathway-building tool (web-based software 
application) was also used (http://www.ingenuitv.com/products/ipa) (see section 5.20). IP A is 
based on prior published knowledge and has been used extensively by the scientific community to 
analyse large datasets, to understand the biological mechanisms embedded in them. The commonly 
regulated gene sets were analysed using the core analysis application of IPA (hereafter referred to 
as IPACA). IPACA helps to assess the enrichment for canonical signaling/ metabolic pathways, 
builds molecular networks with the dataset of interest, and also identifies upstream regulators of the 
given gene set.
When the CFBE-Up, CFBE-Down and cMap-Down commonly regulated genes were 
analysed together using the IPACA application, this identified 7 upstream regulators, among which
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Figure 2.4a. String network of the commonly regulated genes.
The protein-protein interaction among the commonly regulated genes were derived from the String 
database ('http://string-db.org/). The interaction network with at least four proteins are presented. 
Nodes O CFBE-Down, © cMAP-Down, •  CFBE-Up.
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5 were predicted to be activated and 2 were inhibited in the commonly regulated gene sets (Table 
2.4a). Among the activated category there was SLC29A1, a nucleoside transporter, colony 
stimulating factor (CSF2), STAT4, oncosuppressor p73 (TP73), and interferon regulatory factor-1 
(IRF-1), while in the inhibited category there were TAB1 and miR-155. TAB1 binds to TAK1 and 
is involved in the TGF-p signalling pathway, while miR-155 has been shown to be up-regulated in 
lung epithelial cells of CF patients, and has been linked to the hyper-inflammatory phenotype of CF 
(Bhattacharyya et al. 2011). This analysis also identified canonical pathways in which the 
commonly regulated genes were enriched, which included chondroitin/ dermatan sulphate 
biosynthesis, PKA signalling, ERK/MAPK signalling, p53 signalling, p-cell receptor signalling, 
GPCR signalling, integrin signalling, signalling via pattem-recognition receptors, prostate cancer 
signaling, and hereditary breast cancer signalling (Table 2.4b).
Analysis of IPACA also yielded 25 networks that consisted of 35 nodes each. It is important 
to note here that IPA builds networks not only with the genes provided, but it also predicts potential 
interacting nodes to build the networks. The networks with close to two-thirds of the nodes 
included from the list of commonly regulated genes were considered for further analysis. This 
resulted in 8 networks (Figure 2.4.b) with the number of nodes taken from commonly regulated 
genes varying from 22-30, out of the 35 nodes in each network. The top functions associated with 
these networks included several developmental disorders, the cell cycle, DNA recombination/ 
repair, RNA post-transcriptional modifications, cell death and survival, lipid metabolism, and 
infectious diseases (Table 2.4c, Figure 2.4.b). RNA processing was also found earlier by gene 
ontology analysis. Then 117 down-regulated, 402 up-regulated genes of the CFBE dataset and 102 
cMap down-regulated genes were subjected to IPACA analysis separately to test whether these 
datasets particularly affect some other specific pathways or functional networks other than the 
common (CFBE-Up, CFBE-Down and cMap -Down commonly regulated genes analysed together) 
pathways or network functions, as described above. The resulting canonical pathways and networks 
with associated functions are summarised in Table 2.4d, e, f  and Figure 2.4c, d, e. No dataset had 
any significantly inhibited or activated upstream regulators. The CFBE-Up dataset yielded 40 top 
canonical pathways affected, which included p53 signalling, PDGF signalling, insulin receptor 
signalling, p-cell receptor signalling and others, and also yielded 22 networks; interestingly, two

Table 2.4. IPACA o f the commonly regulated genes.
CFBE-Up, CFBE-Down and cMap-Down commonly regulated gene sets analysed using IPACA. a. 
Upstream regulators, b. Identified enriched canonical pathways, c. Top 8 networks, and their 
associated scores and functions.
a
Upstream
regulator
Molecule type Predicted 
activation state
p value
TAB1
mir-155
SLC29A1
CSF2
STAT4
TP73
IRF1
ST ATI
TP53
Enzyme
MiRNA
Transporter
Cytokine
Transcription regulator 
Transcription regulator 
Transcription regulator 
Transcription regulator 
Transcription regulator
Inhibited
Inhibited
Activated
Activated
Activated
Activated
Activated
Activated
Activated
9.65E-04
2.30E-02
1.93E-03
2.73E-03
9.27E-03
1.46E-02
2.79E-02
5.22E-02
6.41E-02
b
Ingenuity canonical pathways -log(p value)
tRNA splicing 3.51E00
Cardiac p-adrenergic signalling 2.97E00
p53 signalling 2.96E00
Relaxin signalling 2.89E00
Chondroitin sulphate biosynthesis 2.47E00
Dermatan sulphate biosynthesis 2.39E00
Protein kinase A signalling 2.36E00
cAMP-mediated signalling 2.1E00
ERK/MAPK signalling 1.83E00
c
Network Score Top diseases and functions
1 46 Developmental disorders, hereditary disorders, neurological diseases
2 39 Infectious diseases, cardiovascular diseases, dermatological diseases 
and conditions
3 37 Organ morphology, skeletal and muscular system development and 
function, connective tissue disorders
4 36 Cell cycle, cellular assembly and organisation, DNA replication, 
recombination and repair
5 30 Cell death and survival, connective tissue development and function, 
RNA post-transcriptional modification
6 29 Lipid metabolism, small molecule biochemistry, infectious diseases
7 29 Post-translational modification, lipid metabolism, molecular transport
8 28 Gene expression, RNA damage and repair, RNA post-transcriptional 
modification
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Figure 2.4b. IPACA networks of the commonly regulated genes.
1-4 Networks of CFBE-Up, CFBE-Down and cMap-Down commonly regulated genes analysed 
together using IPACA. The networks contain Green nodes which are down-regulated genes; red 
nodes which are up-regulated genes and white nodes which are IPACA genes.
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Figure 2.4b. IPACA networks of the commonly regulated genes (continued).
5-8 Networks of CFBE-Up, CFBE-Down and cMap-Down commonly regulated genes analysed 
together using IPACA. The networks contain Green nodes which are down-regulated genes; red 
nodes which are up-regulated genes and white nodes which are IPACA genes.
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networks have one of their top associated functions as “molecular transport” although information 
about the specific kind of molecular transport these networks may be associated was not clear. 
There were also other network-associated functions, like the cell cycle, and DNA replication, 
recombination, and repair, among others. The CFBE-Down dataset yielded 7 canonical pathways, 
which included regulation of cellular mechanics by calpain protease, FAK signalling, tRNA 
splicing, nNOS signalling, relaxin signalling and cardiac p-adrenergic receptor signalling. The 
CFBE-Down dataset also yielded only 6 significant networks that are associated with functions like 
cellular movement, connective tissue development and function, embryonic development, cell 
morphology, haematological system development and function, gene expression, cell death and 
survival, cell cycle, and others. The cMap-Down dataset again yielded 7 canonical pathways, 
which included granzyme B signalling, systemic lupus erythematosus signalling, cardiac p- 
adrenergic receptor signalling, chondroitin sulphate biosynthesis, chondroitin and dermatan 
biosynthesis, dermatan sulphate biosynthesis, glycoaminoglycan-protein linkage region 
biosynthesis, and ERK5 signalling, and also yielded 6 significant networks that are associated with 
functions like cell signalling, gene expression, the cell cycle, DNA replication, recombination, and 
repair, and lipid metabolism.
To summarise, the IP A analysis identified many processes present in the commonly 
regulated genes that were identified earlier, reiterating the possible importance of these pathways in 
the regulation of CFTR proteostasis. This analysis also identified several other pathways, including 
molecular transport, lipid metabolism, integrin signalling and GPCR signaling, as potential 
proteostatic regulators. Apparently these networks or canonical pathways excluded previously 
validated AF508CFTR proteostasis genes (Table 2.5), this may mean that the commonly regulated 
genes are novel regulators of AF508CFTR proteostasis which need further validation. Moreover, 
networks of the commonly regulated genes when analysed particularly yielded connections 
between the many commonly regulated genes and few regulatory kinases and transcription factors. 
The kinases included AKT, CK2, ERK1, ERK2, MAPK, and MEKs, transcription factors HNF4A, 
TP53, and NF-kB, the cytokine TGFJ31, the growth factor VEGF, which were connected to many 
commonly regulated genes. These genes may regulate the many commonly regulated genes, and 
they are also important candidates to be tested for their roles towards AF508CFTR proteostasis.
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Table 2.4d. IPACA o f the cM ap-Down genes.
The cMap-Down gene sets analysed using IPACA. 1. Identified enriched canonical pathways. 2. 
Networks with associated scores and functions.
Ingenuity canonical pathways -log(p value)
Granzyme B signalling 
Systemic lupus erythematosus signalling 
Cardiac p-adrenergic signalling 
Chondroitin sulphate biosynthesis 
Chondroitin and dermatan biosynthesis 
Dermatan sulphate biosynthesis 
Glycoaminoglycan-protein linkage region 
biosynthesis 
ERK5 signalling
2.59E00
1.68E00
1.61E00
1.58E00
1.55E00
1.55E00
1.48E00
1.44E00
2
Network Score Top functions
1 53 Cell signalling, cell cycle, gene expression
2 30 Cellular assembly and organization, DNA 
replication, recombination and repair, cell cycle
3 27 Cellular function and maintenance, cardiovascular 
system development and function, dermatological 
diseases and conditions
4 23 Dermatological diseases and conditions, 
developmental disorders, hereditary disorder
5 22 Metabolic disease, lipid metabolism, small molecule 
biochemistry
6 16 Developmental disorders, skeletal and muscular 
disorders, molecular transport
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Figure 2.4c. IPACA networks of the cMap -Down genes
1-6 Networks of cMap -Down genes analysed using IPACA. The networks contain Grey nodes 
which are cMap down-regulated genes and white nodes which are IPACA genes.
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Table 2.4e. IPACA o f the CFBE-Up genes.
CFBE-Up gene sets analysed using IPACA. 1. Identified enriched canonical pathways. 2. Networks 
with associated scores and functions
1
Ingenuity canonical pathways -log(p value)
p53 signalling
FLT3 signalling in haematopoietic progenitor cells
Prostate cancer signalling
FcyRIIB signalling in B lymphocytes
Role of pattern recognition receptors in recognition of bacteria and 
viruses
B Cell receptor signalling 
Insulin receptor signalling 
Relaxin signalling 
PDGF signalling
2.87E00
2.7E00
2.47E00
2.23E00
2.14E00
2.13E00
2.03E00
2E00
1.92E00
2
Network Score Top functions
1 52 Cellular function and maintenance, haematological system development 
and function, humoral immune response
2 31 Connective tissue development and function, embiyonic development, 
organ development
3 31 Cell cycle, cellular assembly and organization, DNA replication, 
recombination and repair
4 29 Molecular transport, cellular assembly and organisation, haematological 
disease
5 28 Infectious disease, cardiovascular diseases, dermatological diseases and 
conditions
6 23 Carbohydrate metabolism, lipid metabolism, small molecule 
biochemistry
7 21 Amino acid metabolism, nucleic acid metabolism, small molecule 
biochemistry
8 21 Molecular transport, developmental disorders, hereditary disorders
9 19 Cell-to-cell signalling and interaction, reproductive system development 
and function, cellular assembly and organisation
10 19 Hereditary disorder, metabolic disease, cell morphology
11 18 Post-translational modification, cardiac fibrosis, cardiovascular diseases
12 18 Cell morphology, cellular function and maintenance, infectious diseases
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Figure 2.4d. IPACA networks of the CFBE-Up genes.
1-6 Networks of CFBE-Up genes analysed using IPACA. The networks contain Grey nodes which 
are CFBE up-regulated genes and white nodes which are IPACA genes.
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Figure 2.4d. IPACA networks of the CFBE-Up genes (continued).
7-12 Networks of CFBE-Up genes analysed using IPACA. The networks contain Grey nodes 
which are CFBE up-regulated genes and white nodes which are IPACA genes.
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Table 2.4f. IPACA of the CFBE-Down genes.
CFBE-Down gene sets analysed using IPACA. 1. Identified enriched canonical pathways. 2. 
Networks with associated scores and functions.
1
Ingenuity canonical pathways -log(p value)
Regulation of cellular mechanics by calpain protease
FAK signalling
tRNA splicing
nNOS signalling in neurons
Glycogen biosynthesis II (from UDP-D-glucose)
Cardiac p-adrenergic signalling
Relaxin signalling
2.48E00
1.96E00
1.85E00
1.58E00
1.5E00
1.48E00
1.46E00
2
Network Score Top functions
1 36 Cellular movement, connective tissue 
development and function, embryonic 
development
2 28 Developmental disorders, hereditary disorder, 
neurological disease
3 26 Cell morphology, haematological system 
development and function, Gene expression
4 23 Cell morphology, cell death and survival, cell 
cycle
5 23 Cell death and survival, cellular compromise, 
neurological diseases
6 21 Infectious diseases, cardiovascular diseases, 
dermatological diseases and conditions
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Figure 2.4e. IPACA networks of the CFBE-Down genes.
1-6 Networks of CFBE-Down genes analysed using IPACA. The networks contain Grey nodes 
which are CFBE down-regulated genes and white nodes which are IPACA genes.
2.5. Commonly regulated genes/ networks interact with CFTR proteostasis network components
To understand if  the commonly regulated genes/networks are indeed related to regulators or 
components of CFTR proteostasis, the dataset of known CFTR proteostasis regulators was 
collected (the CFTR proteostasis network) (Table 2.5). Then the relationship between the 
commonly regulated genes and the CFTR proteostasis network were studied. The CFTR 
proteostasis network dataset that was built included known proteostatic regulators of CFTR; i.e., 
proteins for which their expression/ activity level changes have been shown to rescue AF508CFTR 
proteostasis. In spite of the presence of some CFTR proteostasis network components in the 
commonly regulated gene lists, there was no statistically significant intersection between the two 
lists. IPACA analysis of several molecular networks of the commonly regulated genes described 
was tested for any relationships with known CFTR proteostasis network genes. To this end, the 
networks were allowed to grow and connect to the CFTR proteostasis network genes. This 
demonstrated that many of the networks of commonly regulated genes had extensive connections 
with the CFTR proteostasis network components, which suggested that although many were not 
part of the CFTR proteostasis network itself, they either regulated or were regulated by CFTR 
proteostasis network components (Figure 2.5a). Using the other method, where the commonly 
regulated genes were combined with the CFTR proteostasis network and subjected to IPACA 
analysis, this demonstrated that there is also an interaction between CFTR proteostasis network 
genes and commonly regulated genes when both are analysed together (Figure 2.5b).
2.6. Commonly regulated genes/ networks control AF508CFTR proteostasis
To experimentally validate the down-regulated commonly regulated genes for their effect 
on AF508CFTR proteostasis, a biochemical assay was used (see section 6.12). The assay has been 
shown to be robust and very sensitive to small changes in the AF508CFTR proteostasis (Farinha et 
al. 2004). To monitor the effects of the drugs on AF508CFTR, CF bronchial epithelial (CFBE41o') 
cells stably expressing AF508CFTR (hereafter referred to as CFBE (Bebok et al. 2005)) were used. 
To test the commonly down-regulated genes that belong to the different gene ontology groups or 
pathways/ networks (mRNA processing, the cell cycle, MAPK pathway, and others), the analysis 
was restricted to those genes that satisfied any one of the following criteria: (i) down-regulated
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Table 2.5. CFTR-Proteostasis Network gene set.
The CFTR proteostasis genes (AF508CFTR correctors/ERAD inhibitors) were collected from 
literature. They were based on either siRNA-based knock-down or cDNA-based over-expression.
CFTR Proteostasis Network genes
siRNA-based knock-down effects Overexpression-based effects
Gene | Reference 
N E D D 4L  j (Caohuy et al. 2009)
Gene
PA R K 2
Reference
(Okiyoneda et al. 2010)
Gene
U SP10
Reference
(Bomberger et al. 2009)
AUP1 | (Christianson etal. 2012) 
DER L3 j (Christianson et al. 2012)
PPID
PPIL2
(Okiyoneda et al. 2010) j SGK1 
(Okiyoneda et al. 2010) j A N X A 2
(Caohuy et al. 2009) 
(Trzcinska-Daneluti et al. 2009)
D N A JC 10 j (Christianson et al. 2012) 
EDEM 1 } (Christianson et al. 2012)
SIAH1
STAM
(Okiyonedaetal.2010) j AP2M 1  
(Okiyoneda et al. 2010) j A Q P3
(Trzcinska-Daneluti et al. 2009) 
(Trzcinska-Daneluti et al. 2009)
ERLEC1 | (Christiansonetal.2012) 
| ESYT1 ] (Christianson et al. 2012) 
FO XRED2 ! (Christiansonetal.2012)
STIP1
STUB1
SYVN1
(Okiyonedaetal.2010) j C 20orf7  
(Okiyoneda etal. 2010) j Cav2  
(Okiyonedaetal.2010) j CCBL1
(Trzcinska-Daneluti et al. 2009) 
(Trzcinska-Daneluti et al. 2009) j 
(Trzcinska-Daneluti et al. 2009) j
H ERPUD1 i (Christianson et al. 2012) TRIP12 (Okiyonedaetal. 2010) j C C K (Trzcinska-Daneluti et al. 2009) j
K IA A 0090
NGLY1
(Christianson et al. 2012) TSG101
UBE2D3
(Okiyoneda et al. 2010) j CCL2 (Trzcinska-Daneluti et al. 2009) j
(Christianson et al. 2012) (Okiyoneda et al. 2010) CR Y A B (Trzcinska-Daneluti et al. 2009) |
PSM D2
SELS
(Christianson et al. 2012) 
(Christianson et al. 2012)
U BE2N
UBE3A
(Okiyoneda et al. 2010) 
(Okiyoneda et al. 2010)
D N A JC 10
D U SP3
(Trzcinska-Daneluti et al. 2009) j 
(Trzcinska-Daneluti et al. 2009) i
T T C 35 |  (Christianson et al. 2012) 
T XN DC16 | (Christiansonetal.2012)
UBE4B
UBE4A
(Okiyoneda et al. 2010) 
(Okiyoneda et al. 2010)
D Y D C 2 | (Trzcinska-Daneluti et al. 2009) j 
EDN1 j (Trzcinska-Daneluti et al. 2009) j
| UBA C2 | (Christianson et al. 2012) 
i UBXN4 i (Christianson etal. 2012)
AHSA1
UBE2J1
(Okiyoneda etal. 2010) j FA M 195A  j (Trzcinska-Daneluti et al. 2009) ' 
(Okiyoneda et al. 2010) j G A PD H  ! (Trzcinska-Daneluti et al. 2009) j
! VCP  
j VCPIP1 
1 DERL1
(Christianson et al. 2012) 
(Christianson et al. 2012) 
(Christianson et al. 2012)
A M FR
COPS5
BCAP31
(Okiyonedaetal.2010) ! GORASP1  
(Tanguy etal. 2008) j H SPA4  
(Wang et al. 2008), | H SPB8
(Trzcinska-Daneluti et al. 2009) j 
(Trzcinska-Daneluti et al. 2009) j 
(Trzcinska-Daneluti et al. 2009) j
j K R T18  
D N AJB12
(Davezac et al. 2004) 
(Grove et al. 2011)
RNF5 (Younger et al. 2006) j H SPBP1  
! LG ALS3
(Trzcinska-Daneluti et al. 2009) ! 
(Trzcinska-Daneluti et al. 2009) j
CALR  
| H DAC 7
(Harada et al. 2006) 
(Hutt et al. 2010)
| Park7 j (Trzcinska-Daneluti et al. 2009) I 
j PFD N 2 1 (Trzcinska-Daneluti et al. 2009) 1
j A T F6  
| SQSTM 1
(Kerbiriou et al. 2007) 
(Luciani et al. 2010)
| PPA R G  | (Trzcinska-Daneluti et al. 2009) j 
| PR G 2 | (Trzcinska-Daneluti et al. 2009) j
| BAG1 
| CDC37
(Okiyoneda et al. 2010) 
(Okiyoneda et al. 2010)
| PR K C I | (Trzcinska-Daneluti et al. 2009) ! 
i R E G 3A  | (Trzcinska-Daneluti et al. 2009) j
| DNAJA1 | (Okiyoneda et al. 2010) 
| DN AJA2 j (Okiyoneda et al. 2010)
! S100A 8 | (Trzcinska-Daneluti et al. 2009) j 
j STAT1 ! (Trzcinska-Daneluti et al. 2009) !
i D N AJA3 j (Okiyonedaetal.2010) 1 TCEB2 ! (Trzcinska-Daneluti et al. 2009)
j D N A JB 2 1 (Okiyonedaetal. 2010) 
' D N A JC 27 ! (Okiyonedaetal.2010)
! T C P10L  ] (Trzcinska-Daneluti et al. 2009) j 
| T FG  1 (Trzcinska-Daneluti et al. 2009)
DN AJC3 i (Okiyoneda et al. 2010) 
DN AJC5 j (Okiyoneda et al. 2010) ------------
i
i
TRIM 31 I (Trzcinska-Daneluti et al. 2009) 
T R N A U 1A P ! (Trzcinska-Daneluti et al. 2009) j
D N A JC 7 j (Okiyonedaetal.2010) j 
H G S I (Okiyonedaetal. 2010) j
UBXN1 1 (Trzcinska-Daneluti et al. 2009) j 
U SP19 | (Hassink etal. 2009)
H sp90A A l i (Okiyonedaetal.2010) 
H SPA8 j (Okiyonedaetal.2010) j
1 UCHL1 (Henderson etal. 2010) j 
! A nxA 5 j (Le Drevo et al. 2008)
M ARC H 2 j (Okiyonedaetal.2010) 
M ARC H 4 | (Okiyoneda et al. 2010)
1 BECN1 ] (Luciani etal. 2012) j 
j U V RAG  | (Luciani et al. 2012)
M D M 2 i (Okiyoneda et al. 2010) 1 C A N X  ! (Norez et al. 2006) j
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Figure 2.5a. IPACA predicted interactions between commonly regulated gene IPACA 
networks and CFTR proteostasis network genes.
Each of the top four IPACA network of commonly regulated genes (white nodes) has a predicted 
interaction (purple line) with many CFTR proteostasis network genes (grey nodes with purple 
border).
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Figure 2.5b. IPACA predicted interactions between CFTR proteostasis network genes and 
commonly regulated genes.
The network contains the commonly regulated genes (green) that have a predicted interaction with 
many CFTR proteostasis network genes (red).
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commonly regulated genes that belong to the enriched biological processes in gene ontology; (ii) 
part of the separate PPI network of cMap and CFBE down-regulated genes obtained from 
STRING; (iii) regulatoiy components, like kinases and transcription factors, that have connections 
to at least three commonly regulated genes in the networks from the separate IPACA of the cMap - 
Down and CFBE-Down gene sets; (iv) down-regulated commonly regulated genes that were of 
general interest because of their regulatory nature, including signalling molecules (kinases- 
phosphatases) and ubiquitination process related components.
Down-regulated genes were considered for validation instead of the up-regulated genes 
simply because of the available efficient small-interfering (si) RNA-based knock-down technology, 
whereas the optimal overexpression of genes at a large scale was limiting for validating the up- 
regulated genes. Finally, this amounted to 107 genes (Table 2.6), among which 69 were commonly 
regulated down-regulated genes (from both the CFBE-Down and cMap -Down groups), and 47 
were selected using IPACA analysis; 9 genes were common between the selected commonly 
regulated genes and the IPACA genes. The CFBE cells were treated with siRNAs targeting each of 
the 107 selected genes, and after 72 h, the effects on AF508CFTR proteostasis were monitored by 
Western blotting. A commonly regulated gene was considered a CFTR proteostasis modulator or a 
hit if  at least 2 out of the 3 siRNAs targeting the gene resulted in a significant change in the band C 
levels compared to the control siRNAs. The results of the screen are summarised in Figure 2.6 a, b. 
Among the 107 genes screened, 74 were found to be CFTR proteostasis regulators, where 32 of 
them increased the levels of band C (correctors or positive modulators) (Figure 2.6c, f), compared 
to the controls, and 42 of them decreased the levels of band C (negative modulators).
The corrector genes elevated the level of both band B and band C (Figure 2.6 f), which might 
reflect a nonspecific transport out of the ER because of the increased endoplasmic reticulum load 
of AF508CFTR. If there is a nonspecific transport then the ratio of amount of band C to band B 
would be simply proportional (Hutt et al. 2010) in control and specific gene siRNA-treated cells. It 
was tested whether the increase in band C was a consequence of a nonspecific effect or of an 
increased trafficking by calculating the ratios of bands C/B. The ratio of band C to band B has been 
be used to indicate the level of post-endoplasmic reticulum glycoforms of CFTR relative to ER 
pool (Hutt et al. 2010). Interestingly, the ratio of bands C/B was higher for most of the corrector
58
Table 2.6. Gene list for validating the effects on AF508CFTR proteostasis.
Genes shortlisted from commonly regulated (cMap-Down and CFBE-Down) genes and IPACA of 
(cMap-Down and CFBE-Down) genes for further testing their influence on the proteostasis of 
AF508CFTR.
Shortlisted Genes
Commonly down regulated genes IPACA genes
RNF215 RGS19 CSNK2A1 MAP2K3
SART1 PPAP2B CSNK2A2 MAP2K4
UBOX5 SPRR1A CSNK2B MAP2K5
NUP50 WTAP MAPK3 MAP2K6
STAG2 TROAP MAPK1 MAP2K7
C14orfl06 DICER 1 MAPK6
DSN1 EHD1 MAPK7
GTSE1 S100A7 MAPK15
FBX07 TOP3A CYC1
MED1 LMNB1 CYCS
CD2BP2 FARSA MED1
SENP6 DCLK1 TP53
YWHAH BIN2 HNF4A
CTDSP1 EXOSC4 VEGFR3
MED 13 SPRR3 VEGFR1
MAP3K11 ZC3H3 KDR
OSMR RBM7 PDGFRB
CAMKK2 DNAJC2 PDGFRA
TEP1 NOL3 PROKR1
PRPF8 CENPA PROKR2
ASB8 ERBB4 ZAP70
SPRR1B AKAP8 SHC3
SC02 ALPK1 OSMR
GEMIN4 MKI67 ERBB4
IVL SHC3 AKT1
ZAP70 PRPF4B AKT3
PDE3A FGFBP1 AKT2
PXN AKAP1 MITF
WDR6 PXN
DGCR8 RELB
CENPE RELA
ONECUT1 NFKB2
MAL NFKB1
KRT34 PDE3A
KIF20A PDE11A
PDE11A PIK3CB
MITF PDC3CD
DHX38 PIK3CG
VHL PDC3CA
FLNB MAP2K1
PATZ1 MAP2K2
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Figure 2.6. siRNA screening of selected genes.
CFBE cells were transfected with each of the 3 silencer select siRNAs for indicated genes for 72 
hours and then the cells were lysed and total proteins were immunoblotted. a. z-Scores of the 
immunoblot-quantified band C corresponding to each single siRNA for selected CR genes, b. z- 
Scores of the immunoblot-quantified band C corresponding to each single siRNA for selected 
IPACA genes. The different partitions of the background represent the indicated changes in band 
C. c. CFBE cells were transfected with mix of three silencer select siRNAs targeting the indicated 
positive hit genes (cut-off of the z-score (2) to classify the positive hits) for 72 hours, lysed, and 
proteins were immunoblotted and fold-increases in band C plotted compared to control siRNA 
treatment (data represent mean ± SEM, n=3).
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Figure 2.6. siRNA screening of selected genes (continued).
CFBE cells were transfected with mix of three silencer select siRNAs targeting the indicated 
positive hit genes for 72 hours, d. Quantified fold-changes in the band C/B ratio compared to 
control siRNA treatment was plotted after cell lysis and protein immunoblot. (Data represent mean 
± SEM, n=3). e. Relative quantity of AF508CFTR mRNA normalised to HPRT1 mRNA is 
determined using the qRT-PCR is plotted comparing to control siRNA treatment (Data represent 
mean ± SD, n=4). f. Immunoblot of CFTR after the treatment with mix of three silencer select 
siRNAs for the classified positive hits (representative of three separate experiments).
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genes (Figure 2.6d), which indicated that the correctors might increase the trafficking of 
AF508CFTR, and so the increased ER load of AF508CFTR is not solely responsible for the 
increased trafficking. The siRNAs used in the study were able to deplete the mRNA of respective 
gene to about 50-70% (Figure 6.3). The relative mRNA levels of AF508CFTR were not changed 
greatly by the treatment of siRNAs for classified positive hits except for the SART1 (Figure 2.6e).
When commonly regulated gene hits were mapped onto the commonly regulated pathways 
obtained earlier, to see which pathways were effective in regulating CFTR proteostasis, the 
commonly regulated genes mapped onto all the three identified commonly regulated pathways/ 
networks: cell-cycle processes (kinetchore/ centromere components), mRNA processing network, 
and regulation of JNK cascade. Among the three down-regulated commonly regulated pathways 
analysed, the mRNA processing network, cell-cycle processes, and JNK pathway (or stress 
activated protein kinase SAPK) regulators/ components included hits that increased as well as 
decreased the levels of band C. There were five ubiquitin ligases that are found in commonly 
regulated genes and VHL and PATZ1, they were associated with positive hits, corrected the 
AF508CFTR, RNF215 was one of the strongest corrector among the screening. While in the cases 
of the keratinocyte differentiation network and the mediator complex network, the former was 
uniformly present in the negative hits with the latter in the positive.
To summarise, screening confirmed that commonly regulated RNA processing, cell-cycle 
related and SAPK networks/ pathways that were monitored were indeed involved in controlling the 
proteostasis of AF508CFTR, and in addition, a few ubiquitin ligases were also found; RNF215 is a 
strong candidate ubiquitin ligase that controls the proteostasis of AF508CFTR.
Discussion
The present study has identified several CFTR proteostasis modulators and validated a set 
of molecular pathways/ networks/ genes that are commonly down-regulated by corrector drugs that 
can partially rescue the folding/ trafficking defects of AF508CFTR. The identified correction 
relevant commonly regulated pathways/ networks provide a novel link between RNA processing, 
cell-cycle components, the JNK cascade and a few novel ubiquitin ligases to AF508CFTR 
proteostasis. Among the RNA processing, cell-cycle components, kinases and ubiquitin ligases that
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were screened, many of these were distributed equally between the positive and negative hits, 
except the ubiquitin ligases, which were distributed almost exclusively to the positive hits. This 
suggests that the ubiquitin ligases present in the commonly regulated genes might be in some way 
required for the retention/ degradation of AF508CFTR.
The commonly regulated genes included a few known proteostasis regulators of 
AF508CFTR, like USP25 and HSPA4 (HSP70), which were present in the up-regulated genes, and 
these are known to help in the rescue of AF508CFTR (Trzcinska-Daneluti et al. 2009; Blount et al. 
2012). On the other hand, there were also UBE2D1 and DNAJA1, which were also present in the 
up-regulated commonly regulated genes, and these are known to be required for degradation of 
AF508CFTR (Younger et al. 2006; Okiyoneda et al. 2010). These examples show that although the 
commonly regulated gene list contained a few known proteostatic regulators of CFTR, it did not 
always correlate the "correction” effect of the drugs with the known action of these proteostatic 
regulators. The screened commonly regulated genes yielded both positive and negative regulators 
of AF508CFTR proteostasis, which might explain the modest correction of AF508CFTR obtained 
by treatment with these drugs; however, the net effect of the correctors was detectable at the level 
of the correction of AF508CFTR. Moreover, our approach identified that depletion of PIK3CB, 
PHC3CG, PDGFRA, PDGFRB and the kinase insert domain receptor (KDR or VEGFR2) rescues 
AF508CFTR.
Recently, a kinase inhibitor screening strategy showed that targeting these genes or 
pathways by inhibitors rescues AF508CFTR not only in CFBE cells, but also in primary human CF 
cells (Trzcinska-Daneluti et al. 2012). This evidence confirms the strength of the meta-analysis of 
the microarray data used as combined with the bio-informatic analysis strategies to find the novel 
proteostasis regulators of AF508CFTR. In the CF patients VEGF-A has been reported to be over 
produced (Martin et al. 2013), which was a known major transducer of signalling through the KDR 
or VEGFR2 (Terman et al. 1992). VEGF is also known to be over produced under conditions of 
ER stress and aberrant calcium homeostasis (Abcouwer et al. 2002). Both ER stress and aberrant 
calcium homeostasis are very much known to be present in CF models, so it was interesting to find 
the KDR or VEGFR2 as a rescuer of AF508CFTR, although the mechanistic insight is still to be 
defined. Casein kinase 2 (CSNK2A1 or CK2) depletion also rescued AF508CFTR, although
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previous studies have shown that the CK2 phosphorylation of wtCFTR is necessary for its 
trafficking to the PM, it has no role in AF508CFTR (Luz et al. 2011). CK2 inhibition was also 
reported to attenuate ER-stress-induced XBP1 cleavage (Hosoi et al. 2012), and moreover, as 
inferred from IPACA, it has interactions with many CFTR proteostasis network genes, which 
indicates that CK2 also might be an important molecule in co-ordinating ER stress to CFTR 
proteostasis network genes, whereby its inhibition has a positive influence on AF508CFTR 
proteostasis. AF508CFTR was also known to have increased the levels of NF-kB (Bodas and Vij 
2010), and that this might contribute to the aberrant proteostasis. This study has also found that 
depletion of NF-kB 2 can rescue AF508CFTR. In addition, depletion of CAMKK2 (activator of the 
CAMK cascade), and MAP3K11 (involved in the JNK cascade) also rescues AF508CFTR. Further 
characterisation of the MAP3K11 and CAMKK2 pathways is described in Chapter 3 and 4, 
respectively.
The RNA-processing molecules like SART1, CD2BP2, NUP50 and PRPF8, and the cell- 
cycle components GTSE1, STAG1 and C14orfl06 depletion also rescued AF508CFTR. The 
molecular mechanism through which these genes affect proteostasis remains to be elucidated. 
Although the rationales behind the correction by these RNA-processing cell-cycle components are 
unknown, depletion of a few of them has been implicated in the prevention of misfolding and the 
aggregation of the Huntingtin and SOD1 proteins (Doumanis et al. 2009; Silva et al. 2011). 
Recently, the RNA-processing protein TDP-1 was shown to regulate protein homeostasis in 
Caenorhabditis elegans (Zhang et al. 2012), which is dependent on the proteostasis regulator DAF- 
16. So it might be that these RNA processing molecules regulate the levels of different RNAs, 
which in turn might affect some of the pathways that control proteostasis. The genes belonging to 
the biological functions of RNA splicing or cell-cycle processes might also be involved in the 
control of AF508CFTR proteostasis, although the mechanisms and rationale is a further avenue for 
study. Depletion of the mediator complex molecules MED 13 and MED1 was associated with 
rescue, and the mechanism by which they influence proteostasis is not clear. The mediator complex 
is known to serve as a bridge to convey information from gene-specific regulatory proteins to the 
basal RNA polymerase II transcription machinery (Malik and Roeder 2005), so depletion of 
mediator molecules might selectively change the transcription in the cell to influence proteostasis.
The reduction in band C levels upon down-regulation of AKAP1, AKAP8 or ERBB4, 
which are related to the cAMP/PKA pathway and its molecules, might indicate that the up- 
regulation of this pathway might be necessary for correction, and indeed the drug up-regulated 
commonly regulated genes have members of the cAMP/PKA pathway. Many of the spliceosomal 
components rescue of AF508CFTR upon down-regulation but PRPF4B, a kinase that is associated 
with the spliceosome which functions during the assembly of the spliceosomal complex decreased 
the AF508CFTR upon down-regulation. The PRPF4B was an apparent contrast to the effects of 
other spliceosomal components that show a rescue of AF508CFTR upon down-regulation. Few of 
the keratinocyte differentiation-related genes were included in the screening, none of them rescued 
AF508CFTR, interestingly keratin 8 and 18 have been shown to rescue AF508CFTR (Davezac et 
al. 2004; Colas et al. 2012). A desumoylation enzyme, SENP6, also rescued AF508CFTR. As 
mentioned above, all of the ubiquitin ligases tested, except VHL and PATZ1, were associated with 
positive hits. Among the ubiquitin ligases, RNF215 was a strong corrector and increased band C 
levels to around 10-fold the control levels. Not much is known about the function or localisation of 
RNF215. Including RNF215, the ubiquitin ligases have strong effects on the control of 
AF508CFTR proteostasis. This opens a new avenue for studying their roles in AF508CFTR 
degradation.
In conclusion the results of this study have rationalised the mechanism of action of the 
known correctors that can rescue AF508CFTR from the ERQC. The drugs appear to act as 
proteostatic correctors, although they do not appear to have one or a few direct genes/ networks/ 
pathways as specific targets, but to induce mild changes in expression of multiple gene leading to 
the AF508CFTR correction. Many of the drugs affected commonly modulated genes are indeed 
novel components of AF508CFTR proteostasis or its regulators. This study also opens the avenue 
for targeting the identified individual genes or pathways in combination to achieve a highly potent 
correction of the basic trafficking defects of AF508CFTR.
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Chapter 3
The stress-activated MAPK pathway controls AF508CFTR proteostasis 
Introduction
In general, proteostasis is believed to be influenced by the chemistry of protein folding/ 
misfolding and by numerous regulated networks of interacting and competing biological pathways 
that manipulate protein synthesis, folding, trafficking, disaggregation and degradation (Balch et al. 
2008). Proteostasis is also regulated by many signalling pathways, like the UPR, HSR, calcium 
signalling, and inflammatory pathways (Balch et al. 2011). It has been postulated that activation of 
stress responsive signalling pathways in particular cellular compartments results in the synthesis 
and/or activation of regulators that orchestrate programmes to enhance the proteostasis capacity 
(Lindquist and Kelly 2011). The production of misfolded proteins that exceeds the degradation 
ability leads to the UPR (Liu and Ye 2011), which increases the ER protein-folding capacity 
through broad transcriptional up-regulation of ER protein-folding and lipid biosynthesis, and 
coordinates the ERAD machinery with a decrease in the folding load through selective mRNA 
degradation and translational repression (Gardner et al. 2013). The UPR is known to be dependent 
on IRE1, PERK and ATF6 (Hartl et al. 2011), and signal transduction includes MAPKs, p38 and 
JNK (Kim et al. 2008). The HSR is involved in sensing abnormally high levels of misfolded or 
aggregated proteins in the cytosol and nucleus, and it coordinates signalling to lead to the reduction 
in the load on the proteostasis network. Thus, at the same time as blocking non-essential protein 
synthesis and degrading mRNA, there is an increase in the concentration of proteostasis network 
components through transcription and translation (Lindquist and Kelly 2011). The HSR involves 
well-established transcriptional regulators, like the HSF-1 and FOXO transcription factors (Hartl et 
al. 2011), and rapid signal-transduction events dependent on the stress-activated protein kinases 
JNK and p38 (Dorion and Landry 2002). Recently, the JNK pathway and Slpr (a MAP3K) 
phosphorylation have been shown to be required for the Drosophila HSR (Gonda et al. 2012). It 
has also been shown that HSR controlled mechanisms regulate the proteostasis network, which can 
in turn lead to the rescue of AF508CFTR (Calamini et al. 2012).
The MAPKs p38 and JNK are referred to as stress activated protein kinases (SAPKs), 
because they are preferentially activated by inflammatory cytokines and cell stress, including UV 
light, X-rays, hydrogen peroxide, heat and osmotic shock, and withdrawal of growth factors (Ichijo 
1999). The MAPK signalling cascade (Figure 3) is also activated following growth factor 
activation (Wagner and Nebreda 2009), and this system has been evolutionarily conserved from 
yeast to humans (Ichijo 1999). This cascade regulates the expression of cytokines and proteases, 
cell-cycle progression, cell adherence, motility and metabolism, and influences cell proliferation, 
differentiation, survival, apoptosis and development, and hence it is critical for cellular homeostasis 
(Cuevas et al. 2007). The canonical architecture of the MAPK pathway includes three kinases, 
MAP3K, MAP2K and MAPK, whereby MAP3K phosphorylates MAP2K, which in turn 
phosphorylates MAPK (Ichijo 1999) (Figure 3).
In the MAPK cascade, MAP3Ks are differentially activated by upstream stimuli, including
cytokines, antigens, toxins, stress and MAP4Ks, and they provide a mechanism to merge the
activation of different downstream MAP2Ks and MAPKs with the cellular responses to each
stimulus (Qi and Elion 2005; Cuevas et al. 2007). The p38 pathway has the upstream activator of
MAP2Ks as MKK3 and/or MKK6, and of the JNK pathway, MKK4 or MKK7. The knock-out of
p38 alpha is embryonically lethal in mice (Risco and Cuenda 2012). By contrast the knock-out of a
single JNK isoform is not lethal, although the knock-out of JNK1 and JNK2 together is
embryonically lethal (Yamasaki et al. 2012). This indicates that SAPKs are essential for normal
growth and development. Hogl is a yeast homologue of SAPK, and it has been demonstrated to be
activated at late stages of UPR and to maintain ER homeostasis (Bicknell et al. 2010). Stress
induction in the ER of mammalian cells by perturbations that lead to accumulation of misfolded
proteins was demonstrated to activate JNKs (Urano et al. 2000). There is also evidence from
different model systems that accumulate misfolded protein, like the poly Q mutant huntingtin
(HTT), and in Alzheimer's disease (AD), and Parkinson's disease (PD), leads to activation of JNK
and p38 (Savage et al. 2002; Borsello and Forloni 2007; Klegeris et al. 2008; Morfini et al. 2009;
Reijonen et al. 2010). It was also shown that the ERAD substrate rhodopsin P23H mutant in
Drosophila also results in activation of JNK and p38 (Galy et al. 2005). More recently, stress-
induced activation of the p38 pathway has been shown, which, in turn, leads to phosphorylation of
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Figure 3. MAPK cascade.
a. The hierarchical organization of canonical MAP kinase cascade, b. MAP kinase cascade that 
was hypothesised to control proteostasis of AF508CFTR.
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Ubc6e (Menon et al. 2013). However, whether the activation of these SAPKs is necessary for the 
degradation of these stress-causing proteins is not known.
Interestingly, in C. elegans, it has been shown that the RAS-MAPK pathway participates in 
EGF-induced proteostasis and activation of proteasomal signalling (Liu et al. 2011; Rajalingam and 
Dikic 2011). There is also well-documented evidence of SAPKs being activated upon oxidative 
stress (Son et al. 2011). Taken together, these data indicate that the SAPK pathways which 
responds to various stresses, might integrate the proteostasis network with the general stress 
response, to form integrated stress-response pathways. This pathway has been targeted for anti­
inflammatory treatment in several clinical trials (Bogoyevitch and Arthur 2008; Graczyk 2013) 
(http://clinicaltrials.gov/ct2/show/NCT01630252) successfully, with little or no apparent side 
effect.
Initial studies that analysed the mechanisms of action of the corrector drugs led to the 
identification SAPK signalling in the correction of AF508CFTR (section 2.6). So the role of the 
SAPK pathway in regulating the proteostasis of AF508CFTR was investigated further. This led to 
the discovery of several SAPK pathway components that when depleted by siRNA acted as 
correctors of AF508CFTR. The present study also discovered that the SAPK pathway has a potent 
effect on the ERAD and proteostasis of AF508CFTR. SAPK pathway has many characterised 
inhibitors (Bogoyevitch and Arthur 2008) that are interesting to be tested for AF508CFTR 
correction. Several inhibitor drugs of this pathway were tested some of them acted as novel 
correctors of AF508CFTR proteostasis. One of the SAPK pathway upstream kinase MAP3K11, has 
been shown to be activated by upstream activators, like TGF-p (Kim et al. 2004) and TNF-a 
(Brancho et al. 2005), which are known CF genetic modifier (Collaco and Cutting 2008), and also 
by ROS (Hong and Kim 2007), which are known to be involved in CF pathogenesis (Luciani et al. 
2010). The presence of pro-inflammatory cytokines and stress such as oxidative stress and ROS are 
documented in CF pathology (Brown et al. 1996; Mitola et al. 2008; Luciani et al. 2010). The 
present study also demonstrates that oxidative stress and inflammatory cytokines like TNF-a and 
TGF-p can activate this SAPK pathway, to lead to increased ERAD of AF508CFTR. This indicates 
that SAPK pathway links inflammation and oxidative stress to AF508CFTR proteostasis.
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Results
3.1. The MAP3K11-JNK pathway controls the proteostasis ofAF508CFTR
Meta-analysis of AF508CFTR corrector-drug-induced microarrays led to the identification of 
several regulatory genes/ networks/ pathways that control CFTR proteostasis (section 2.6). The 
demonstrated positive hits included MAP3K11 and MAP2K7 (MKK7). These indicate a kinase 
cascade, which are of great interest because there are well-developed kinase inhibitors that are 
available for many kinases, and they have provided particularly interesting targets for therapy 
(Cohen 2002; Sawyer et al. 2013). Thus, an interesting hit was MAP3K11, and when tested, these 
published siRNAs to MAP3K11 (Swenson-Fields et al. 2008; Chen et al. 2010) also reproduced the 
correction effect seen with the siRNAs used in the screening. All of the five siRNAs that were 
tested had an effect on the AF508CFTR proteostasis, as monitored by the biochemical assay (see 
section 6.12) that showed a clear increase in the Golgi processed band C (Figure 3.1a,b), thus 
demonstrating that the effect of these siRNAs on the ERQC is most probably mediated by 
MAP3K11. The best results here in terms of correction were obtained with siRNA 1 which was 
used in the further analysis described below.
MAP3K11 is part of the validated commonly regulated pathway that is known to activate at 
least four pathways, including JNK (Brancho et al. 2005), p38 (Kim et al. 2004), ERK (Chadee and 
Kyriakis 2004) and NF-kB  (Hehner et al. 2000) under various conditions, and it is also known to 
have kinase-independent functions in the regulation of signalling to RhoA (Swenson-Fields et al. 
2008). Downstream of MAP3K11 in JNK cascade, MAP2K7 (which is also upstream of JNK) can 
rescue AF508CFTR levels and promote its proteostasis (see section 2.6), while the other two arms 
downstream of MAP3K11, as the ERK and p38 pathways, cannot rescue AF508CFTR levels upon 
down-regulation. It has been reported that the down-regulation of MAP3K11 leads to a reduction 
in the levels of I-kB, an inhibitor of N F-kB hence, activating N F-kB (Cole et al. 2009). 
Interestingly, the present study identified N F-kB among the positive hits (rescue of AF508CFTR 
upon down-regulation), along with MAP3K11, which suggests that the MAP3K11-N F -kB axis 
might not be relevant in the correction by MAP3K11.
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Figure 3.1. The MAP3K11-JNK pathway controls AF508CFTR proteostasis.
CFBE cells were transfected with indicated siRNA for 72 hours, lysed and immunoblotted. a. 
Representative immunoblot of the experiments shown in (b) b. Fold-change of band C quantified 
from immunoblot (n=3) shown in (a), c. Immunoblot of depletion of different JNK and p38 family 
proteins, depletion of MAP3K11 was used as positive control for correction, d. Representative 
immunoblot of the experiments shown in (e). e. Fold-change of band C quantified from 
immunoblots (n=3) shown in (d) Ahal and RMA1 siRNAs were used as positive control for the 
correction. Data represent mean ± SD (**P <0.01, ***P < 0.001).
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Figure 3.1. The MAP3K11-JNK pathway controls AF508CFTR proteostasis (continued).
CFBE cells were transfected with indicated siRNA for 72 hours, lysed, proteins immunoblotted for
CFTR and quantified f. Fold-change in band B is plotted compared to control siRNA treatment
(n=3). g. Quantified C/B ratio is plotted (n=3). h. FleLa cells were transfected indicated siRNA for
72 lysed and proteins were immunoblotted for CFTR (representative of five separate experiments).
i. CFBE cells were transfected with indicated cDNA for 24 hours, lysed, proteins were
immunoblotted for CFTR, fold-change band B quantified and plotted (n=3), with representative
immunoblot shown in the insert. Data represent mean ± SD (*P < 0.05, **P < 0.01, ***P < 0.001).
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To further validate the involvement of the MAP3K11-JNK pathway in the correction of 
AF508CFTR, three INK family of proteins were depleted using siRNA approach in CFBE cells. 
Down-regulation of JNK2 led to AF508CFTR rescue (Figure 3.1c), while JNK1 or JNK3 did not 
lead to significant increases in band C. As there is extensive cross-talk between the p38 and JNK 
pathways, siRNAs against p38 family of proteins were also tested in the assay, and there was no 
significant increase in band C levels when each of the p38 family of proteins were depleted 
(Figure 3.1c). Therefore, in the MAP3K11-JNK pathway, MAP3K11, MAP2K7 and JNK2 
depletion lead to the rescue of AF508CFTR (the efficacy of depletion of gene is presented in the 
section 6.3), and biochemically, the rescue levels were comparable to those obtained by down- 
regulation of the known rescuers RMA1 and Ahal (Figure 3.Id, e). An expression database 
(http://biogps.orgl has shown that JNK2 is highly expressed in bronchial epithelial cells compared 
to other cells, which probably explains the strong effects observed with JNK2 compared to other 
JNK isoforms. Although the increase in band C levels was also accompanied by an increase in 
band B levels (Figure 3.1e), there was a significant change in the band C/B ratio of AF508CFTR 
(Figure 3.If), which suggests increased export or decreased peripheral quality control. If the 
amount of band c is due to a nonspecific transport then the ratio of amount of band C to band B 
would be simply proportional in control and specific gene siRNA-treated cells. (Hutt et al. 2010). 
Hence the rescue seen above may not be due to the nonspecific increase in the transport.
To further test the effects of the JNK pathway on AF508CFTR, the activity of the pathway 
was enhanced to see whether this indeed controls ERQC. If the pathway controls or enhances 
ERQC, up-regulation of the pathway components should have the opposite effect, and reduce the 
levels of AF508CFTR. To achieve this, cDNA of the upstream activators of the SAPK pathway 
CDC42 (activator of MAP3K11), MKK7 (activator of JNK) and active JNK2 fused to MKK7 were 
transfected into CFBE cells. The activators activated JNK, as examined by phosphorylated cJUN 
(Figure 3.1h), and this was accompanied by a reduction in the levels of band B of AF508CFTR 
(Figure 3.1g, h). Thus, the reduction in the JNK pathway activity led to a stabilisation and 
enhanced export of AF508CFTR from the ER, and the activation of the pathway led to a reduction 
in the levels of AF508CFTR. This demonstrates that the JNK pathway, or specifically the 
MAP3K11-mediated JNK pathway, is indeed a regulator of AF508CFTR proteostasis.
3.2. The MAP3K11-JNK pathway regulates the ER-associated degradation ofAF508CFTR
An observation that stands out from the experiments described above and in the siRNA 
screening was that the rescue of AF508CFTR is invariably accompanied by an increase in the 
levels of band B. Furthermore, this was also accompanied by an increase in the band C/B ratio. The 
increase in band B levels associated with the depletion of the MAP3K11-JNK pathway 
components might be caused by either an increase in the synthesis or a decrease in the rate of 
degradation of AF508CFTR at the ER level. Quantitative RT-PCR after the siRNA treatment 
against the MAP3K11-JNK pathway showed no changes in the levels of CFTR mRNA (Figure 
3.2a), which indicated that the increased band B levels were apparently not due to increased mRNA 
synthesis of AF508CFTR. However, the possibility of increased translation of CFTR mRNA 
cannot be excluded.
To determine whether the down-regulation of the MAP3K11-JNK pathway decreases the 
ERAD of AF508CFTR, a cycloheximide chase assay was performed, to measure the half-lives (ty2) 
of proteins (Okiyoneda et al. 2010; Alvarez-Castelao et al. 2012). AF508CFTR is continuously 
subjected to degradation in the ER, so when protein synthesis is blocked, the kinetics of the 
reduction in the levels of AF508CFTR (band B) monitored by Western blotting reflects the kinetics 
of ERAD of AF508CFTR. This reduction in the levels of the ER-associated protein (band B of 
AF508CFTR) is due to a combined effect of ERAD and the exit of the protein from the ER to the 
Golgi complex. Both of these processes can be monitored by measuring the changes in the levels of 
band B and the Golgi processed band C. Control CFBE cells and CFBE cells treated with siRNAs 
targeting the MAP3K11-JNK pathway were treated with cycloheximide for 20,40 and 60 min, and 
the changes in the levels of band B were monitored by Western blotting (Figure 3.2b). During the 
chase, there was no increase in the band C levels, which suggested that during this period, there 
was no significant export of AF508CFTR out of the ER, while the band B levels gradually 
decreased with a ty2 of ~7 min in the control cells. In the case of the siRNA-treated cells, the 
reductions in the levels of band B was much less than that of the control cells, and the ty2 was about 
~13 min for the JNK knock-down, to about 24 min for the MAP3K11 knock-down cells. Thus, the 
effect on the reductions in the rates of ERAD of AF508CFTR was more prominent for The 
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Figure 3.2. MAP3K11-JNK pathway regulates the ERAD of AF508CFTR.
CFBE cells were transfected with indicated siRNA for 72 hours before processing the sample for 
analysis, a. Relative levels of AF508CFTR mRNA quantities determined by RT-PCR (n=3). b. 
Kinetics of CFTR band B disappearance was quantified from immunoblot after cycloheximide 
chase (lOOmg/ml) at indicated times and expressed as fold change to the initial amount (time 0) 
from the experiments shown in (c) (n=3). c. Representative immunoblot after cycloheximide chase 
(lOOmg/ml) at different times as indicated, d. ZsProSensor-1 transfected and expressed for 24 h 
after 48 h of depletion of the indicated genes. MG 132 is used as positive control for inhibition of 
proteasome. e. Immunoblot of the ubiquitin conjugated proteins analysed from indicated siRNA 
treated cells (representative of three separate experiments). Data represent mean ± SD.
MAP3K11, JNK2 did not lead to accumulation of ZsProSensor-1 whereas MG 132 (proteasome 
inhibitor) treatment for 3 hours led to evident accumulation of ZsProSensor-1 (Figure 3.2d). Then 
to test whether the pathway affects the ubiquitination process itself, the ubiquitin conjugates were 
monitored in the total protein isolated from the cells depleted with MAP3K11 and JNK2. If there is 
any change in ubiquitin conjugation to the proteins (down regulation of ubiquitin ligases) there will 
be a decrease in the poly-ubiquitin conjugates in the cell (Xu et al. 2010; Oh et al. 2013). There 
was no change in the poly-ubiquitin conjugates in the MAP3K11 and JNK2 depleted cells (Figure 
3.2e) suggesting that the ubiquitination process and the proteasome were unaffected.
3.3. The MAP3K11-JNK pathway does not affect folding ofAFS08CFTR or exit from the ER
As noted before, the down-regulation of the SAPK pathway induces an increase in the band 
C/B ratio of AF508CFTR (Figure 3.If), which suggests that either the folding/ export of 
AF508CFTR is enhanced, or the stability of band C at the PM is increased. To determine whether 
AF508CFTR folds better when the MAP3K11-JNK pathway is down-regulated, the tiypsin 
sensitivity of AF508CFTR was monitored (Rosser et al. 2008; Glozman et al. 2009) after knock­
down of MAP3K11, a key component of the SAPK pathway. As expected, NBD1 and NBD2 of 
wtCFTR were resistant to trypsin-mediated digestion compared those of AF508CFTR (Figure 
3.3a), similar to what has been shown before (Rosser et al. 2008). Down-regulation of MAP3K11 
did not significantly change the trypsin sensitivity of AF508CFTR, which suggests that the increase 
in the intensity of band C should not be ascribed to a detectable increase in folding of AF508CFTR. 
It is important to note that increased folding of AF508CFTR by low temperature treatment (26 °C 
for 24 h) led to a visible change in the folding of AF508CFTR as measured by trypsin sensitivity of 
the NBD1 domain, which demonstrated that the assay was sensitive for the detection of changes in 
folding (Figure 3.3a). At this stage, it is not possible to rule out the subtle improvements in folding 
that were below the sensitivity levels of the assay used, but improved folding appears to contribute 
little towards the increased levels of band C.
With no apparent change in folding as measured by the trypsin sensitivity, there is the 
possibility that the export of AF508CFTR might be enhanced. The kinetics of transport of cargoes 
out of the ER was then measured using VSVG-GFP transport to the Golgi complex under control
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Figure 3.3. The MAP3K11-JNK pathway does not affect folding or exit from the ER.
a. Immunoblot of limited proteolysis of wtCFTR and AF508CFTR treated with siRNAs. Cell 
lysates were subjected to immunoblotting with the indicated antibodies (either anti-NBDl or anti- 
NBD2 CFTR) (representative of three separate experiments). The low temperature 26°C was used 
as positive control for folding of AF508CFTR. b. Kinetics of VSVG transport. VSVG-GFP was 
transfected for 24 h at 40 °C after 48 h of siRNA treatments, as indicated, and then transferred to 
32 °C. The cells were lysed for biochemical assay (section 6.9) at indicated time, and the lysates 
were treated with endoH and immunoblotted for VSVG (representative of two separate 
experiments).
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and MAP3K11 knock-down conditions. VSVG has been used extensively as a marker to study the 
biochemical and molecular basis for transport along the secretory pathway both in vivo (Tisdale et 
al. 1992) and in vitro (Davidson and Balch 1993). VSVG is a type I transmembrane protein that has 
two N-linked carbohydrate chains and is transported from the ER to the Golgi apparatus. Its 
transport through the Golgi can be followed by the processing of two oligosaccaride chains from 
the high mannose endoH-sensitive form (which is found in the ER and pre-Golgi compartments) to 
the endoH-resistant form (which is found in the Golgi). The processing intermediates can be easily 
distinguished by SDS-PAGE (Davidson and Balch 1993). The first endoH-resistant form 
corresponds to the transport of VSVG from the ER to the early Golgi compartment where one or 
both of the oligosaccaride chains becomes endoH resistant by the action of the resident 1,2- 
mannosidases and glycosyltransferases (Davidson and Balch 1993); (Tisdale et al. 1992). The 
subsequent transport of VSVG to the TGN results in the appearance of the fully processed form, 
which contains two complex endoH-resistant oligosaccarides (Davidson and Balch 1993), (Tisdale 
et al. 1992). The appearance of sequential processing intermediates allows the direct examination 
of the effects of treatments on both ER-to-Golgi and intra-Golgi transport in the same experiment 
(Davidson and Balch 1993); (Tisdale et al. 1992). When the endoH resistance was examined (as 
described section 6.9) and the kinetics of VSVG-GFP was calculated there was no significant 
change in the kinetics of the tested cargo up on MAP3K11 depletion (Figure 3.3b).
3.4. The MAP3K11-JNK pathway regulates the peripheral quality control o f AF508CFTR
As the MAP3K11-JNK pathway does not control either the folding of AF508CFTR or its
exit out of the ER, as inferred from above set of experiments, an alternative possibility to explain
the increased band C/B ratio is the stabilisation of the mutant protein at the PM. AF508CFTR that
arrives at the PM is known to undergo peripheral or PM-associated quality control, where the
mutant protein is recognized by the quality control system of chaperones and ubiquitin ligases and
is ubiquitinated and degraded (Okiyoneda et al. 2010). Moreover, the quality control system
operating at the PM level overlaps significantly with that operating at the ER, and given that the
ERQC of AF508CFTR is affected under the conditions examined, there was a high probability of a
compromise in the peripheral quality control too. To determine the effects of the MAP3K11-
directed siRNAs on the degradation of PM-associated AF508CFTR an established procedure was
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Figure 3.4. The MAP3K11-JNK pathway regulates the peripheral quality control of 
AF508CFTR.
CFBE cells were treated with siRNAs as indicated and were kept at 26 °C for 36 h. Then the cells 
were shifted to 37 °C for 1.5 h with 100 pg/ml cycloheximide, before being were lysed, as 
indicated, at 37 °C and immunoblotted. a. Kinetics of the degradation of band C as fold change to 
initial amount (Time-0) in the experiments shown in (b) (n=3) b. Representative immunoblot with 
the treatment of the siRNAs indicated. Ahal was used as positive control for peripheral quality 
control. Data represent mean ± SD.
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used (see section 6.10) (Okiyoneda et al. 2010). Degradation of band C occurred with a t/2 of 
approximately 2 h, and the depletion of MAP3K11 increased the half-time of degradation to about 
4 h (Figure 3.4a,b), which suggested that the peripheral quality control of AF508CFTR is 
compromised in the absence of the MAP3K11 -initiated pathway. In conclusion, inhibiting the 
MAP3K11-mediated pathway markedly reduces the efficiency of the both the ER-associated and 
the PM-associated quality control and degradation machineries, which results in relatively large 
increases in the mutant protein at the PM.
3.5. Upstream activators and downstream targets of the ofMAP3K11-JNK pathway participate 
in the control o f AF508CFTR proteostasis
MAP3K11 is known to be phosphorylated and activated by different MAP4Ks: 
HPK1/MAP4K1 (Arnold et al. 2005), GCK/MAP4K2 (Chadee et al. 2002), and GSK3B (Mishra et 
al. 2007), and by direct binding to the CDC42/Rac (Zhao et al. 2007) family proteins. Thus, to 
investigate the upstream MAP4K involved in the activation of the MAP3K11-JNK pathway, each 
of these upstream regulators were down-regulated using siRNAs and the effects on AF508CFTR 
were monitored using the biochemical assay (see section 6.12). Here, down-regulation of 
MAP4K1, CDC42 and Rac2 led to increases in the band C levels, with CDC42 showing the 
strongest response (Figure 3.5a).
The JNK pathway that forms a part of the SAPK pathway has been well studied, with 
several known downstream targets reported. Therefore, to understand the possible targets of this 
pathway, the details of several characterised substrates were collected from the published literature. 
This list included transcription factors, proteostatic components, and those involved in apoptosis 
regulation. Then these components were down-regulated using siRNA-mediated knock-down, to 
determine their effects on AF508CFTR proteostasis.
Among the targets BAG3 and HSF1 down-regulations were especially strong for the rescue 
of AF508CFTR, while the ATF1 led to modest but significant rescue (Figure 3.5b). Thus BAG3 
appeared to be an ideal target of the MAP3K11-JNK pathway for the rescue of AF508CFTR. 
Although BAG3 was not identified in the CFTR interactome study performed (see section 3.9), 
other studies have shown an interaction (Wang et al. 2006), which suggests that BAG3 can
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Figure 3.5 Upstream activators and downstream targets of the MAP3K11-JNK pathway also 
correct AF508CFTR.
CFBE cells were treated with siRNAs, as indicated, for 72 h and lysed and immunoblotted. a. Fold- 
increase in band C quantified from the immunoblots (n = 3) of the tested upstream activators, with 
representative immunoblot. b. Fold-increase band C of the tested downstream targets quantified 
from immunoblots (n =3), with representative immunoblot. Ahal and RMA1 siRNAs were used as 
positive control for the correction. Data represent mean ± SD.
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probably act indirectly to achive AF508CFTR rescue. Another interesting observation was that the 
knock-down of HSF1, which is a known proteostasis regulator (Balch et al. 2008), also led to 
partial correction of AF508CFTR, and previous studies have correlated the HSF1 activation to 
CFTR correction (Calamini et al. 2012). The other transcription factors c-JUN and ATF1 
individually contributed to the rescue, indicating a transcriptional component in the action of the 
MAP3K11-JNK pathway. These observations thus opened an avenue to further explore the 
transcriptional effect of this pathway.
3.6. Inflammatory cytokines and ROS enhance AF508CFTR degradation
To understand the physiological relevance of the SAPK pathway that regulates the ERQC, 
the physiological upstream activators of the pathway were explored. MAP3K11 is known to be 
involved in the activation of JNK by TNF-a, TGF-p and ROS. Interestingly, TGF-p and TNF-a 
have been suggested to be genetic modifiers of CF (The Cystic Fibrosis Genotype-Phenotype 
Consortium 1993). If these cytokines indeed control the ERQC via MAP3K11, then in the case of 
overexpression of the SAPK activators (Figure 3.1 i), the activation of the cytokine receptors by 
their respective ligands would activate a pathway that enhances the degradation of AF508CFTR.
To study the action of cytokines, CFBE cells were treated with TNF-a or TGF-P levels of 
band B for AF508CFTR were examined. As shown in figure 3.6, addition of TNF-a or TGF-p led 
to immediate decreases in the levels of band B of AF508CFTR. These reductions were maximal at 
15 min after the addition of TNF-a or TGF-P, and by 60 min, the levels of band B of AF508CFTR 
recovered to the pretreatment levels (Figure 3.6a, b). To understand whether the MAP3K11- 
mediated pathway is indeed involved in this cytokine-mediated effect, the cells pretreated with 
MAP3K11-directed siRNAs were exposed to TNF-a or TGF-p. While the control cells showed 
reductions in the levels of AF508CFTR after these cytokine treatments, the siRNA-treated cells did 
not show any changes in the levels of AF508CFTR after the TNF-a or TGF-P treatments, which 
suggested that the MAP3K11-mediated pathway is indeed required for the regulation of 
AF508CFTR proteostasis by TNF-a and TGF-p (Figure 3.6b, c). As the levels of TNF-a and TGF- 
P recovered by 60 min after the start of this treatment, it was next analysed whether chronic 
administration of TNF-a or TGF-P also leads to changes in AF508CFTR proteostasis. To this end,
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Figure 3.6. Inflammatory cytokines and ROS enhance AF508CFTR degradation.
a. CFBE cells were treated with 50 ng/ml TGF-p or TNF-a for the indicated times and lysed and 
immunoblotted for CFTR, b. Fold change of band b quantified and expressed as to initial amount 
(time-0) (n = 3) from the experiments in (a), c. Control and MAPK3K11-depleted CFBE cells were 
treated with 50 ng/ml TGF-p or TNF-a for 15 minutes, lysed, immunoblotted for CFTR, d. Band B 
levels of AF508CFTR were quantified from the experiments in (c), expressed as fold change 
compared to initial amount (time-0) (n = 3), e. Control and MAPK3K11-depleted CFBE cells were 
treated with 1 mM H2O2 for 15 mins, lysed, immunoblotted for CFTR, f. The AF508CFTR band B 
levels were quantified from the experiments in (e), expressed as fold change compared to initial 
amount (time-0), (n = 3). Data represent mean ± SD.
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CFBE cells were treated for 72 h with TNF-a or TGF-p, with the fresh addition of the cytokines 
every 24 h. This chronic treatment with physiologically relevant concentrations of TNF-a or TGF-P 
did not lead to detectable changes in AF508CFTR proteostasis.
Another group of potent activators of the SAPK pathway are the ROS (Hong and Kim 
2007). Moreover, ROS have been reported to be enhanced in CF cells, and they are produced in 
large number by neutrophils and other cells during inflammatory reactions that are common in 
patients with CF (Hull et al. 1997). Thus, CFBE cells were treated with 1 mM H2O2 for 15 min, and 
strikingly, this enhanced degradation was nearly completely inhibited by the absence of MAP3K11 
(Figure 3.6d,e). Thus, the SAPK pathway activated by inflammatory cytokines, and more 
significantly by ROS, via MAP3K11 is a potent controller of AF508CFTR proteostasis.
3.7. Small molecule inhibitors o f the MAP3K11-JNK pathway can correct AF508CFTR
The MAP3K11-JNK signalling pathways have well-characterised inhibitors (Cui et al. 
2007). As the down-regulation of the pathway is associated with the rescue of AF508CFTR, the 
effects of inhibitors that inhibit the kinase activity of the MAP3K11-JNK pathway components 
were analysed, considering the rescue of AF508CFTR and the potential for therapeutic use. 
Moreover, a recent study where kinase inhibitors were screened for the correction of the 
AF508CFTR defect identified inhibitors that also target the MAP3K11-JNK pathway, which 
included oxozeaenol and kenpaullone (Trzcinska-Daneluti et al. 2012). Oxozeaenol targets 
MAP3Ks mainly through TAK1 (Ninomiya-Tsuji et al. 2003), and kenpaullone targets GSK3B. So 
batteries of inhibitors of the MAP3K11-JNK pathway were tested, using CFBE cells over 24 h, 
and then their effects on AF508CFTR were analysed. The well-characterised corrector VX-809 was 
used as the control for AF508CFTR rescue, which demonstrated very robust correction and 
increased the levels of band C to about 4-8-fold in the biochemical assay (as described in section
6.12). When AF508CFTR-expressing CFBE cells were treated with the JNK inhibitors (JNKi) a 
very robust increase in the levels of band C was obtained with the treatment of JNKi II (or 
SP600125), JNKi IX and JNKi XI (Figure 3.7b,c); oxozeaenol and kenpaullone also rescued 
AF508CFTR efficiently (Figure 3.7b,c), as has been reported (Trzcinska-Daneluti et al. 2012). The 
fold-increase in the levels of band C was comparable to that obtained with VX-809 (~4-8-fold). All
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Figure 3.7. Small-molecule inhibitors of the MAP3K11-JNK pathway correct AF508CFTR.
a. CFBE cells treated with JNKi II for the indicated times, lysed, and AF508CFTR correction was 
analysed by immunoblot (representative of three separate experiments), b. Representative 
immunoblot of CFBE cells that were treated with indicated drugs for 48 h and immunoblotted for 
AF508CFTR. c. Immunoblot quantified fold change band C levels from the experiments in (b), at 
indicated drug concentration (x-axis), fold change expressed as compared to DMSO treatment 
(n=3). d. Representative immunoblot of AF508CFTR from CFBE cells that were treated with the 
indicated drugs (25 pM JNKi II, 30 pM Kenpaullone, 10 pM Oxozeaenol) alone or in combination 
with 5 pM VX-809 for 48 hours, e. Immunoblot quantified fold change band C levels from the 
experiments in (d) expressed as compared to DMSO treatment (n=3). Data represent mean ± SD.
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of these three inhibitors of JNKi have different chemical structures, and while JNKi II and JNKi IX 
are ATP-competitive inhibitors of JNK, JNKi XI is an inhibitor of the substrate/ scaffold binding to 
JNK. This suggests that the rescue is not mediated by compounds with similar chemical structures, 
but rather due to specific inhibition of JNK. As oxozeaenol is reported to be a major Takl inhibitor 
(Ninomiya-Tsuji et al. 2003), TAK1 knock-down was also examined, but it did not have any effects 
on AF508CFTR proteostasis, so the corrective effect of oxozeaenol which is known to also inhibit 
other MAP3Ks at higher concentration (Ninomiya-Tsuji et al. 2003) might be mediated by its 
effect on other MAP3Ks including MAP3K11. The other MAP3K11 inhibitors K252a (Pan et al. 
2005) and URMC-099 (Marker et al. 2013), and JNK inhibitors JNK I, JNK VII and JNK XIII 
were tested, these did not correct the AF508CFTR; the reason for the lack of action o f these other 
inhibitors remains unknown.
Importantly the levels of correction obtained with the JNK inhibitors were better than the 
corrector compounds (Table 2.1a) from which the pathway was derived. The corrector drugs (Table 
2.1a) were obtained by random screening procedures, and this process of determining their 
mechanisms of action to specifically target the relevant network/pathway like MAP3K11-JNK 
pathway is justified by the increased rescue obtained. The effect of one of the inhibitors, JNKi II 
(SP600125), was also tested in HeLa cells expressing AF508CFTR, and this led to an increase in 
the levels of band C, although this increase was not as robust as for CFBE cells. The increase in 
band C levels started at about 25 pM JNKi II and reached a plateau at about 50 pM JNKi II. Again, 
as for the siRNA treatments, the increases in the levels of band C were accompanied by increases 
in the levels of band B. To study the time course of action of the JNKi on the correction of 
AF508CFTR, CFBE cells were treated with 50 pM JNKi II from 6 h to 72 h. A detectable increase 
in band C required at least 24 h of JNKi II treatment (Figure 3.7a), and this effect reached a peak 
level by around 24 h to 48 h. There was then no further detectable change in band C levels up to 72 
h. Thus, inhibitors of the potential MAP3K11-regulated, MAP3K11-JNK pathway can correct the 
basic defect of the folding/ trafficking of the mutant AF508CFTR.
During the course of above study, it was also noted that the MAP3K11-JNK pathway
inhibitor treatment using JNKi II, oxozeaenol and kenpaullone led to an increase in band B levels
that was accompanied by an increase in band C levels, which was similar to that obtained by the
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siRNA-mediated knock-down of the MAP3K11 pathway. In contrast, the treatment with VX-809, 
which is a known pharmacochaperone, allowed increased exit from the ER with little or no change 
in band B levels, which resulted in an increased band C/B ratio. This suggested that JNKi II, 
oxozeaenol and kenpaullone act at different steps of AF508CFTR biosynthesis, as they mainly 
increased the stability in the ER. Thus, it was hypothesised that combining these would lead to 
increased stability of band B mediated by JNKi II that can be efficiently rescued by VX-809. 
Indeed, when JNKi II, oxozeaenol and kenpaullone were individually combined with VX-809 for 
48 h, this led to very efficient synergy between the drugs, and a rescue that reached nearly 8-fold 
greater than the effects of VX-809 alone (Figure 3.7d), as measured by the levels of band C in the 
biochemical assay (as described in section 6.12). Given that in a phase Ha clinical study, VX-809 
was reported not to show statistically significant changes in lung function or patient-reported 
outcomes (Clancy et al. 2012), the observed additive/ synergistic effects here provides an exciting 
opportunity to explore this further.
3.8. The MAP3K11-JNK pathway depletion partially restores functional AF508CFTR
To determine whether the rescued AF508CFTR is indeed functional, the chloride 
conductance in CFBE cells after siRNA-mediated knock-down of MAP3K11 and JNK was 
investigated using an SPQ fluorescence assay; this indicated that the rescued AF508CFTR is indeed 
functional (Figure 3.8a, b, c, d). Then the conductance was also analysed by a halide sensitive (HS) 
yellow fluorescent protein (YFP) assay (Pedemonte et al. 2011) using HS-YFP stably transfected 
into CFBE cells (see section 6.16). This assay also showed that JNKi II, oxozeaenol and 
kenpaullone indeed increased the conductance (Figure 3.8e). JNKi II, oxozeaenol and kenpaullone 
were also examined in polarised CFBE cells for the correction of AF508CFTR by measuring the 
trans-epithelial short-circuit current using an Ussing chamber system (see section 6.17). The Ussing 
chamber system showed an increase in the chloride current upon treatment with oxozeaenol and 
kenpaullone (Figure 3.8f, g, h), but not with JNKi II (Figure 3.8h). In summary, the inhibitors 
targeting the MAP3K11-JNK pathway corrected AF508CFTR, which is then functionally active in 
gating the chloride through the PM even in polarised CFBE cells.
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Figure 3.8. MAP3K11-JNK pathway depletion partially restores functional AF508CFTR.
a, b, c. CFBE cells were treated with the indicated siRNAs for 72 hour and the iodide efflux was 
measured using SPQ, an iodide sensitive fluorescent dye. The change in fluorescence was plotted 
until 20 mins for a control and siRNA treatment. The CFTR channel was stimulated with Fsk 
(forskolin) and Gen (genestin) after 8 Mins a. MAP3K11 siRNA-treated and b. JNK siRNA- 
treated CFBE cells c. Calculated rate of iodide efflux (n=50 cells), d. Rate constant measured by 
the changes in the fluorescence of iodide-sensitive YFP expressed in CFBE cells after cAMP 
stimulation after the pre-treatment with the indicated siRNA for 72 hour (n=50 cells), e. Rate 
constant measured by the changes in the fluorescence of iodide-sensitive YFP expressed in CFBE 
cells after cAMP stimulation after the pre-treatment with the indicated drugs for 48 hour (n=50 
cells). VX-809 was used as positive control for the functional rescue.
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Figure 3.8. MAP3Kll-nJNK pathway depletion partially restores functional AF508CFTR 
(continued).
Polarised CFBE cells expressing AF508CFTR were treated with indicated drugs for 48 hours, and 
short-circuit current (Isc) was measured using the Ussing chamber assay system (n=3). f. 
Oxozeaenol, g. Kenpaullone, h. JNKi II were treated at indicated concentration. VX-809 was used 
as positive control for the fimctional rescue. Data represent mean ± SEM (n=3).
3.9. The MAP3K11-JNK pathway modifies the interactome o f AF508CFTR
To understand how the MAP3K11-mediated SAPK pathway regulates AF508CFTR 
proteostasis, the interactome of AF508CFTR after treatment with JNKi II for 24 h was analysed by 
mass spectrometry and compared to the interactome of wtCFTR and AF508CFTR, which were also 
analysed in parallel. For this study, HeLa cells expressing an HA-tagged version of the wtCFTR or 
AF508CFTR were used. The wtCFTR interactome had 90 components, while that of AF508CFTR 
had 107, and AF508CFTR after JNKi II treatment had 141 components (Table 3.9). Comparison 
with the earlier published CFTR interactome (Wang et al. 2006) showed very minimal overlap, 
with only 12 common interactors of the AF508CFTR and six common interactors in the wtCFTR 
interactome. Given that two different heterologous systems were used for the studies (the earlier 
published study used BHK cells), the minimal overlap suggests that there are large differences in 
the proteostatic machinery and/or their regulation between these cell lines. Comparison of the 
wtCFTR and AF508CFTR interactomes obtained from HeLa cells pointed to several interesting 
observations (Table 3.9).
Nearly two-thirds of the components were common to both the wtCFTR and AF508CFTR 
interactomes (quantitative information based on the peptide count is not considered), and even the 
nature of the components were the same; e.g., ribosomal proteins, folding degradation machinery, 
and RNA processing machinery. This is surprising, given that the majority of the proteins are ER 
localised in the case of AF508CFTR, while the majority are Golgi processed and localised to the 
PM for wtCFTR. Nevertheless, the number of cytosolic proteostatic components associated with 
wtCFTR was nearly half of that associated with AF508CFTR, as expected. In spite of the absence 
of quantitative information that would help in the interpretation of the interactome data, the 
observation that the wtCFTR interactome (localised mainly in the post-ER compartments) had as 
many ER luminal components as that of the AF508CFTR suggests that wtCFTR has more affinity 
for these components than AF508CFTR. Considering the qualitative information the interactome of 
AF508CFTR after JNKi II treatment showed substantial increases in components o f the ribosomal/ 
translational machinery and RNA-processing components, compared to the untreated conditions. 
Among the folding/ degradation machinery, there was a slight reduction in the cytosolic folding/
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Table 3.9. Interactome o f CFTR
The HeLa cells expressing wtCFTR, AF508CFTR or AF508CFTR were treated with JNKi II for 24 
h. Then the CFTR-interacting proteins were determined by co-immunoprecipitation followed by 
mass spectrometry.
Total Lost compared to AF508CFTR Gained compared to 
AF508CFTR
AF508CFTR wtCFTR AFSOSCFTR™0 wtCFTR AF508CFTRjnk‘ wtCFTR AF508CFTRJN“
ACLY ACLY HSPE1 AKR1C3 AKR1C2 ADRM1 ADRM1
ACTN4 ACTN4 YWHAE ANXA5 ANXA3 ANXA7 ANXA7
ADRM1 AHCY PSMC4 CANX ANXA5 ATAD3A ATAD3A
AHCY AKR1C3 RPS2 CCT2 CAD ATIC CCT3
ALDOA ALDOA RPS3 CFL1 CALR BAG2 CCT5
ANXA1 ANXA1 RPS3A DNAJC10 CANX CAPRIN1 CKAP4
ANXA2 ANXA2 RPS4X ELAVL1 CAPZA1 CCT3 CLTC
ANXA7 ANXA5 RPS8 FUBP1 CBR1 CCT5 CSE1L
ATAD3A CANX RPSA HIST2H2AA4 CFL1 CCT6A EEF1A1
ATIC CCT2 RPLPO HIST4H4 CPS1 CCT7 EIF4A1
BAG2 CCT4 RPL12 HNRNPF DHX15 CCT8 EZR
CAPRIN1 CFL1 RPL14 HNRNPH3 DNAJC10 CKAP4 FAF2
CCT3 CKB RPL23A KPNB1 EEF1G CSE1L FKBP4
CCT4 CLTC RPL3 MDH2 ELAVL1 EEF1A1 FSCN1
CCT5 DDX3X RPL7A MSN FLNB EEF1D GPI
CCT6A DDX5 RPL8 PCBP1 FLNC ERLIN2 GSTP1
CCT7 DHX9 HSPA5 PRDX2 G3BP1 EZR HLA-C
CCT8 DNAJC10 AHCY PRDX6 HNRNPA1 FAF2 ILF2
CKAP4 EIF4A1 AKR1C2 RPL10A HNRNPAB FKBP4 IMPDH2
CKB ELAVL1 ACTN4 RPS12 HNRNPD FSCN1 MAT2A
CLTC ENOl ENOl RPS2 HNRNPF HLA-C PPIA
CSE1L ERLIN1 ANXA1 RPS29 HNRNPH3 HNRNPH1 PPIB
DDX3X EWSR1 ANXA2 RPS8 HNRNPU HSP90AA1 PSMD11
DDX5 FASN ANXA3 SF3B3 HUWE1 HSPE1 PSMD3
DHX9 FUBP1 ANXA5 UBC ILF3 IGF2BP3 PTBP1
EEF1A1 FUS ACLY VARS KHSRP MAT2A RPL23
EEF1D GPI DHX9 XRCC5 KPNB1 MYH9 RPS18
EIF4A1 GSTP1 DDX3X ZYX LARS P4HB RPS25
ENOl HIST2H2AA4 BAG2 MCM7 PABPC4 RPS27
ERLIN1 HIST4H4 ATIC MDH2 PHB2 SFPQ
ERLIN2 HNRNPA2B1 CANX MSN PPIB SLC25A5
EWSR1 HNRNPC CALR NONO PSMB6 SND1
EZR HNRNPF CAPRIN1 PCBP1 PSMD11 STIP1
FAF2 HNRNPH3 CFL1 PCBP2 PSMD3 TCP1
FASN HNRNPM CKB PDIA4 RPL12
FKBP4 HNRNPUL1 MCM7 PRDX6 RPL23
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Table 3.9. Interactome o f CFTR (continued)
Total Lost compared to 
AF508CFTR
Gained compared to 
AF508CFTR
AF508CFTR wtCFTR AF508CFTRjnki wtCFTR AFS08CFTRJI,,a wtCFTR AF508CFTR,Ma
FSCN1 HSP90B1 DNAJC10 PSMC4 RPS18
FUS HSPA1A RPN1 RBM14 RPS27
GPI HSPA5 TRIM21 RPL14 RUVBL2
GSTP1 HSPA8 ELAVL1 RPL23A SFPQ
HLA-C HSPB1 EEF1D RPL24 SLC25A5
HNRNPA2B1 ILF2 EEF1G RPL27A SND1
HNRNPC IMPDH2 TUFM RPL3 TCP1
HNRNPH1 KPNB1 HSP90B1 RPL5 UFD1L
HNRNPM LGALS3BP ERLIN1 RPL7A VDAC2
HNRNPUL1 LMNA FASN RPL8
HSP90AA1 MDH2 FLNB RPN1
HSP90B1 MSN FLNC RPS2
HSPA1A MVP ALDOA RPS21
HSPA5 NCL LGALS3BP RPS3A
HSPA8 PABPC1 HSPA1A RPS4X
HSPB1 PCBP1 HSPA8 RPS5
HSPE1 PDIA3 TRAP1 RPS8
IGF2BP3 PDIA6 HSPB1 RPS9
ILF2 PFN1 HSP90AA1 SLC3A2
IMPDH2 PGK1 HNRNPA2B1 SNRPA
LGALS3BP PLS3 HNRNPC SYNCRIP
LMNA PPIA HNRNPD TAF15
MAT2A PRDX2 HNRNPF TARS
MVP PRDX6 HNRNPH1 TFRC
MYH9 PTBP1 HNRNPH3 TLN1
NCL RPL10A HNRNPUL1 TRAP1
P4HB RPLPO HNRNPU TXNDC5
PABPC1 RPS12 SYNCRIP UBA1
PABPC4 RPS2 KPNB1 UBAC2
PDIA3 RPS25 IGF2BP3 VDAC1
PDIA6 RPS29 ILF3 XRCC5
PFN1 RPS3 MVP YBX1
PGK1 RPS8 MDH2
PHB2 RPSA MSN
PLS3 SDHA MYH9
PPIA SEC23A NONO
PPIB SERPINH1 YBX1
PSMB6 SF3B3 NCL
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Table 3.9. Interactome o f CFTR (continued)
Total Lost compared to 
AF508CFTR
Gained compared to 
AF508CFTR
AF508CFTR wtCFTR AF508CFTRjnki wtCFTR AFSOSCFTR™0 wtCFTR AF50*CFTRjn“
PSMD11 SRI PGK1
PSMD3 STIP1 PLS3
PTBP1 TAGLN2 PCBP1
RPL12 TFG PCBP2
RPL23 TKT PABPC1
RPLPO TPI1 PABPC4
RPS18 TRIM21 LMNA
RPS25 TUFM DDX5
RPS27 UBC PHB2
RPS3 VARS P4HB
RPSA VCL PDIA3
RUVBL2 VCP PDIA4
SDHA XRCC5 PDIA6
SEC23A XRCC6 TFG
SERPINH1 YWHAE DHX15
SFPQ ZYX G3BP1
SLC25A5 RBM14
SND1 EWSR1
SRI FUS
STIP1 RUVBL2
TAGLN2 SERPINH1
TCP1 SDHA
TFG CCT7
TKT CCT8
TPI1 CCT6A
TRIM21 TLN1
TUFM TXNDC5
UFD1L TARS
VCP TAGLN2
VDAC2 VCP
XRCC6 TKT
YWHAE TPI1
UFD1L
UBA1
VCL
VDAC1
VDAC2
XRCC6
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Table 3.9. Interactome of CFTR (continued)
Total Lost compared to 
AF508CFTR
Gained compared to 
AF508CFTR
AF508CFTR wtCFTR WiWXUEZ wtCFTR AF508CFTR™a wtCFTR AF508CFTRJfaa
XRCC5
RPS21
RPS5
RPS9
SLC3A2
RPL24
RPL27A
RPL5
CAD
CPS1
CBR1
HUWE1
ERLIN2
CAPZA1
KHSRP
HNRNPAB
HNRNPA1
HNRNPM
LARS
PRDX6
PFN1
PSMB6
SEC23A
SRI
CCT4
TAF15
SNRPA
UBAC2
94
degradation machinery (from 15 in untreated, to 12 after JNKi II treatment), while there was a 
slight increase in the ER luminal folding/ degradation machinery (from 9 to 13 components after 
treatment), which reflects the behaviour of the wtCFTR, as discussed above. Next, to determine 
whether the interactome of AF508CFTR treated with JNKi (AF508CFTRJNKi) resembles that of 
wtCFTR, these were compared. For the proteins that were present in the AF508CFTRJNKi 
interactome but absent in the AF508CFTR interactome, there was little overlap with that of the 
wtCFTR-specific proteins. An interesting candidate among the overlapping components was 
calnexin, as it has been shown that while wtCFTR is sensitive to modulation through calnexin 
dependent proteostasis; AF508CFTR is insensitive, with any such modulation suggesting that 
wtCFTR is probably in an advanced stage of folding/quality control, which AF508CFTR does not 
reach.
The presence of calnexin in the AFSOSCFTR^1 interactome suggests that the JNKi II 
treatment promotes AF508CFTR to an advanced folding/quality control stage. Among the proteins 
that were absent in the comparison of untreated AF508CFTR, the wtCFTR and AFSOSCFTR™1^  
interactomes showed substantial overlap. Among these components there were known proteostatic 
components involved in ERAD, including proteasomal subunits (PSMD3 and PSMD11) and FAF2 
(or UBXD8), a known regulator of proteostasis of apolipoprotein B (ApoB) and also a regulator of 
triglyceride synthesis. Interesting components that had no previous established roles in ERAD 
included chaperonin subunits and ribosomal subunits. When the differences between the 
AF508CFTR and AFSOSCFTR^1 interactomes were scrutinised, in addition to differences that 
were similar to those seen between the wtCFTR and AF508CFTR interactome, it was noted that the 
AFSOSCFTR™0 interactome lost interactions with STIP1 (HOP), unlike the wtCFTR interactome. 
HOP has been reported to be involved in AF508CFTR proteostasis, and reduction in its levels by 
siRNA-mediated knock-down has been reported to rescue AF508CFTR (Marozkina et al. 2010). 
Moreover, siRNA-mediated depletion of HOP was also known to partially correct the AF508CFTR 
(Marozkina et al. 2010).
To summarise, the JNKi II treatment transforms the AF508CFTR interactome slightly, to 
mimic the wtCFTR interactome, and results in several changes in the interactome of AF508CFTR.
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These changes lead to a reshaping of the proteostasis content for resemblance to that of wtCFTR, 
and probably explain the escape of AF508CFTR from the ERQC.
Discussion
This study identified a novel role for the MAP3K11-JNK pathway in the regulation of the 
quality control of AF508CFTR at the ER and the PM. Characterised inhibitors of this pathway led 
to a rescue of AF508CFTR from the ERQC. Moreover, initial investigations of this pathway 
revealed a relationship between mainly oxidative stress, inflammation and intracellular 
proteostasis, providing a possible link to integrate cellular proteostasis with cellular homeostasis. 
The inactivation of the pathway affected the ERAD of AF508CFTR and partially rescued the 
channel function. Most importantly, a previous study has demonstrated that the MAP3K11-JNK 
pathway inhibitors used in the present study, namely oxozeaenol and kenpaullone, are active in the 
correction of conductance in primary cells from CF patients (Trzcinska-Daneluti et al. 2012), 
which further supports the therapeutic potential of targeting this pathway.
MAP3K11-mediated control of AF508CFTR proteostasis is mediated through the JNK 
(JNK2) arm of the pathway. Nevertheless, the knock-down of MAP3K11 leads to quantitatively 
more rescue than down-regulation of JNK, which suggested that other MAP3K11-activated 
pathways also contribute to the regulation of AF508CFTR proteostasis in additive or synergistic 
ways. The JNK pathway is known to activate the ubiquitin ligase ITCH, which controls the 
proteostasis of phosphorylated c-jun and thus acts as a negative feedback loop in the JNK pathway 
(Gallagher et al. 2006). Although ITCH does not regulate AF508CFTR proteostasis (Okiyoneda et 
al. 2010), this example provides a precedent as to how the JNK pathway might control protein 
degradation via the ubiquitin-proteasome pathway. The JNK pathway is also known to activate 
downstream transcription factors that are known to control processes relevant to proteostasis, like 
the HSR (HSF1) (Park and Liu 2001), and it is also known to target some proteins, like MFN2 
(Leboucher et al. 2012) and BimEL (Leung et al. 2008), to proteasomal degradation by direct 
phosphorylation.
The depletion of downstream transcriptional regulators of the JNK pathway e.g., HSF1 and
ATF1, at least partially reproduces the rescue obtained with MAP3K11 or JNK depletion, which
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suggests a transcriptional programme downstream of the JNK pathway that resets the proteostatic 
environment of the cell. On the other hand, the swift MAP3K11-dependent effects on the levels of 
AF508CFTR observed after the treatment with ROS or inflammatory cytokines suggests a post- 
transcriptional regulation of proteostatic components involved in the control of AF508CFTR by 
this pathway. The MAP3K11-JNK pathway appears to control the degradation of AF508CFTR at 
the level of both the ER and the PM. Whether multiple components of the proteostatic environment 
are affected to achieve this regulation at two subcellular locations, or whether the same components 
can act at both levels, is not clear. A recent study has shown that many components of the 
ubiquitin-proteasome system that regulate AF508CFTR proteostasis at the level of the ER are also 
involved in the regulation of degradation of AF508CFTR at the level of the PM (Okiyoneda et al. 
2010), which suggests that the same proteostatic regulators might be involved in both locations.
In addition, it is possible that changes in the ERAD of AF508CFTR allow sufficient time 
for AF508CFTR to fold (although this was not detectable in these assays here), which reduces the 
targeting of the protein by the PM quality control system. Which of these proteostasis machinery 
components are regulated by post-translational or transcriptional means by the MAP3K11-JNK 
pathway remains unclear. To address the corrector mechanisms of the pathway, the present study 
used interactome analysis of AF508CFTR with and without corrector (JNKi II) treatment. This 
analysis suggested several changes, which include a probable advancement in the folding pathway, 
as indicated by the increased interaction with the calreticulin/ calnexin pathway, and the reduction 
in the association of HOP with AF508CFTR. Interestingly it is already known that reduction in the 
levels of HOP can rescue AF508CFTR from the quality control (Marozkina et al. 2010). Further 
validation is necessary to examine the importance of other changes that were seen to either gain or 
lose upon the JNKi II treatment. Further investigations using microarrays and phosphoproteomics 
are necessary to understand the molecular targets of the MAP3K11-JNK pathway.
The MAP3K11-JNK pathway appears to be under the control of mainly ROS and
inflammatory cytokines. The reduction mediated by ROS was robust compared to that of the
cytokines TNF-a or TGF-0, which were transient. The role of ROS/ oxidative stress in the control
of AF508CFTR proteostasis is interesting, as the increased inflammatory response due to the
presence of neutrophils in the CF lung leads to increased ROS levels (Hull et al. 1997) that can lead
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to further worsening of the phenotype, by a reduction of AF508CFTR levels. Both TNF-a and 
TGF-p act as genetic modifiers in the case of CF, and their increased levels have been correlated 
with the worsening of lung function (Davies et al. 2005). How the increased levels of TNF-a and 
TGF-p lead to a probable worsening of lung function is not clear at present. The present study 
suggests a role for these cytokines in maintaining the intracellular levels of AF508CFTR, and it 
provides a possible molecular link between the levels of TNF-a and TGF-P and the worsening of 
lung function. The ROS and inflammatory cytokines produced by the immune cells present in the 
inflammed lungs can be seen as activators of the pathway.
Recent studies have also shown that the CF cells in isolation continue to show a hyper- 
inflammatory phenotype with increased intracellular ROS (Luciani et al. 2010), which might act in 
a cell-autonomous way to activate this pathway, or maintain tonically active levels of the pathway. 
In line with this, there is the observation that a reduction in the levels of the pathway components 
(MAP3K11 and JNK) under steady-state conditions with no addition of exogenous cytokines or 
ROS can still lead to increases in the levels of AF508CFTR, which suggests that this pathway is 
tonically active in the cell. It was also shown that ROS scavenging agents, like N-acetylcysteine or 
cystamine, can act as correctors (Luciani et al. 2010), further validating the importance of ROS 
management in AF508CFTR proteostasis. These observations indicate that the increased 
inflammatory and oxidative stress phenotype caused by the absence of AF508CFTR further reduces 
the levels of AF508CFTR; as such a vicious cycle of inflammation, ROS and intracellular 
proteostasis might operate under the CF conditions. This study provides an example of where the 
tonically active pathway controls intracellular proteostasis in a cell autonomous way, and can be 
coupled or integrated with the physiology/ pathology o f the organism.
MAP3K11 and JNK inhibition has been shown to be neuroprotective in neurodegenerative 
misfolding diseases like Alzheimer’s, Parkinson's and Huntington’s diseases (Borsello and Forloni 
2007). The present study has established the relevance of the MAP3K11-JNK pathway for the 
correction of the basic folding and trafficking defects of AF508CFTR. Furthermore, the 
MAP3K11-JNK pathway might be a target in many other misfolding mutations that are subjected 
to ERAD, like mutants of ATP7B, ATP8B1, alpha-1-antitrypsin, and others, which is an open 
avenue for further exploration.
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Chapter 4
The calcium/ calmodulin-dependent kinase cascade regulates 
AF508CFTR proteostasis 
Introduction
Calcium calmodulin dependent kinases (CaMKs) are activated by the intracellular second 
messenger calcium (Ca2+) and are important in processes like growth-factor and hormone signaling, 
cell-cycle regulation, gene expression, and apoptosis (Berridge 2001; Hook and Means 2001). 
Calcium functions in signalling by forming a complex with calmodulin (CaM), which serves as a 
ubiquitous intracellular Ca2+ receptor. CaM increases its affinity for a large number of CaM- 
binding proteins upon Ca2+ binding, like CaMKs (CaMKI, CaMKII, and CaMKJV). For full 
activation of CaMKI and CaMKIV, phosphorylation by upstream CAMKK1 or CAMKK2 
(CaMKKa or CaMKKp, respectively) is also required, which leads to the concept of a CaMK 
cascade like that of the MAPK cascade (Hook and Means 2001). In addition to a role in cascades, 
CAMKK2 is also a physiologically relevant upstream activator of AMP-activated protein kinase 
(AMPK) (Hawley et al. 1995), which is known to be hyperactivated in CF (Hallows et al. 2006). 
CaMKII is a very important regulatory kinase, but it is not a component of a CaMK cascade 
(Colomer and Means 2007). The CaMKII substrates are implicated in homeostatic regulation of the 
cell, and in neuronal function (Hudmon and Schulman 2002).
CaMKI and CaMKII are ubiquitously expressed; CAMKK2 is expressed mainly in the 
brain, and also at low levels in testis, spleen and lung (Racioppi and Means 2012). CAMKK2 is 
known to function in both autonomous and Ca2+/CaM (Ca/CaM)-dependent manners, which 
involves a wide variety of stimuli, including LPS-mediated TLR4 activation, ghrelin-mediated Gq- 
coupled growth-hormone secretagogue activation (Racioppi and Means 2012), and hypoxia- 
mediated ROS accumulation (Mungai et al. 2011). GSK3p and CDK5 are known to control the 
autonomous activity of CAMKK2 by phosphorylation (Green et al. 2011). The signals along the 
CAMKK2 pathway are reported to control cytoskeletal remodelling, energy homeostasis (Racioppi
and Means 2012), autophagy (Hoyer-Hansen et al. 2007), and inflammation (Racioppi et al. 2012).
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There is evidence that the intracellular Ca2+ concentration ([Ca2+]j) is enhanced in CF cells, 
and that this enhanced [Ca2+]j also appears to contribute to the pathology (Ribeiro 2006; Antigny et 
al. 2011). Calcium signalling is also postulated to influence the proteostasis network (Powers et al.
2009). Drugs inhibiting L-type Ca2+ channels in the PM, like diltiazem and verapamil, lead to 
increased transcription and translation of numerous cytoplasmic and ER chaperones that controlled 
the proteostasis network to enhance the folding, trafficking, and activity of lysosomal enzymes (Mu 
et al. 2008). Moreover, drugs that inhibit Ca2+ pump, including thapsigargin and curcumin, have 
been shown to rescue AF508CFTR from the ERQC (Norez et al. 2006), thus motivating further 
characterisation of this pathway.
Interestingly, CAMKK2 is one of the drug down-regulated genes that upon down- 
regulation can rescue AF508CFTR. Further testing of the downstream kinases of the CAMKK2 
cascade (Figure 4.1a) led to the identification of other kinases that can rescue AF508CFTR. The 
CAMKK2 cascade might also control the proteostasis of AF508CFTR.
Results
4.1. The CAMKK2-CAMK1, CAMKK2-AMPK cascades rescue AF508CFTR
As mentioned earlier in the introduction downstream kinases that are activated by 
CAMKK2 include CAMK4, CAMKI and AMPK. While knockdown of CAMK4 did not show any 
effects on AF508CFTR, the down-regulation of CAMKI and AMPK led to an increase in the 
AF508CFTR band C levels that was similar to that obtained with CAMKK2. This suggested that 
these two arms of the CAMKK2 pathway probably regulate CFTR proteostasis (Figure 4.1b, c). 
Moreover, the activation of AMPK using the treatment of CFBE cells with the well-known AMPK 
activator 2-deoxyglucose (Wang et al. 2011) led to a drastic decrease in band B of AF508CFTR 
(Figure 4 .Id). CAMKK2 is also known to function in a Ca/CaM-dependent manner (Racioppi and 
Means 2012), so several upstream Ca2+-binding calmodulin proteins and a few Ca2+ channels were 
tested by the siRNA-based approach. Among these, CALML5 is a CaM-like Ca2+-binding protein, 
and ITPR2 is a receptor for inositol 1,4,5-trisphosphate (a second messenger that mediates the 
release of [Ca2+]), and these marginally rescued AF508CFTR (Figure 4.1e). It appears that calcium
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Figure 4.1. CAMKK2 cascade rescue AF508CFTR.
a. Model CaMKinase cascade, b. Representative immunoblot of the CFBE cells that were treated 
with siRNAs as indicated for 72 h and lysed and immunoblotted for CFTR. c. Fold change in band 
C quantified from immunoblots (n = 3) of the experiments in (a), d. CFBE cells were treated with 
AMPK activator (2-deoxyglucose 25 mM) for 3 hours, fold-change in band B quantified from 
immunoblots (n=3) and expressed and fold change compared to untreated, with representative 
immunoblot. e. The siRNAs targeting upstream activators of the CAMKK2 cascade were treated 
to CFBE cells as indicated for 72 h and fold-increases in band C were quantified from immunoblots 
(n = 3). Data represent mean ± SD (**P < 0 .01 , ** * P  <  0 .0 0 1 ).
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which is reported to be enhanced under CF conditions (Ribeiro 2006), can influence the quality 
control of AF508CFTR, and this process might be signalling dependent, with the participation of 
the upstream Ca2+-binding CALML5 protein and the Ca2+-releasing ITPR2 receptor, which 
confirms the role o f the CaM kinase cascade in AF508CFTR proteostasis.
4.2. CAMKK2 and AMPK are connected to the CFTR proteostasis network
To determine the candidate downstream effectors of the CAMKK2 pathway that are 
involved in the control of CFTR proteostasis, bioinformatic analysis was used. The CAMKK2 
pathway (Figure 4.2) components that were partially correcting the AF508CFTR and the CFTR 
proteostasis network (see table 2.5) components were combined, and the interactions between these 
were analysed using P A  analysis (see section 6.20). The CAMKK2 pathway signal transducer 
AMPK (PRKAA1 and PRKAA2) is shown to interact with several components of the ERAD 
machinery that is known to regulate AF508CFTR proteostasis, including VCP, UBE2I and HSPA4 
(Figure 4.2). When the interactions between CAMKK2 and the CFTR proteostasis network were 
studied, it became obvious that the CAMKK2 pathway had connections with the components 
involved in intracellular protein degradation, the trafficking machinery.
Many ubiquitin ligases, the autophagy component (SQSTM1), the proteosomal component 
(PSMD11) and VCP are known to associate with AMPK, although whether they are 
phosphorylated by AMPK and if this phosphorylation regulates their activity in not known. One 
particular case, NEDD4L, is interesting, as AMPK is known to activate NEDD4L, an ubiquitin 
ligase that is involved in degradation of AF508CFTR at the post-ER level (Caohuy et al. 2009). 
The CAMKK2 pathway might regulate the NEDD4L which might contribute to the regulation of 
AF508CFTR proteostasis, along with the other potential modifications of protein degradation and 
trafficking machinery components. While for the membrane trafficking machinery, both SEC24A 
and AP2B1 are known to be phosphorylated by AMPK, again, the function of this modification is 
not known. Moreover, activation of the AMPK complex is reported to decrease the mRNA of 
STAT1 (Meares et al. 2013). A study has shown that STAT1 overexpression rescues AF508CFTR 
(Trzcinska-Daneluti et al. 2009). Therefore, the inhibition of AMPK might promote STAT1 
activity, and this in turn might affect the proteostasis of AF508CFTR.
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Figure 4.2. CAMKK2 and AMPK interact with the CFTR proteostasis network.
CAMKK2 cascade molecules (green) interact with known CFTR proteostasis network genes 
(grey), as predicted by the IP A analysis. (PRKAA1= AMPKal, PRKAA2=AMPKa2 are catalytic 
subunits of AMPK)
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Discussion
The present study reveals a role of the CaM kinase cascade dependent on CAMKK2 in 
rescuing AF508CFTR, through its CAMKI and AMPK arms. Although CAMKK2 was the only 
kinase found in the commonly regulated genes, other CAMKK2 pathway components were 
inferred from the literature survey. Down-regulation of each of these genes showed that few of the 
downstream and upstream molecules of this pathway are also involved in the correction of 
AF508CFTR. This strategy potentially identified the other relevant genes of the same pathway, 
irrespective of whether or not they are modulated by the drugs.
Although the presence of AF508CFTR leads to increased intracellular calcium (Ribeiro 
2006), it is not known whether Ca2+-dependent signalling is hyperactivated in the AF508CFTR 
cells compared to wtCFTR. The [Ca2+]i is known to be directly linked with the activity of 
Ca2+-sensitive kinases. CAMKK2 (Hoyer-Hansen et al. 2007), and AMPK (Kroemer et al. 2010) 
will be activated by the abnormal [Ca2+]i under stressed conditions, and these upstream sensors will 
immediately transmit the signals to downstream substrates for the adjustment of cellular 
metabolism in the new microenvironment. Furthermore, the CaM kinase cascade can also be 
activated by signalling through Gq-coupled receptors, inositol 1,4,5-trisphosphate-mediated release 
of Ca2+ via activation of the IP3 receptor, and Ca2+ entry into cells via PM ion channels, and also by 
Toll-like receptors (Racioppi and Means 2012) and ROS (Mungai et al. 2011). Thus CAMKK2 
might act as a signalling hub that can receive and decode signals transmitted by means of many 
diverse cellular regulatory pathways.
Therefore, higher levels of calcium might act as physiological activator of the CaM kinase 
cascade and maintain it at a tonically active state, to contribute to AF508CFTR proteostasis. 
Moreover, it is documented that AF508CFTR-mutant primary CF cells have higher AMPK activity 
(Hallows et al. 2006), which suggests that the AF508CFTR condition might indeed have an active 
CaM kinase cascade. The siRNA-based knock-down of the members of this CaM kinase cascade, 
namely CAMKK2, AMPK and CAMKI, led to higher levels of band B, which indicates that there 
might be a compromise in the ERAD of AF508CFTR. However, whether up-regulation of this 
pathway enhances ERAD or ERQC was not explored, except that AMPK activation by drug led to
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increased clearance of AF508CFTR. Another interesting point to be noted is that AMPK is also 
known to be activated by VEGF via CAMKK2 (Stahmann et al. 2010), VEGF is also reported to be 
over-produced under CF conditions (Martin et al. 2013). It is important to note that depletion of the 
VEGF receptor VEGFR2/ kinase insert domain receptor was found as one of the correctors in the 
present study (see section 2.6), which indicates further that the CaM kinase cascade might be 
physiologically important for AF508CFTR proteostasis. As AMPK phosphorylates the R domain 
on CFTR (King et al. 2009), which decreases its open probability, so another benefit of targeting 
AMPK or the CAMKK2 pathway might be that there will be an increase in the channel open 
probability.
There were interactions predicted between CAMKK2, AMPK and the known CFTR 
proteostasis network genes. Whether AMPK phosphorylates these components and modulates their 
activities is not known. While it is known that VCP is involved in the extraction of proteins from 
the ER for degradation and it is phosphorylated by the p38 MAPK pathway, and that this 
phosphorylation can regulate its activity, whether it is also phosphorylated by AMPK and if this 
phosphorylation can regulate its activity is not known. A recent study in C. elegans showed that 
increased [Ca2+]i increased the activation of a known proteostasis regulator, HSF1, which is 
dependent on Ca2+-dependent kinases (Silva et al. 2013). This indicates that the CaM kinase 
cascade might indeed be relevant in proteostasis. Moreover, the PM L-type calcium channel 
blockers diltiazem and verapamil helped the trafficking of N370S and L444P mutant 
glucocerebrosidase. Although the mechanism is not clear, these L-type calcium channel blockers 
diltiazem and verapamil led to increases in the expression of several chaperones (Mu et al. 2008), 
again indicating the ability of calcium-dependent signalling processes in the regulation of 
proteostasis. The ER calcium channel, SERCA, inhibitor thapsigargin has already been shown to 
correct AF508CFTR (Egan et al. 2002), but whether thapsigargin has any effect on the CaM kinase 
cascade is not clear. The CAMKK2 inhibitor STO609 (Tokumitsu et al. 2003) was tested, but it did 
not have any effects on AF508CFTR, probably because of the non-specific effects of STO609. 
Furthermore, the mechanistic insight into how this depletion of the CAMKK2-dependent CaM 
kinase cascade rescues AF508CFTR and influences its proteostasis and its physiological relevance 
is the topic for further investigation.
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Chapter 5
General discussion
5.2. Meta-analysis method potentially identified novel links to AF508CFTR proteostasis.
The present study used meta-analysis/ fuzzy intersection analysis of gene expression to 
initially define the mode of action that is common to different corrector drugs for the correction of 
AF508CFTR. This thus focussed on the commonly regulated genes/ networks/ pathways that are 
important for the proteostasis and rescue of AF508CFTR. The gene expression data for many of the 
corrector drugs was obtained from the public Connectivity Map database (cMap; 
http://www.broadinstitute.org/ cmap/). Indeed, the biomedical field has been greatly influenced by 
the availability of various ‘-omics’ technologies more recently. Moreover, public data repositories 
and databases like Gene Expression Omnibus (GEO; http://www.ncbi.nlm.nih.gov/geo/) and the 
Library of Integrated Network-based Cellular Signatures (LINCS; http://lincs.hms.harvard.edu/db/) 
now provide almost overwhelming datasets for many given drugs, physiological states, and disease 
conditions. These datasets can help to solve new hypotheses and might improve our overall 
biological understanding. Using these repositories, many meta-analyses has been carried out 
previously to identify common transcriptional effects of neoplastic transformation and progression 
(Rhodes et al. 2004), and the commonly dysregulated genes in pancreatic cancer (Grutzmann et al. 
2005).
Although there are many instances where gene-expression meta-analyses have been used to 
understand the mechanisms in the context of disease, there have been very few examples of meta­
analyses of the gene expression profiles that are promoted by many drugs, to reveal mechanisms 
that are common among these drugs. The present study is one such investigation, designed to 
dissect out the mechanisms of action that are common to many corrector drugs through an analysis 
of gene expression. More recently, an investigation into the mechanisms of action using gene 
expression among several anticancer drugs that are translation inhibitors revealed the commonly 
regulated HSF1 target (Santagata et al. 2013). Although this method allows the inclusion of 
pathways that are also not modulated by all of the drugs, there remains a high probability of
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missing pathways that are common to a veiy few drugs, or those that are unique to individual 
drugs, which does not exclude the presence of other correction-relevant genes/ pathways/ networks 
that are particular to an individual drug. An alternative method might be useful for this purpose, 
where each drug is analysed individually for correction-relevant genes/ pathways/ networks. 
However, the currently used method of meta-analysis of microarray drugs followed by bio- 
informatic analysis has confirmed the potential to identify novel links to AF508CFTR proteostasis. 
Otherwise it would have been hard to arrive at the common mechanisms targeted by the many 
corrector drugs and link them to proteostasis by using more conventional hypothesis-driven studies. 
From the basic science perspective, although there is now a substantial body of data on the 
biophysics and cellular mechanisms of CFTR folding and AF508CFTR misfolding in vitro, there 
remain major gaps in our knowledge of how critical components of the quality control machinery 
recognize the folding defect in tissues (Lukacs and Verkman 2012). The present study employed a 
new strategy to shed lights on this gap and discovered several novel components that affect the 
quality control of AF508CFTR. This discovery may help to identify correctors with improved 
potency and efficacy.
The approach (Figure 5a) used in the present study returned several pathways/ molecules 
(Figure 5b) that are interesting from a therapeutic point of view (with many also being 
‘druggable’). A previous kinase inhibitor screening (Trzcinska-Daneluti et al. 2012) identified 
several hits that can correct AF508CFTR, and many of these drugs might target the genes that have 
been shown to rescue AF508CFTR in the present study. This evidence strongly supports the 
strength of the approach used in the present study. The present meta-analysis approach might be 
more efficient than small-molecule screening approaches for the identification of candidates for 
therapy. These corrector genes identified in the present study (Figure 5b) also emphasizes the 
further studies that seek to better understand the individual contribution of these proteins in CFTR 
folding.
The depletion of PIK3CB, PIK3CG, PDGFRA, PDGFRB, VEGFR2/KDR and
VEGFR1/FLT1 were successful in correcting the basic AF508CFTR (section 2.6), and
interestingly, inhibitors that can target these molecules have been identified also as rescuing
AF508CFTR in a more cystic-fibrosis-relevant model: primary human bronchial epithelial cells
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Figure 5.1. Strategy of meta-analysis yielded corrector pathways/ networks/ genes.
a. Flow diagram of the meta-analysis strategy, b. Pathways/networks that rescue AF508CFTR.
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affected by cystic fibrosis (Trzcinska-Daneluti et al. 2012). There is an immediate need to test the 
battery of available inhibitors of the corrector genes, which might lead to the identification of many 
novel and efficient therapeutic candidate drugs.
5.2. The MAP3K11-JNK pathway is a new target to develop therapeutics for cystic fibrosis.
The hypothesis driven approaches led to the discovery of many molecules, such as PDE5 
inhibitors (e.g. sildenafil) (Dormer et al. 2005), alpha-glucosidase inhibitors (e.g. miglustat) (Norez 
et al, 2006) and histone deacetylase inhibitors (e.g. SAHA) (Hutt et al, 2010), small molecule 
screening approaches led to the discovery of aminoarylthiazoles, quinazolinylaminopyrimidinones, 
bisaminomethylbithiazoles class chemical molecules (e.g. Corr-4a) (Pedemonte et al, 2005), 
quinazolines (e.g. VRT-325) (Loo et al, 2005), the sildenafil analogues like KM11060 (Robert et 
al, 2008), galfenine (Robert et al, 2010), chlorzoxazone (Carlile et al. 2007) and up to date the most 
potent corrector VX-809 (Van Goor et al, 2011), and CFTR model based virtual computational 
screening approaches has led to the discovery many more AF508CFTR correctors (Kalid et al. 
2010; Odolczyk et al. 2013). After all these efforts there is no available efficient corrector for the 
AF508CFTR defect. The accumulating information on AF508CFTR indicate that it may not be 
possible to fully correct the trafficking defect with a single compound (Pedemonte and Galietta 
2012). Several in vitro studies point out that a large rescue may be obtained only with a 
combination of correctors. More effective correctors may be identified by high-throughput 
screening of compounds with novel and unexplored structure, by exploiting the increasing 
information available on CFTR structure, or by taking advantage of the identification of important 
proteins of the CFTR interactome. In this respect, discovering the proteins with a high relevance 
for AF508CFTR quality control/ proteostasis has been highlighted (Pedemonte and Galietta 2012). 
The present study gives an example where the discovery of proteins that control the proteostasis 
has led to discovery of novel correctors drugs for AF508CFTR defect. The present study also opens 
a venue to try many more drugs that target the druggable proteins like PI3KCB/G, PDGFRA/B, 
KDR, FLT etc. which were potent AF508CFTR correctors.
Moreover, the MAP3K11-JNK cascade and the CAMKK2 cascade are also involved in 
proteostasis and rescue of AF508CFTR (section 3.1, section 4.1). There is evidence that these
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cascades might be activated during the cystic fibrosis condition. In cystic fibrosis, reports have 
indicated increased p38 activity (a downstream target of MAP3K11) (Berube et al. 2010), 
increased Ca2+ levels (upstream of CAMKK2) (Ribeiro 2006), and hyperactivity of AMPK 
(downstream of CAMKK2) (Hallows et al. 2006). Inhibitors of JNK, and also oxozeaenol, which 
can reduce JNK activity (Ninomiya-Tsuji et al. 2003), can rescue AF508CFTR. In a clinical trial 
for cancer, oxozeaenol was also seen to correct AF508CFTR (Trzcinska-Daneluti et al. 2012). The 
present study provides the observation that ROS and cytokines can influence intracellular 
proteostasis of AF508CFTR (section 3.6). It will be interesting to test further whether the cystic 
fibrosis condition, which is known to involve high Ca2+ levels, has a hyperactive CAMKK2 
cascade, which might influence proteostasis of AF508CFTR. The CAMKK2 cascade can also be 
targeted in the future using the many inhibitors that are available.
5.3. Increase in efficiency ofAF508CFTR rescue by combination o f correctors.
The development of correctors of the AF508CFTR defect has been hampered by an 
apparent upper limit of improvement (5%-10%), which is probably caused by the multiplicity of 
the steps/ factors involved in the folding/ trafficking of AF508CFTR. Recent studies have shown 
that simultaneously targeting multiple steps in the folding pathway of AF508CFTR can help to 
overcome this apparent limit (Okiyoneda et al. 2013). Okiyoneda et al. (2013) argued that to have 
AF508CFTR levels comparable to those of wt-CFTR, it is necessary to restore the inter-domain 
interactions. Ideally, any AF508CFTR corrector should enhance AF508CFTR folding and 
traficking from the ER, stablise it at the plasma membrane, and decrease the gating problem 
(increase the channel opening and closing capacity). This might be achieved by a combination of 
three classes of corrector compounds: class I, which target NBD1-MSD2 (VX-809); class II, which 
target NBD2 (corr-4a); and class III, which restore the energy defect (glycerol). Corr-4a is very 
toxic and therapeutically inapplicable. The concept of drug combination in CF (e.g., a corrector 
plus a potentiator) is already accepted (Pedemonte and Galietta 2012). So the search for 
compounds of class II and class III is still a need. Further efforts of screenings either of chemical 
libraries or CFTR model based computational are warranted to identify the highly efficient 
molecules under each class. Novel hypothesis driven approaches can also aid in this quest of new 
class of compounds.
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While the studies of Okiyoneda et al. (2013) mainly focused on the use of pharmaceutical 
chaperones that bind and promote folding of AF508CFTR, here, in the present study, I targeted the 
modulation of the proteostatic machinery. This will not only allow AF508CFTR to overcome ER 
quality control, but also to stabilise the plasma membrane pool. The present observation of the 
different targets of the MAP3K11-JNK pathway and VX-809 along the AF508CFTR folding 
pathway, suggests that their therapeutic potential is complementary. The correction or rescue 
effects of the JNK inhibitor oxozeaenol in combination with VX-809 are highly synergistic in 
biochemical assays (section 3.7). Although the same synergistic effects must be tested further at the 
level of chloride conductance, this observation highlights a new strategy that can be used in 
combination with the above-mentioned classes of correctors. Whether this new strategy will lead to 
better inter-domain interactions and decrease the energetic defect has yet to be determined. The 
observations from the present study reveal many molecular targets, and it is now necessary to test 
molecules that target the corrector genes described in the present study, for the development of new 
therapies for cystic fibrosis caused by the AF508 mutation.
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Chapter 6
Materials and methods 
Materials
VX-809 was from Selleckchem (Houston, USA), oxozeaenol, and kenpaullone were from 
Tocris Bioscience (Bristol, UK). Puromycin, anti-CFTR M3A7 mouse monoclonal antibody, HRP- 
conjugated anti-mouse, anti-rabbit and anti-rat IgG antibodies, Luminata Crescendo Western HRP 
substrate, and PVDF membranes for protein blotting were from Merck Millipore (Massachusetts, 
USA). Nitrocellulose membranes for protein blotting were from Perkin Elmer (Massachusetts, 
USA). BCA protein estimation kits, SuperSignal West Femto Chemiluminescent Substrate, X-ray 
films, and coverslips for 24 well plates were from Thermo scientific (Waltham, USA). CellROX® 
Green, Lipofectamine 2000, Opti-MEM Glutamax, MEM, DMEM, MEM-NEAA 100x, G418, 
DPBS-10x, dithiothreitol, florescent tagged anti-mouse, anti-rabbit, and anti-rat IgG, Dynabeads 
protein A, G, and foetal bovine serum (FBS) were from Life Technologies (California, USA). The 
siRNAs used along with the provider are listed in Table 6.3. Glutamine 100x, penicillin/ 
streptomycin 100x and FBS were from Euroclone SPA (Milano Italy). Trypsin 10x for cell culture 
was from Biochrom (Cambridge USA). Protease inhibitor cocktails and phosphatase inhibitor 
(PhosSTOP) were from Roche (Basal Switzerland). Anti-JNK, anti-phosphoJNK, anti-cJUN, anti- 
phosphocJUN, anti-MAP3Kl 1, and anti-ubiquitin antibodies were from Cell Signaling Technology 
(Danvers, Massachusetts, USA). The mouse anti-HA antibody was from Covance (Princeton, New 
Jersey, USA). Anti-Hsp70, anti-Hsp90, anti-Hop, and anti-Hsp40 antibodies were from Enzo 
Lifescienes (Farmingdale, NY, USA). The rabbit anti-Derlinl antibody was from Abeam 
(Cambridge, UK). The mouse anti-hCFTR antibody clone 24.1 was from R&D Systems 
(Minnneapolis, USA). The rat anti-CFTR was kindly provided by CFTR Folding Consortium. 
Plasmid constructs containing mouse JNK2 (MKK7B2Jnk2a2-Plasmid #19727), MKK7 (Plasmid 
#14622) and GFP-Ub (GFP-ubiquitin) (Plasmid #11928) were from Addgene (Cambridge USA). 
The ZsProSensor-1 proteasome sensor was from Clontech (California, USA). The plasmid for 
temperature-sensitive VSVG tagged with GFP (VSVG-GFP) was a kind gift from Dr. Jennifer
Lippincott-Schwartz, NICHD, NIH, Bethesda, USA. The CDC42 plasmid was from A. Hall, Sloan- 
Kettering Institute, New York, NY, USA. The plasmid containing P-glycoprotein wt and the 
G268V and DY490 mutants were a kind gift from Dr. David M. Clarke, University of Toronto, 
Canada. hERG wt and the G601S mutant plasmids were a kind gift from Dr. Alvin Shrier, McGill 
University Life Sciences Complex, Montreal, Quebec, Canada. HiSpeed Plasmid Maxi kits for 
Plasmid DNA preparation, RNeasy Mini kits for RNA isolation, and QuantiTect Reverse 
Transcription kits were from Qiagen (Hilden, Germany). Anti-CFTR rat monoclonal (3G11) 
antibody was kindly provided by CFTR Folding Consortium, USA. Anti-a-actin, anti-a-tubulin 
antibodies, cell culture plastics, and all the other chemicals where purchased from Sigma Aldrich 
(St. Louis, USA). HeLa cells expressing HA-tagged wtCFTR and AF508CFTR (Okiyoneda et al.
2010) were a gift from Dr Gergely L. Lukacs, McGill University, Montreal, Quebec, H3G 1Y6, 
Canada. CFBE41o‘ cells expressing untagged wtCFTR and AF508CFTR (Bebok et al. 2005) 
(referred to as CFBE cells here) were a gift from Dr. J. P. Clancy, Gregory Fleming James Cystic 
Fibrosis Research Center, Birmingham, AL, USA. CFBE41o' cells expressing halide sensitive YFP 
(CFBE-YFP) were a kind gift from Dr. Luis Galietta, Istituto Giannina Gaslini, Italy.
Methods
6.1. Cell culture
All of the cells were grown in 95% air and 5% CO2, and at 37 °C. The CFBE cells were 
cultured in MEM supplemented with 10% FBS, MEM NEAA, penicillin/ streptomycin, glutamine 
and 2 pg/ml puromycin. They were routinely grown on culture plates and flasks coated for 30 
mins with a coating prepared as follows: 10 pg/ml fibronectin adhesion-promoting peptide (Sigma- 
Aldrich), 100 pg/ml albumin from bovine serum (Sigma-Aldrich), and 30 pg/ml bovine collagen 
type I ((BD Transduction Laboratories) dissolved in MEM (Lei et al. 1996). CFBE-YFP cells were 
cultured in the same medium as the CFBE cells, but supplemented with 50 pg/ml G418. HeLa cells 
expressing wtCFTR and AF508CFTR were cultured in DMEM supplemented with 10% FBS, 
penicillin/ streptomycin, glutamine and 1 pg/ml puromycin.
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6.2. Plasmid preparation
Single colonies of bacteria transformed with the plasmid of interest or stored as a glycerol 
stock were inoculated into 2 ml LB containing the appropriate selective antibiotic(s), and grown at 
37 °C under continuous shaking (200 rpm) for 6-8 h. This preculture was used to inoculate 200 ml 
LB containing the selective antibiotic(s) and grown overnight at 37 °C with continuous shaking. 
Then bacteria were collected by centrifugation at 4,000x g  for 15 min at 4 °C, and processed using 
HiSpeed Plasmid Maxi kits, according to the manufacturer protocol. The plasmid DNA obtained 
was resuspended in Tris-EDTA (Ethylenediaminetetraacetic acid) (TE) buffer (10 mM Tris-HCl 
pH 8.0 and 1 mM EDTA) and stored at -20 °C.
6.3. Transfection o f the siRNA and cDNA plasmids
The siRNAs used in the present study are listed in the table 6.3a. The silencer select 
siRNAs from Life Technologies were used at 20 nM, Sigma Aldrich and Qiagen siRNAs were used 
at 50 nM. For siRNA-mediated knock-down in CFBE cells, about 80,000 to 90,000 cells were 
plated in 12-well plates, and after 12 h they were transfected with the siRNAs using Lipofectamine 
2000, according to the manufacturer protocol. The transfection mix was added to the cells in 
serum-free medium, i.e., opti-MEM, and 12 h after the transfection, the opti-MEM was replaced by 
normal CFBE cell medium.
For HeLa cells expressing AF508CFTR, about 35,000 to 40,000 cells were plated in 12- 
well plates, and after 12 h the cells were transfected with the Sigma siRNA at 50 nM, using 
Lipofectamine 2000, according to the manufacturer’s protocol. The transfection mix was added to 
the cells in antibiotic-free medium, and after 12 h of transfection the medium was replaced by 
normal antibiotic-containing medium. The siRNA treatments were for 72 h, before processing the 
cells for analysis. The efficiency of depletion of only AF508CFTR corrector genes were 
determined by qRT-PCR (see section 6.21) of total RNAs isolated from AF508CFTR expressing 
CFBE cells (Figure 6.3). The primers used for the qRT-PCR is listed in table 6.3b.
For plasmid DNA expression, approximately 150,000 CFBE cells expressing AF508CFTR 
were plated in 12-well plates, and 12 h after plating they were transfected with 2 pg DNA, using 
the Lipofectamine 2000, according to the manufacturer’s protocol.
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Table 6.3a. The siRNAs used in the study.
Silencer select siRNA from Life Technologies (USA)
Gene Symbol Sense siRNA Sequence 1 Sense siRNA Sequence 2 Sense siRNA Sequence 3
AKAP1 UCAACAUCAUGUAGACAAAtt UCAACAUCAUGUAGACAAAtt GGUGUACUAUUCUCCAGCAtt
AKAP8 GCAGUACAGUGAAUGCCGAtt GCAGUACAGUGAAUGCCGAtt CGGAAGCAGUUCCAACUUUtt
AKT1 GCGUGACCAUGAACGAGUUtt GCGUGACCAUGAACGAGUUtt GAACAAUCCGAUUCACGUAtt
AKT2 CAACUUCUCCGUAGCAGAAtt CAACUUCUCCGUAGCAGAAtt CGGGCUAAAGUGACCAUGAtt
AKT3 GUAACAUCUGAGACAGAUAtt GUAACAUCUGAGACAGAUAtt GGACUAUCUACAUUCCGGAtt
ALPK1 CCAUGAGCAAGAACGAUUAtt CCAUGAGCAAGAACGAUUAtt GGAAGUGAAUUAUCACGUUtt
ASB8 CUUCCCACAUGAUAAUGUAtt CUUCCCACAUGAUAAUGUAtt GGAUUACAACAAUGAUACAtt
BIN2 GGUCUCUCCUAAUCCAGAAtt GGUCUCUCCUAAUCCAGAAtt GAUGAACGAUUUGAACAAAtt
C14orfl06 GGAUCUGAUAAGACAAAUAtt GGAUCUGAUAAGACAAAUAtt GGAUAUCCAAAUUAUCUCAtt
CALM1 AGGCAUUCCGAGUCUUUGAtt AGGCAUUCCGAGUCUUUGAtt UGACAAACUUAGGAGAAAAtt
CALM2 AAAGGAAUUGGGAACUGUAtt AAAGGAAUUGGGAACUGUAtt GCACAAUUGACUUCCCUGAtt
CALM3 AGAUGAUCAGGGAGGCUGAtt AGAUGAUCAGGGAGGCUGAtt GACUUCCCGGAGUUCCUGAtt
CALML3 GAGCUGACCUUAGGACCGAtt GAGCUGACCUUAGGACCGAtt GCUGUAACCUGUUCCUAUUtt
CALML5 GCCCAGCUAAGGAAACUCAtt GCCCAGCUAAGGAAACUCAtt CGGUUGACACGGAUGGAAAtt
CALML6 UAAUGGGAGUUUACCAUGAtt UAAUGGGAGUUUACCAUGAtt CCACCCUGCAGAAUCCUGUtt
CAMKK2 GGCACAUCAAGAUCGCUGAtt GGCACAUCAAGAUCGCUGAtt GCAUCGAGUACUUACACUAtt
CD2BP2 GAAUAUAAGUGGGAGAACAtt GAAUAUAAGUGGGAGAACAtt ACUACUUCCUGAACCGGGAtt
CENPA GACUUUAGUUUGUGAGUUAtt GACUUUAGUUUGUGAGUUAtt UCAUAGAAGAUGUAUCAUAtt
CENPE GGUUGACUCAGAUACUACAtt GGUUGACUCAGAUACUACAtt GGCUGUAAUAUAAAUCGAAtt
CSNK2A1 GGCUCGAAUGGGUUCAUCUtt GGCUCGAAUGGGUUCAUCUtt AGAUGUACGAUUAUAGUUUtt
CSNK2A2 GGAGUACAAUGUUCGUGUAtt GGAGUACAAUGUUCGUGUAtt GAUCCACACUUCAACGAUAtt
CSNK2B AGAGUGACCUGAUUGAGCAtt AGAGUGACCUGAUUGAGCAtt GGCUCUACGGUUUCAAGAUtt
CTDSP1 GCCCAGGACUCAGACAAGAtt GCCCAGGACUCAGACAAGAtt CGGACUUCAUCAUCCCUGUtt
CYC1 CAGCUACCAUGUCCCAGAUtt CAGCUACCAUGUCCCAGAUtt GGGAAGCUGUUCGACUAUUtt
CYCS AGUACAUCCCUGGAACAAAtt AGUACAUCCCUGGAACAAAtt UGAUCUUUGUCGGCAUUAAtt
DCLK1 CGAUAUAAAGUCGGAAGAAtt CGAUAUAAAGUCGGAAGAAtt GAUCGACUGCUAGAGAGUAtt
DGCR8 CCCUGUCUAUAAUUUCUUUtt CCCUGUCUAUAAUUUCUUUtt GGAUCAUGACAUUCCAUAAtt
DHX38 G AAGGAAUUUC AUUU G AC Att GAAGGAAUUUCAUUUGACAtt CGAUUCUGGUUAUUGCAAAtt
DICER 1 GAUCCUAUGUUCAAUCUAAtt GAUCCUAUGUUCAAUCUAAtt CAGCAUACUUUAUCGCCUUtt
DNAJC2 GAACCAAGAUCAUUAUGCAtt GAACCAAGAUCAUUAUGCAtt CGAUUUGAAGGUCCAUAUAtt
DSN1 GGUGAUGGAUGAACUGCAAtt GGUGAUGGAUGAACUGCAAtt GUCUAUCAGUGUCGAUUUAtt
EHD1 AGAUCUACCAGAAGAUUGAtt AGAUCUACCAGAAGAUUGAtt AGACCACCUUCAUCCGACAtt
ELAVL1 ACUUAUUCGGGAUAAAGUAtt ACUUAUUCGGGAUAAAGUAtt UGAACUACGUGACCGCGAAtt
ERBB4 CCCUUUUGUUUCUCGGAGAtt CCCUUUUGUUUCUCGGAGAtt CCCUUAC AAUGC AAUU G AAtt
EXOSC4 GGGCCCUAGUGAACUGUCAtt GGGCCCUAGUGAACUGUCAtt GGCAGAUGGUGGGACCUAUtt
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Table 6.3a. The siRNAs used in the study (continued).
Silencer select siRNA from Life Technologies (USA)
Gene Symbol Sense siRNA Sequence 1 Sense siRNA Sequence 2 Sense siRNA Sequence 3
FARSA CCUUCACUCCGGUCAAGUAtt CCUUCACUCCGGUCAAGUAtt CGGAAAAACCUACUGCGAAtt
FBX 07 GAAUGACGACAGUAUGUUAtt GAAUGACGACAGUAUGUUAtt GGCUUUUACCCGACAAGCAtt
FGFBP1 CAAUUGGACCAUGAAUUUUtt CAAUUGGACCAUGAAUUUUtt GG A A AC A AGUU GCCCGG A Att
FLNB GCACGGUCACUGUUAGAUAtt GCACGGUCACUGUUAGAUAtt GAUCGUGUGAUGUCAAAUAtt
FLT1 GGUGAGUAAGGAAAGCGAAtt GGUGAGUAAGGAAAGCGAAtt CCCUGAUGGAAAACGCAUAtt
FLT4 CCAGCAUCCUGACCAUCCAtt CCAGCAUCCUGACCAUCCAtt CGAGGUCAUUGUGCAUGAAtt
GEMIN4 CGUUGACACUUCUGCCGAAtt CGUUGACACUUCUGCCGAAtt CGGUGCCUCUCUUUGGAUAtt
GTSE1 GGAAUUAAAUAAUCCGGUUtt GGAAUUAAAUAAUCCGGUUtt CGGCCUCUGUCAAACAUCAtt
HNF4A UGAGUAUGCCUACCUCAAAtt UGAGUAUGCCUACCUCAAAtt UCAUCUUCUUUGACCCAGAtt
ITPR1 GGUCAACCGUUACUAUGGAtt GGUCAACCGUUACUAUGGAtt GCACGACAGUGAAAACGCAtt
ITPR2 GCUUAAUCCUGAUUAUCGAtt GCUUAAUCCUGAUUAUCGAtt GGUGUCUAAUCAAGACGUAtt
ITPR3 GCAUCGUCACUGUCAUGAAtt GCAUCGUCACUGUCAUGAAtt CCACCUUGCAGAAAACCGAtt
IVL CCAUCAAAGCAAGAGGAAAtt CCAUCAAAGCAAGAGGAAAtt CAGCAGGACGGACAACUAAtt
KDR CAUGUUCUCUAAUAGCACAtt CAUGUUCUCUAAUAGCACAtt CCAUCGUCAUGGAUCCAGAtt
KJF20A GGAACAUAGUCUUCAGGUAtt GGAACAUAGUCUUCAGGUAtt CGGCUAUGCGAGGAUCAAAtt
KRT34 GCAUACGCAGGAUCCUGGAtt GCAUACGCAGGAUCCUGGAtt CUUACCUGCUUUUCCAUUAtt
LMNB1 GGACUUGGAGUUUCGCAAAtt GGACUUGGAGUUUCGCAAAtt GAAUCGUUGUCAGAGCCUUtt
MAL CUGUUGGUAUUGUCCACAAtt CUGUUGGUAUUGUCCACAAtt GGUCCAUGGUGGAAGACGAtt
MAP2K1 GGAACCAGAUCAUAAGGGAtt GGAACCAGAUCAUAAGGGAtt UGUUCAGUCUGGAAUUUCAtt
MAP2K2 GAUCAGCAUUUGCAUGGAAtt GAUCAGCAUUUGCAUGGAAtt GAACUUGACGAGCAGCAGAtt
MAP2K3 GGUCGACUGUUUCUACACUtt GGUCGACUGUUUCUACACUtt CCCGGACCUUCAUCACCAUtt
MAP2K4 GCAACUGUGAAAGCACUAAtt GCAACUGUGAAAGCACUAAtt GGUAAACGCAAAGCACUGAtt
MAP2K5 GCCCUCCAAUAUGCUAGUAtt GCCCUCCAAUAUGCUAGUAtt GUAAUGGAACAGCAAGUAAtt
MAP2K6 GGAUACAUCACUAGAUAAAtt GGAUACAUCACUAGAUAAAtt GGUGGACUCUGUUGCUAAAtt
MAP2K7 CGUCAUUGCCGUUAAGCAAtt CGUCAUUGCCGUUAAGCAAtt GACAGUUUCCCUACAAGAAtt
MAP3K11 CGUGAUCUCAAGUCCAACAtt CGUGAUCUCAAGUCCAACAtt GCGUAGCUGUUAACAAGCUtt
MAPK1 CAGGGUUCCUGACAGAAUAtt CAGGGUUCCUGACAGAAUAtt CAACCAUCGAGCAAAUGAAtt
MAPK15 AGAACGACAGGGACAUUUAtt AGAACGACAGGGACAUUUAtt UGAACGCAGUCAUCCGGAAtt
MAPK3 GGACCGGAUGUUAACCUUUtt GGACCGGAUGUUAACCUUUtt UGAUGGAGACUGACCUGUAtt
MAPK6 CCAUCCUUACAUGAGCAUAtt CCAUCCUUACAUGAGCAUAtt CUAGGUAUAUGGACUUAAAtt
MAPK7 GCUGAACAUCAGUACUUCAtt GCUGAACAUCAGUACUUCAtt GAGGAAUUCUUAAACCAGUtt
MED1 GCUGGUCCCUUGGAUAAGAtt GCUGGUCCCUUGGAUAAGAtt GACCAGUCCUUGUCUAUGAtt
MED13 GAAACGAUGUGAGUAUGCAtt GAAACGAUGUGAGUAUGCAtt CCUGCUAUGUCUUCGGUUAtt
MITF CCGUGGACUAUAUCCGAAAtt CCGUGGACUAUAUCCGAAAtt GAAACUUGAUUGAUCUUUAtt
MK167 CGUCGUGUCUCAAGAUCUAtt CGUCGUGUCUCAAGAUCUAtt CAUCAACGCGUUUAGGGAAtt
NFKB1 GGCUCAUGUUUACAGCUUUtt GGCUCAUGUUUACAGCUUUtt CCACCUUCAUUCUCAACUUtt
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Table 6.3a. The siRNAs used in the study (continued).
Silencer select siRNA from Life Technologies (USA)
Gene Symbol Sense siRNA Sequence 1 Sense siRNA Sequence 2 Sense siRNA Sequence 3
NFKB2 GGUUCUAUGAGGAUGAUGAtt GGUUCUAUGAGGAUGAUGAtt CC AC AG AU GU GC AU AA AC Att
NOL3 GGUGACUUCUCUCCACAUAtt GGUGACUUCUCUCCACAUAtt AGGGAGGGCUUAGAGCUCAtt
NUP50 GAAGGACUGUCGAAUGGAAtt GAAGGACUGUCGAAUGGAAtt CUGUUUU AC AAG A AAG AC Att
ONECUT1 GAAUUGCAAAUCACCAUUUtt GAAUUGCAAAUCACCAUUUtt GGUCAGCAAUGGAAGUAAUtt
OSMR GU AACUGC AUUC A AC UUG Att GUAACUGCAUUCAACUUGAtt GACUCACAAGAAACCUAUAtt
PATZ1 GCGCCGAUAUAAUGCUCUUtt GCGCCGAUAUAAUGCUCUUtt GUGGUAAGGUGUUCACUGAtt
PDE11A CCAUCGUGAUAUAUUUCGAtt CCAUCGUGAUAUAUUUCGAtt CGGGAGAGAUUAGAGCUCAtt
PDE3A GCAGUGACAUUGUACAGAAtt GCAGUGACAUUGUACAGAAtt GUAUUCUCAAAAACGUAUAtt
PDGFRA CUCUAGGAAUGACGGAUUAtt CUCUAGGAAUGACGGAUUAtt GGCCUUACUUUAUUGGAUUtt
PDGFRB GGAACGUGCUCAUCUGUGAtt GGAACGUGCUCAUCUGUGAtt GAGCAACUUUGAUCAACGAtt
PIK3CA GACUAGCUAGAGACAAUGAtt GACUAGCUAGAGACAAUGAtt GUAAUUACCCAGAUCCUAUtt
PIK3CB CUCCAAAUGUUGCGCUUGAtt CUCCAAAUGUUGCGCUUGAtt GGGAAAGCUGGACUACUAAtt
PIK3CD GUGAGAAAUUUGAACGGUUtt GUGAGAAAUUUGAACGGUUtt GACUAAUAAUAGUGAGAAAtt
PIK3CG GCUUUAGAGUUCCAUAUGAtt GCUUUAGAGUUCCAUAUGAtt GCUGCACGACUUUACCCAAtt
PPAP2B ACUGAAAACUGGUGAGACAtt ACUGAAAACUGGUGAGACAtt GGCUACAUUCAGAACUACAtt
PROKR1 AGACAGAGCAGAUCCGCAAtt AGACAGAGCAGAUCCGCAAtt AGAACGACACCGUCAAGUAtt
PROKR2 CCCUCUACGUCUCCACCAAtt CCCUCUACGUCUCCACCAAtt ACAGAAACGGUCCUCUUUAtt
PRPF4B GGAAAUAGGUCUAGUACUAtt GGAAAUAGGUCUAGUACUAtt CAGUUGAUUUAAGAGGUAAtt
PRPF8 CCCUACAUGUGAACAACGAtt CCCUACAUGUGAACAACGAtt GCAGAUACAUUGAUCGCAUtt
PXN CCUGGAGAACUAUAUCUCAtt CCUGGAGAACUAUAUCUCAtt GAACGACAAGCCUUACUGUtt
RBM7 CCACAUCUCCUAGCAGGUAtt CCACAUCUCCUAGCAGGUAtt CAAUUUAGAUCAGGAAGUAtt
RELA CCCUUUACGUCAUCCCUGAtt CCCUUUACGUCAUCCCUGAtt GGAGUACCCUGAGGCUAUAtt
RELB GCUACGGCGUGGACAAGAAtt GCUACGGCGUGGACAAGAAtt GG AUUU GCCG AAUU AAC A Att
RGS19 AGCAUGUGGUAGACGAGAAtt AGCAUGUGGUAGACGAGAAtt GGGAGGGCAUCAACAAGAAtt
RNF215 GAGUGGAAGUUGACCUUGUtt GAGUGGAAGUUGACCUUGUtt UGCCCACUGUGCAAAUUCAtt
S100A7 AGAAGAUUGAUUUUUCUGAtt AGAAGAUUGAUUUUUCUGAtt CCUUAGUGCCUGUGACAAAtt
SART1 GCUCUAUCCUGUCCAAGUAtt GCUCUAUCCUGUCCAAGUAtt GCAUCGAGGAGACUAACAAtt
SC02 AGUUACCGCGUGUACUACAtt AGUUACCGCGUGUACUACAtt CGGCUGAGCAGAUCUCAGAtt
SENP6 CAACGACAGAACUAACAGAtt CAACGACAGAACUAACAGAtt GCACCUUUAGGCGAAGGAAtt
SHC3 GGACACGACUGACUAUGUUtt GGACACGACUGACUAUGUUtt CCAAACAGAUCAUAGCGAAtt
SPRR1A GAAUCAUAAUCGCUCCUUUtt GAAUCAUAAUCGCUCCUUUtt GCUGUCACCCUGAAUCAUAtt
SPRR1B GAAUGUGCUAUGAAGCUUUtt GAAUGUGCUAUGAAGCUUUtt AAGAGAGACUUAAGAUGAAtt
SPRR3 CAAAGUUCCUGAGCAAGGAtt CAAAGUUCCUGAGCAAGGAtt GCUACACCAAGGUCCCUGAtt
STAG2 GGUAGAUGAUUGGAUAGAAtt GGUAGAUGAUUGGAUAGAAtt CCACUGAUGUCUUACCGAAtt
TEP1 GUAGGACCCUAAUAUCGAUtt GUAGGACCCUAAUAUCGAUtt CUGAUGAGGCGGAUACUAAtt
TLR4 GAGCCGCUGGUGUAUCUUUtt GAGCCGCUGGUGUAUCUUUtt CAUUGAAGAAUUCCGAUUAtt
TOP3A CGGCUUGCCUAGUUCUCUAtt CGGCUUGCCUAGUUCUCUAtt CAGGUUAAAGUUAAAGUUUtt
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Table 6.3a. The siRNAs used in the study (continued).
Silencer select siRNA from Life Technologies (USA)
Gene Symbol Sense siRNA Sequence 1 Sense siRNA Sequence 2 Sense siRNA Sequence 3
TP53 GUAAUCUACUGGGACGGAAtt GUAAUCUACUGGGACGGAAtt GAAAUUUGCGUGUGGAGUAtt
TROAP CAGGCAGAGACAUCACAAAtt CAGGCAGAGACAUCACAAAtt CGUGGACCAGGAGAACCAAtt
UBOX5 ACAGUAACUUUGGUGUAAAtt ACAGUAACUUUGGUGUAAAtt GUCUUACUGAAAAACCAGAtt
VHL CAUCCAUUCUACAUCCGUAtt CAUCCAUUCUACAUCCGUAtt GCUCUACGAAGAUCUGGAAtt
WDR6 GCAUCGGAUGGUUAAGGUAtt GCAUCGGAUGGUUAAGGUAtt AGGUCAAGCUUCUAGAGAAtt
WTAP AGACUAAAGACAAACUGGAtt AGACUAAAGACAAACUGGAtt AGAUCUUAACUCUAAUGAUtt
YWHAH CAAGGUGUUUUACCUGAAAtt CAAGGUGUUUUACCUGAAAtt CACUAAACGAGGAUUCCUAtt
ZAP70 AGAACUUUGUGCACCGUGAtt AGAACUUUGUGCACCGUGAtt GAACUGUACGCACUCAUGAtt
ZC3H3 ACGUGGUCAUCAAAGUUAAtt ACGUGGUCAUCAAAGUUAAtt AGAACGUGGUCAUCAAAGUtt
Control 1 CCGCACUCCUGAACUUGAAtt GCACCGUCCUAAUCGUCGAtt GCUGGGUGGCGGAUAAGUAtt
Control 2 CAGUCGAAGAAGAUGGUUAtt CGAGUCCGUGGAUAUCGUUtt ACCGCACUCCUGAACUUGAtt
The siRNA purchased from Sigma-Aldrich (USA)
Gene Symbol Sense siRNA Sequence
MAP3K11 GGGCAGUGACGUCUGGAGUUU
MAPK8 GUGGAAAGAAUUGAUAUAUAA
MAPK9 AAGAGAGCUUAUCGUGAACUU
MAPK10 CCGCAUGUGUCUGUAUUCAUA
MAPK11 CAGGAUGGAGCUGAUCCAGUA
MAPK12 CUGGACGUAUUCACUCCUGAU
MAPK13 CCGGAGUGGCAUGAAGCUGUA
MAPK14 AACUGCGGUUACUUAAACAUA
MKK4 AUUGGACGAGGAGCUUAUG
MKK7 AGACUGCCUUACUAAAGAU
MKK6 AAGGCUUGCAUUUCUAUUGGA
MKK3 CCGGGCCACCGUGAACUCACA
ASK1 CCUGUGCUAACGACUUGCUUG
CAMK1 CAGGUGCUGGAUGCUGUGAAA
AKT1 AAUCACACCACCUGACCAAGA
PRKAA1 (AMPK) CCCACGAUAUUCUGUACACAA
PRKAA2(AMPK) CCGAAGUCAGAGCAAACCGUA
RMA1-1 GCGCGACCUUCGAAUGUAA
RMA1-2 CGGCAAGAGUGUCCAGUAU
CAMKK2-1 GGAUCUGAUCAAAGGCAUC
CAMKK2-2 GCAUCGAGUACUUACACUA
MAP3K11-1 GCAGCGACGUGUCGAGCUU
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Table 6.3a. The siRNAs used in the study (continued).
The siRNA purchased from Sigma-Aldrich (USA)
Gene Symbol Sense siRNA Sequence
MAP3K11-2 GCAGUGACGUCUGGAGUUU
MAP3K11-3 GGGCAGUGACGUCUGGAGUUU
MAP3K11-4 CUGGAGGACUCAAGCAAUG
MAP3K11 -5 GGAGGAGUCACAGCAUACATT
AHSA1(AHA1)-1 AUUGGUCCACGGAUAAGCU
HSF1 CGGAUUCAGGGAAGCAGCUGGUGCA
ATF2 AAUGAAGUGGCACAGCUGA
cMYC AACAGAAAUGUCCUGAGCAAU
cJUN UACCUCAGCAACUUCAACCCA
BAG3 AACAGGUGCAGUUUCUCGAUGGGUC
RAC1 UUUACCUACAGCUCCGUCUUU
RAC2 AACUACUCAGCCAAUGUGAUG
RAC3 CGCGCCCAUGCAGGCCAUCAA
GSK3B GUAAUCCACCUCUGGCUAC
MAP4K1 CUGACUAAGAGUCCCAAGA
BRAF AAGUGGCAUGGUGAUGUGGCA
MAP4K2
CDC42
ATF1
ATF6
ELK1
TP53
ASK1
BAG1
Not Available
BAG2
BAG3
CHOP
BCL2L1
SQSTM1
MDM2
EIF2AK2
XBP1
The rest of the siRNAs used were purchased from Qiagen (Germany).
Table 6.3b. Primers used for qRT-PCR.
The Primers were collected from public database (http://pua.mgh.harvard.edu/primerbank/)
Gene Forward Primer Sequence 
(5’ 3')
Reverse Primer Sequence 
(5’ 3’)
Primer 
Bank ID
ASB8 CAGAGCAAATACTCTCTCTCCGA TCTGACACCATACAGGCACAG 45333920cl
MIS18BP1 CAGGCACACTTACTCCTGTAAAA GAGGTAGTAGCCTCTGTTAGCA 194473999cl
CALML5 GGTTGACACGGATGGAAACG ACTCCTGGAAGCTGATTTCGC 8393159al
CAMKK2 CATGAACGGACGCTGCATCT ACAGTCCTGCATACCCGTGAT 259490264c2
CD2BP2 ACACTCTTTGGATAGCGATGAGG GGTTAAAGGGTGTGATCCGAAC 343887346cl
CSNK2A1 GGTGGAATGGGGAAATCAAGAT TGATGATGTTGGGACCTCCTC 29570791al
CTDSP1 AGACCCCAGTCCAATACCTG GACGCTTCAACACGTAGACCT 332308971 cl
DSN1 CTCAGCCGGTCTATCAGTGTC AGTGTCCCTTAGGAAAGGTTCAA 223890152cl
FBX07 GATTCAGAGCATTCTTCACTCCA GCCCTAACATACTGTCGTCATTC 74229026c1
FLT1 GAAAACGC AT AATCTGGGACAGT GCGTGGTGTGCTTATTTGGA 229892219c3
GTSE1 CAGGGGACGTGAACATGGATG ATGTCCAAAGGGTCCGAAGAA 25397041lc l
ITPR2 CACCTTGGGGTT AGTGGATGA CTCGGTGTGGTTCCCTTGT 95147334c1
KDR GTGATCGGAAATGACACTGGAG CATGTTGGTCACTAACAGAAGCA 195546779c2
MAP2K7 GGGACGTTCATCACCAACAC GCCACTGTCATCTTGCCCA 40806198c2
MAP3K11 GCAGCCCATTGAGAGTGAC CACTGCCCTTAGAGAAGGTGG 56237030cl
MAPK15 AGAAGCCGTCCAATGTGCTC CAAGGGTGTATCGGTGCGA 95147355c3
MED1 GAGGGCATCAACATTTGGTCA AGATGAGAGCCCAGTCCATTC 154813205c2
MED 13 TTGCTGGTGTCCGAATGATCT CGTAACCGAAGACATAGCAGGAT 102468716c3
NFKB2 GGGCCG AA AG ACCT ATCCC CAGCTCCGAGCATTGCTTG 117320530c3
NUP50 GGTAGCCTTTGGTTCTCTTGC TGTGATAGGCATTTCCGACAC 82659110c2
OSMR AATGTCAGTGAAGGCATGAAAGG GAAGGTTGTTT AGACCACCCC 270288819c2
PDGFRA TTGAAGGC AGGC ACATTT ACA GCGACAAGGTATAATGGCAGAAT 172072625c3
PDGFRB AGCACCTTCGTTCTGACCTG TATTCTCCCGTGTCTAGCCCA 68216043d
PIK3CB TATTTGGACTTTGCGACAAGACT TCGAACGTACTGGTCTGGATAG 365777410cl
PIK3CG GGCGAAACGCCCATCAAAAA GACTCCCGTGCAGTCATCC 21237724c1
PROKR1 TGGGGTTCATGGATGACAATG AACGTCCTGGAATTGGTCACA 44921613d
PRPF8 TGACAAAAGGGTTTACTTGGGTG CTCATTGACGAAGGAAATGGCT 91208425c2
RNF215 GGAGACTGGCATCCCTCAAGA GGTGAAACTCGTGCTTACAGG 63025219c2
SART1 CCAGCTCCAAAACTAGCTCAG AAGGCCATAGGGTTGATGACA 119393884c 1
SENP6 TCCTGTAAGGTTAAGTCGGCT AGATAGAGGAGGAGTAGGCTGAT 156105702c 1
STAG2 TGGCGTGTTAGTACGGCAATG GCTTGTATGTCGAAATGCTCTGA 112789533c3
TEP1 ATTTGTACCGTGTGAACAACAGC GAATCAAACCAACGACCCAAAG 225735570c2
UBOX5 GCCTCATCTAGCAGAGTGTCT GTGGCT AAACACCACTTGGCT 40806195c2
YWHAH GACATGGCCTCCGCT ATGAAG ATGCTGCTAATGACCCTCCAG 6174446lc l
JNK2/MAPK9 GAAACTAAGCCGTCCTTTTCAGA TCCAGCTCCATGTGAATAACCT 205277408cl
ATF1 CACAGATGGAGTACAGGGACT GACCACCTGATTGCTGGGC 304361768c3
CAMK1 TGCTGTCCTGCACAAGATCAA GCTCCGTGTAGAAGCCTTTTT 325995171c2
GSK3B GGCAGCATGAAAGTTAGCAGA GGCGACCAGTTCTCCTGAATC 225903415c1
HSF1 GC ACATTCCATGCCCAAGT AT GGCCTCTCGTCT ATGCTCC 132626772c2
CDC42 CCATCGGAATATGTACCGACTG CTCAGCGGTCGT AATCTGTCA 89903014cl
RAC2 CAACGCCTTTCCCGGAGAG TCCGTCTGTGGATAGGAGAGC 27881480cl
MAP4K1/HPK1 ATCCCTCGGCGGATCAGAT CACGTCGTCAT AGTCATCGTC 110611904c3
PRKAA1 GGCACGCCATACCCTTGAT TCTTCCTTCGTACACGCAAATAA 94557300c2
PRKAA2 CTGTAAGCATGGACGGGTTGA AAATCGGCTATCTTGGCATTCA 157909838c2
HPRT1 ACCAGTCAACAGGGGACATAA CTTCGTGGGGTCCTTTTCACC 164518913c2
CFTR AAAAGGCCAGCGTTGTCTCC AAACATCGCCG AAGGGCATT A 90421312c!
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Figure 6.3. The siRNAs targeting the corrector genes reduce the mRNA of respective genes.
CFBE cells were transfected with mix of three silencer select siRNAs targeting the indicated genes 
for 72 hours, total RNA was isolated and subjected qRT-PCR. The relative mRNA quantity of 
indicated genes are plotted as a percentage compared to control treatment. Data represent mean ± 
SD (n=2).
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6.4. Cell lysis
Cells were washed three times with pre-chilled DPBS, then the cells were lysed using radio- 
immunoprecipitation analysis (RIPA) buffer (150 mM NaCl, 1% Triton X-100, 0.5% deoxycholic 
acid, 0.1% SDS, 20 mM Tris-HCl, pH 7.4). The cells were lysed in the plate kept on ice by adding 
pre-chilled RIPA buffer supplemented with a protease inhibitor cocktail and a phosphatase 
inhibitor, while observing the phosphorylated proteins. The cell lysates were centrifuged at 15,000 
ref for 15 mins, before proceeding to SDS-PAGE analysis.
6.5. Protein estimation
Pierce BCA Protein Assay kits were used to quantify the protein concentrations in cell 
lysates, following the manufacturer’s protocol.
6.6. SDS-PAGE
The SDS-PAGE apparatus was from Hoefer Scientific Instruments (Germany) and 16 cm x 
18 cm gels were used. Protein from the cell lysates contained final concentrations of sample buffer 
(62.5 mM Tris-HCl, pH 6.8, 2% SDS, 10% glycerol, 0.001% bromophenol, 125 mM 
dithiothreitol). The samples were incubated at 37 °C for 30 min before loading onto the SDS- 
PAGE. Thirty millilitres of separating gel was prepared by mixing the reagents as shown in Table
5.6. Then 10 ml stacking gel was prepared (4% acrylamide, 5.6 ml water, 1.7 ml 30% acrylamide, 
2.5 ml stacking buffer, 100 pi 10% SDS, and 100 pi 10% ammonium persulphate (APS), lOpl 
tetramethylethylenediamine (TEMED)). The protein samples were loaded into the wells in the 
polymerised gels and electroporated for 4 h at 35 mA, or overnight at 8 mA, using the running 
buffer of 25 mM TRIZMA base, 200 mM glycine, 0.1% (w/v) SDS.
6.7. Immunoblotting
The polyacrylamide gels and 3 mm Whatman papers were soaked for 15 min in chilled 
transfer buffer (25 mM TRIZMA base, 200 mM glycine, 20% (v/v) methanol). The gels were 
placed on a wet sheet of 3MM paper and covered with a nitrocellulose membrane that had been 
wetted in transfer buffer. This was then covered with another wet 3MM paper, to form a 
‘sandwich’, and then this was assembled into the blotting apparatus (Hoefer Scientific Instruments,
1 2 2
Table 6.6. Separating gel composition
Ingredients for 30 ml separating gel for different percentage of SDS-PAGE.
SDS-
PAGE
(%)
Acryl
amide
30% (ml)
Tris-HCl-1.5M 
pH-8.8 (ml)
Water
(ml)
SDS-10%
(Hi)
APS-10%
(pl)
TEMED
Gil)
6 6 7.5 16.5 300 160 16
7 7 7.5 15.5 300 160 16
8 8 7.5 14.5 300 160 16
9 9 7.5 13.5 300 160 16
10 10 7.5 12.5 300 160 16
11 11 7.5 11.5 300 160 16
12 12 7.5 10.5 300 160 16
13 13 7.5 09.5 300 160 16
14 14 7.5 08.5 300 160 16
15 15 7.5 07.5 300 160 16
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Germany). The protein transfer was carried out at 400 mA for 4 h. At the end of the transfer, the 
nitrocellulose filter was soaked in Ponceau red solution (0.2% Ponceau red in 5% (v/v) acetic acid) 
for 5 min, to visualise the protein, and then rinsed with 5% acetic acid to remove excess dye.
The nitrocellulose filters were cut into strips with a razor blade around the molecular 
weight of proteins of interest. These strips of nitrocellulose were incubated in the blocking solution 
(either 5% [w/v] bovine serum albumin or 5% skimmed milk in TBS-T (0.1% [w/v] Tween-20,150 
mM NaCl, 20 mM Tris-HCl, pH 7.5) for 1 hour at room temperature. The blocking solution was 
then replaced with the primary antibody in 5% (w/v) bovine serum albumin in TTBS for 2 h at 
room temperature or overnight at 4 °C. After this incubation, the antibody was removed and the 
strips were washed three times in TTBS, for 10 min each. Next, these washed strips were incubated 
for 1 h at room temperature with the appropriate HRP-conjugated secondary antibody in the 
blocking solution. After this, they were washed three times in TTBS, for 10 min each. After this 
washing, the strips were incubated with the ECL reagents, according to the manufacturer’s 
instructions for ECL-based detection using X-ray film. The X-ray film was scanned between 200 
dpi to 600 dpi and the protein bands were analysed using the ImageJ gel analysis tool 
(http://imagei.nih.gov/ii/).
6.8. Partial trypsin digestion of CFTR
Partial trypsin digestion of CFTR was carried our as described previously (Du et al. 2005; 
Rosser et al. 2008; Glozman et al. 2009). Cells were grown in 10-cm plates, and after the treatment, 
the cells were washed three times with 10 ml phosphate-buffered saline (PBS; 137 mM NaCl, 2.7 
mM KC1, 8.1 mM Na2HP0 4 , 1.5 mM KH2PO4, 1 mM CaCk, 0.5 mM MgCl2) and then scraped into 
5 ml PBS. The cells were pelleted at 500 ref for 5 min at 4 °C. The cell pellet was resuspended in 1 
ml hypertonic buffer (250 mM sucrose, 10 mM Hepes, pH 7.2), and then homogenised using a ball 
bearing homogeniser. The nuclei and unbroken cells were removed by centrifugation at 600 ref for 
15 min. The membranes were then pelleted by centrifugation at 100,000 ref for 30 min 
(Aleksandrov et al. 2001), and then they were resuspended in trypsin buffer (40 mM Tris, pH 7.4,2  
mM MgCh, 0.1 mM EDTA). Then, 50 pg proteins was added to different trypsin concentrations, 
and incubated for 15 min on ice. The reaction was stopped with the addition of
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phenylmethylsulfonyl fluoride to 1 mM, and the samples were immediately denatured in sample 
buffer (62.5 mM Tris-HCl, pH 6.8, 2% SDS, 10% glycerol, 0.001% bromophenol, 125 mM 
dithiothreitol) at 37 °C for 30 min. The samples were run on 4% to 16% SDS-PAGE (Tris-glycine) 
and transferred onto nitrocellulose membranes. These membranes were blocked for 1 h in 5% milk 
with TBS-T. The membranes were then treated with the primary antibody overnight at 4 °C. NBD1 
was probed using the 3G11 CFTR antibodies from the CFTR Folding Consortium; NBD2 was 
probed by using the M3A7 clone CFTR antibody from Millipore (Massachusetts, USA). Blots were 
developed by ECL, and quantified using NIH ImageJ analysis of the scanned films.
6.9. EndoH resistance assay
CFBE cells were treated with siRNA and after 48 hours VSVG-GFP was transfected for 24 
hours and cells were kept at 40°C. Then the cells are shifted to 32°C for 15, 30, 60 and 120 minutes 
and after each time point the cells were lysed. Cells immediately lysed at 40°C were considered as 
0 minute. VSVG transport through the Golgi can be followed by the processing of two 
oligosaccaride chains from the high mannose endoH-sensitive form to the endoH-resistant form. 
The processing intermediates can be easily distinguished by SDS-PAGE (Davidson and Balch 
1993). The appearance of sequential processing intermediates allows the direct examination of ER- 
to-Golgi transport (Davidson and Balch 1993).
6.10. Plasma membrane quality control assay
Plasma membrane quality control was accessed using the previous described method 
(Okiyoneda et al. 2010). CFBE cells were treated with a control siRNA and siRNA against 
MAP3K11, and kept at low temperature (26 °C) for 36 h, to allow the mutant protein to reach the 
PM, which led to increased levels of band C. Then, the cells were shifted to 37 °C for 1.5 h with 
100 |ig/ml cycloheximide before turnover measurements were started (0 h), at 37 °C (the 
temperature at which the mutant protein at the PM is subjected to accelerated ubiquitination and 
degradation). The cells were lysed at 0, 1,3 and 5 h, and the kinetics of degradation of band C was 
examined by immunoblotting.
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6.11. Immunoprecipitation o f CFTR
Cells expressing CFTR were washed in cold PBS, scraped into PBS, pelleted and 
resuspended in the Triton lysis buffer (25 mM Tris, pH 7.4, 150 mM NaCl, 1% Triton X-100 and 
protease inhibitors). The anti-CFTR antibodies were incubated with the cell lysate overnight with 
light agitation at 4 °C, and the anti-CFTR-antibody complex was pulled down using Dynabeads 
kits, according to manufacturer’s protocol.
6.12. Biochemical assay for CFTR correction
Cells expressing either wtCFTR or AF508CFTR or AF508CFTR treated with correcting or 
test conditions were lysed and immunoblotted. On SDS-PAGE the wtCFTR shows two bands 
approximately at 140 kDa (band B) which is core glycosylated protein at ER, but when it passes 
through Golgi and secretory pathway it becomes modified by Golgi enzymes and runs at 170 kDa 
(band C) (Figure 6.12). But AF508CFTR usually shows only the 140 kDa (band B) as it fails to 
proceed through the secretory pathway, but when treated with corrective conditions like 26°C 
partial amount of AF508CFTR also pass along the secretory pathway through the Golgi and 
become modified by Golgi enzymes to shows considerable amounts of band C (Figure 6.12). This 
assay has proved very sensitive and robust to detect the small correction or changes in CFTR 
proteostasis (Farinha et al. 2004).
6.13. Interactome o f CFTR upon treatment o f drugs
CFTR-expressing Hela cells were grown in 150-mm plates. When the cells were about
80% confluent, 5 pM JNKi II (SP600125) was added to the AF508CFTR samples, with an
equivalent amount of dimethylsulphoxide added to the wtCFTR and AF508CFTR control cells. The
treatment was terminated at 24 h. The cells were then processed for the interactome study, by being
lysed using Triton lysis buffer. Then, 8 mg protein of the HeLa cell lysates expressing either
wtCFTR or AF508CFTR were incubated for 2 h with 500 pi settled resin of mouse IgG-agarose,
for pre-cleaning. They were then incubated overnight with 500 pi mouse monoclonal anti-HA-
agarose at 4 °C, and washed 3 times with RIPA buffer. CFTR was eluted by incubating the samples
for 2 h at 4 °C with 250 pi RIPA buffer with 100 pg/ml of HA peptide. The non-specific
interactome was the eluent of 8 mg of AF508CFTR-expressing cells incubated overnight with 500
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Figure 6.12. Biochemical assay of CFTR correction
wtCFTR at the ER after glycosylation shows approximately at 140 kDa (band B) and when it 
passes through the Golgi and secretory pathway it becomes modified by Golgi enzymes and runs at 
170 kDa (band C) which is found at the PM. AF508CFTR usually undergoes ER glycosylation and 
shows 140 kDa (band B), but it fails to proceed through Golgi and secretory pathway. When treated 
with correctors like 26°C partial amounts of AF508CFTR pass through the Golgi and secretory 
pathway and become modified by Golgi enzymes and shows a significant amount of band C.
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pi settled resin and mouse IgG-agarose eluted in the same manner as for CFTR. The interactome 
mass spectrometry was carried out by Dr. Maria Monti, Department o f Chemical Sciences, 
"Federico II" University of Naples, Naples, and at CEINGE Biotecnologie Avanzate s.c.a r.l., 
Naples, Italy.
As previously published (Zito et al. 2007) the eluted samples were subjected to 12% SDS 
PAGE and stained with GelCode Blue Stain Reagent (Pierce). Protein bands were excised from the 
gel and destained by repeated washings with 50 mM NH4HCO3, pH 8.0, and acetonitrile. Samples 
were reduced and carboxyamidomethylated with 10 mM DTT and 55 mM iodoacetamide in 50 
mM NH4HCO3 buffer, pH 8.0. Tryptic digestion of the alkylated samples was performed at 37 °C 
overnight, using 100 ng trypsin. MALDI mass spectra were recorded on an Applied Biosystems 
Voyager DE-PRO mass spectrometer equipped with a reflectron TOF analyser and used in delayed 
extraction mode. One pi of peptide mixture was mixed with an equal volume of a-cyano-4- 
hydroxycynnamic acid as matrix (in acetonitrile/50 mM citric acid [70:30, v/v]), applied to the 
metallic sample plate and air dried. Mass calibration was performed using the standard mixture 
provided by the manufacturer. Raw data, reported as monoisotopic masses, were then introduced 
into the MASCOT peptide mass fingerprinting search programme (Matrix Science, Boston, USA) 
and used for protein identification. It was decided to list the protein interactors based on the 
qualitative information without giving much importance to the quantitative information like peptide 
count. The proteins which were present in the nonspecific interactome sample were not considered. 
The proteins detected in test samples and that were not present at the nonspecific interactome are 
noted as test samples interacting partner. The proteins identified were listed in Table 3.9.
6.14. Immunofluorescence
The cells were grown on coverslips and fixed with 4% paraformaldehyde for 10 min at room 
temperature, and then permeabilised with 0.2% saponin in blocking solution (PBS containing 1% 
bovine serum albumin, 50 mM N H 4CI). For the antibody-based detection, the fixing was followed 
by incubation with antibodies to the antigen of interest in the same blocking solution, for 1 h at 
room temperature, followed by the secondary antibodies labelled with Alexa Fluor dyes 
(Invitrogen). The coverslips were then mounted in the mounting media (16% [w/v] Mowiol 4-24
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[EMD Millipore, USA] and 30% [v/v] glycerol in PBS), and examined under a confocal 
microscope (LSM710; Carl Zeiss). The images were then acquired with the pinhole set to 1 and 
under non-saturating conditions, using the 63x objective. The images were acquired using the Zen 
software system (Carl Zeiss).
6.15. SPQ iodide efflux
The iodide-sensitive fluorescent indicator, SPQ (Molecular Probes, Eugene, OR, USA) was 
introduced into the cells in a hypotonic solution of iodide buffer (130 mM Nal, 4 mM KNO3, 1 mM 
Ca(N0 3 )2, 1 mM Mg(N0 3 )2, 10 mM glucose and 20 mM HEPES, pH 7.4) diluted 1:1 with water 
and containing a final concentration of 10 pM SPQ. The cells were loaded for 20 min at 37 °C in a 
humidified chamber with 5% CO2. The SPQ-loaded cells were then mounted on a LSM510 Meta 
confocal microscope with a 37 °C heated stage, and perfused with iodide buffer. Changes in the 
CFTR-mediated SPQ fluorescence were monitored at the 445 nm in response to excitation at 340 
nm during the perfusion at 37 °C in nitrate buffer (Nal replaced with 130 mM NaNCb) for 10 min, 
with 20 pM forskolin plus 50 pM genistein or 20 pM forskolin plus 20 pM genistein. The peak 
iodide efflux rate (usually 12 min after the forskolin plus genistein addition) of untreated and 
treated cells was calculated according to the Stem-Volmer relationship, as follows: (Fo/F) - 1 = 
KCQ where F is the observed fluorescence, Fo is the fluorescence in the absence of a quenching 
anion, CQ is the concentration of the quenching anion, and K is the Stem-Volmer quench constant. 
The rates were calculated using Sigma Plot Version 7.1 for each mean fluorescence trace generated 
from 50 cells examined per population per coverslip.
6.16. HS-YFP assay for CFTR activity
Twenty-four hours after plating, the CFBE cells expressing AF508CFTR and HS-YFP 
were incubated with the test compounds at 37 °C for 24 h to 48 h. At the time of assay, the cells 
were washed with PBS and stimulated for 30 min with 20 pM forskolin in the absence or presence 
of 50 pM genistein. The cells were then transferred to Zeiss LSM 700 confocal microscope where 
the images were acquired using an open pinhole at a rate of 330msec/ffame, at ambient temperature 
for CFTR activity determination. Each assay consisted of a continuous 300 s fluorescence reading 
with 30 s before and rest after injection of an iodide-containing solution (PBS with Cl" replaced by
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I-; final I" concentration in the well, 100 mM). To determine fluorescence quenching rate (QR) 
associated with 1“ influx, the final 200 s of data for each well were fitted with a mono-exponential 
decay and decay constant K was calculated using GraphPad Prism software.
6.17. Ussing chamber assay for short-circuit current recordings
The Ussing chamber experiments were carried out using polarised CFBE epithelia 
performed 7-10 days after their seeding cells, when the transepithelial resistance was >1,000 
H-crn2, with the Snapwell inserts mounted in a self-contained Ussing chamber system (vertical 
diffusion chamber; Coming Life Sciences, (St. Louis, USA). The transepithelial short-circuit 
currents of the CFBE epithelia were measured. The apical and basolateral sides contained the same 
solution (126 mM NaCl, 0.38 mM KH2PO4, 2.1 mM K2HPO4, 1 mM MgSCL, 1 mM CaCL, 24 mM 
NaHCCb, 10 mM glucose), bubbled with 5% CO2 in air. The hemichambers were connected to 
DVC-1000 voltage clamps (World Precision Instruments, Inc., Sarasota, FL, USA) via Ag/AgCl 
electrodes and 1 M KC1 agar bridges. The transepithelial currents were digitised using PowerLab 
4/25 data acquisition system, and stored on a computer. All of the measurements were carried out 
at 37 °C.
6.18. Meta-analysis of microarrays
The meta-analysis microarray profiles were carried out separately for the two gene sets. 
First, the cMap set was made up of 11 correctors (Table 2.1), the gene signatures of which were 
provided from the Prototype Ranked Lists obtained from Iorio et al. (Iorio et al. 2010) which was 
based on Affymetrix. The CFBE set was made up of 13 correctors, the gene signatures of which 
were obtained using the Agilent platform by treating CFBE41o' cells stably transfected with 
AF508CFTR, for 24 h. The CFBE dataset gene signature was obtained at Dr. D.Y. Thomas 
Laboratory, Department of Biochemistry, McGill University, Montreal, quality control, Canada, in 
collaboration with our Laboratory, and part of these microarray data have already been published 
(Zhang et al. 2012). The microarray data from the CFBE cells were then processed to obtain the 
ranked lists based on the fold-change of the probe; the highest up-regulated gene ranked first and 
lowest down-regulated gene ranked last. For each of the corresponding Prototype Ranked Lists or 
ranked lists, the top and bottom 20% of the probes were selected, which identifies the most up-
130
regulated and down-regulated probes, respectively. The 20% threshold was arbitrary, but it has 
been shown to represent most up-regulated and down-regulated probes for the cMap dataset (Iorio 
et al. 2010); a similar 20% threshold was used for the CFBE dataset. The common probes that lay 
in the top or bottom 20% of the cMap and CFBE drug sets were computed separately; there was 
one common down-regulated gene among the 11 cMap drugs, and there was one common up- 
regulated gene among the CFBE drugs. Then, a less stringent fuzzy intersection (Iorio et al. 2010) 
procedure was used to search for genes commonly up-regulated or down-regulated by a subset of 
the 11 cMap drugs and the 13 CFBE drugs. Keeping the up-regulated and down-regulated probes in 
each dataset separate, the probes that were common (=n) to any N number of drugs out of the 11 
drugs of the cMap dataset and the 13 drugs of the CFBE dataset were computed (Figure 2.2); N 
ranging from 1 to 11 for the cMap data, and 1 to 13 for the CFBE data. The ideal cut-off would be 
when N corresponds to the best enrichment in the number of common probes in the specific drug 
set, nobserved, with respect to the ones due to random chance, nrandom. Thus, a null hypothesis was 
built by sampling 1,000 configurations: for the cMap dataset, 11 Prototype Ranked Lists which 
were randomly selected from the 1,000 cMap drugs dataset; and for the CFBE dataset, 13 ranked 
lists which were randomly selected from 1,000 profiles computed by random shuffling of the total 
probes determined. For each value of N, the mean number of common probes by random chance 
n random was computed (Figure 2.2). This process determined the number of common probes to be 
expected using a group of unrelated drugs. The first requirement for choosing the cut-off was that 
the corresponding nobserved is unlikely to be due to chance, by selecting P values below 0.05. Taking 
the cMap drug dataset, no value of N had any significant increase in nobserved/ n random for the up- 
regulated genes; in contrast, the commonly down-regulated genes for cut-off 8 or 9 were 
statistically significant. The cMap dataset cut-off was set to 8, to increase the number of probes, 
and random probes ( n random) were less (better nobserved/ nrandom). Although cut-offs of 7, 6 and 5, 
statically significant, they were not considered because of a poor nobserved/ nrandom. For the CFBE 
dataset, the computed n random was very small compared to the cMap dataset, and this might be due 
to the different statistical methods used, because 1,000 drug microarray profiles were not available 
using the Agilent platform, so that 13 random ranked lists could be picked for determining the 
nrandom. The cut-off for the CFBE dataset was set to 9, which was almost the same percentage cut­
off (-70%) that was selected for the cMap dataset, and moreover, the calculated nobserved/nrandom was 
also statistically significant. This intersection procedure resulted in 541 up-regulated probes that 
corresponded to 402 genes (Table 2.2a), 191 down-regulated probes that corresponded to 117 
genes from the CFBE dataset, and 108 down-regulated probes corresponding to 102 genes from the 
cMap dataset (Table 2.2b).
6.19. String protein-protein interactions
The gene set was the input to the string database (http://string-db.org/f (Franceschini et al. 
2013) to identify the predicted interactions among the proteins. The required confidence was set to
0.7 and the active prediction methods used were neighbourhood, gene fusion, co-occurrence, co­
expression, experiments, and databases.
6.20. Ingenuity pathway analysis
The gene sets were analysed using the core analysis (CA) application of the Ingenuity 
Pathway Analysis (IPA), a web-based software application. The P A  core analysis (IPACA) maps 
these genes onto canonical pathways, predicts the upstream regulators, and also converts them into 
a set of relevant networks of a maximum of 35 focus genes (can be changed to 70 or 140), based on 
the Ingenuity Pathways Knowledge Base of the Global Molecular Network (GMN), which is 
composed of thousands of genes and gene products that interact with each other. Each network has 
an assigned significance score based on the P value (calculated Fischer’s exact test), the probability 
of finding focus genes in a set of genes randomly selected from GMN. The higher the number of 
focus genes in a network, the higher the score will be (a score of 53 means the respective P  value 
10E-53), and the higher the rank of the network will be. Each network also has predicted biological 
functions associated with it. The up-regulated and down-regulated genes of the CFBE dataset and 
the down-regulated genes of the cMap dataset were analysed separately and as a pool, to infer any 
common pathways or networks modulated among them.
6.21. QRT-PCR analysis
The total RNAs were isolated from samples using the GenElute™ 96 Well Total RNA Purification 
Kit (Sigma) according to the manufacturer’s protocol. Then cDNAs were derived from these RNA
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samples using the High Capacity cDNA Reverse Transcription Kit (Life Technologies) according 
to the manufacturer’s protocol. Then these RNA samples were subjected to PCR using 
LightCycler® 480 SYBR Green I Master using LightCycler® 480 (Roche) according to the 
manufacturer’s protocol. Then the relative amount of mRNA were calculated using 2(-Delta Delta 
C(T)) method (Livak and Schmittgen 2001).
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